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Infection is a common problem for critically ill patients. About half of the intensive care patients 
are considered to have an infection. Despite the advances made in modern medicine, the mortality 
and morbidity due to infection in critically ill remains unacceptably high.  
Timely initiation of antibiotic therapy with an appropriate spectrum for the likely 
pathogen after source control has been shown to have a significant impact on outcome, and 
have therefore been widely promoted. However, almost no information is available about 
the effect of appropriate dosing.  
The antibiotic dosing regimen, administered to the infected critically ill patient, is 
determined by pharmacokinetic studies in healthy volunteers with normal physiology. 
Research has shown that the key pharmacokinetic determinants are markedly different in 
critically ill patients. Moreover, infections in critically ill patients are often caused by 
microorganisms with decreased susceptibility compared to other clinical settings, which 
further renders optimal dosing more difficult. The overall result is that a standard dose of 
antibiotic leads to very variable concentrations in critically ill patients and that a significant 
proportion of patients may not reach optimal concentrations associated with maximal 
effect.  
Considering this, individually tailored antibiotic therapy may be a useful strategy to 
maximize antibiotic efficacy while minimizing toxicity. The aim of this work was to 
investigate the pharmacokinetic variability of -lactam antibiotics in critically ill patients and 
investigate methods to improve dosing in this patient population.  
As first part of this thesis, a fast and accurate chromatographic method was developed 
for quantification of the most commonly used -lactam antibiotics in our hospital, and we 
also explored the pre-analytical stability of these compounds. Multiple pharmacokinetic 
studies were undertaken and we demonstrated high pharmacokinetic variability both 
between patients, as well as within the same patient over time. We also demonstrated that 
a high creatinine clearance is a risk factor for subtherapeutic drug concentrations after 
standard dosing, even when extended infusions are used. For cefepime during continuous 
renal replacement therapy, we investigated the influence of dialysis settings on cefepime 
 
concentrations. In a simulation study, we found that the probability to achieve therapeutic 
exposure was lower for narrower spectrum antibiotics using conventional dosing compared 
to the broad-spectrum antibiotics for a selection of microorganisms for which de-escalation 
can be undertaken. A more practical part of this research consisted of stability experiments 
of meropenem, amoxicillin and amoxicillin/clavulanic acid for their use as a continuous 
infusion. Last but not least, a randomized controlled trial was undertaken investigating the 
potential of dose adaptations based on daily therapeutic drug monitoring of meropenem 
and piperacillin/tazobactam in critically ill patients with normal kidney function.  
As an overall conclusion, this project has contributed to the knowledge on the altered 
pharmacokinetics in critically ill patients, and has investigated some strategies to improve 
dosing, however there are still many questions that need to be answered before we can 
truly move to patient-tailored antibiotic therapy, such as the relationship between plasma 
concentrations and concentrations in the infected tissue, as well as the relation between 
















Infecties zijn een ernstig probleem bij kritiek zieke patiënten. Ongeveer de helft van de 
patiënten op intensieve zorgen hebben af te rekenen met een infectie. Ondanks de vooruitgang in de 
moderne geneeskunde blijft de mortaliteit en morbiditeit te wijten aan infecties in deze patiënten zeer 
hoog.  
Het tijdig toedienen van antibiotica met een geschikt spectrum vormt hierbij de 
hoeksteen van de behandeling. Het belang hiervan is aangetoond in verschillende studies. Er 
is echter heel weinig evidentie omtrent het belang van geschikte dosering, en het bereiken  
van adequate concentraties.   
Welke dosis van het antibioticum moet toegediend worden aan de kritiek zieke 
patiënt met een infectie is bepaald aan de hand van farmacokinetische studies uitgevoerd in 
gezonde vrijwilligers. Onderzoek heeft echter aangetoond dat de belangrijkste 
farmacokinetische determinanten in intensieve zorg patiënten sterk verschillend zijn ten 
opzichte van gezonde vrijwilligers. Bovendien zijn infecties in deze patiënten vaak 
veroorzaakt door minder gevoelige microorganismen, in vergelijking met andere klinische 
settings, wat de antibioticadosering nog meer bemoeilijkt. Hierdoor leidt één 
standaarddosering van antibiotica tot erg variabele concentraties in kritiek zieke patiënten, 
waarbij een significant deel van de patiënten suboptimale concentraties bereikt.  
Mogelijks kan individueel aangepaste antibioticatherapie een goede strategie zijn om 
dosering te optimaliseren met maximale efficaciteit en minimale toxiciteit. Het doel van dit 
werk was om  de farmacokinetische variabiliteit van β-lactam antibiotica in kritiek zieke 
patiënten beter in kaart te brengen, alsook om methoden te onderzoeken die kunnen leiden 
tot betere dosering in deze patiëntengroep.  
Als eerste onderdeel van deze thesis werd een snelle en accurate chromatografische 
methode ontwikkeld en gevalideerd voor de kwantificatie van de meest gebruikte -lactam 
antibiotica in dit ziekenhuis, en ook de pre-analytische stabiliteit werd onderzocht. 
Meerdere farmacokinetische studies werden uitgevoerd, waarbij we een grote 
farmacokinetische variabiliteit aantoonden, zowel tussen verschillende patiënten, als binnen 
eenzelfde patiënt. We toonden ook aan dat een hoge creatinineklaring een risicofactor is 
 
voor subtherapeutische concentraties na standaarddosering, zelfs wanneer de antibiotica 
toegediend werden over een langere tijdsperiode (extended infusie).   Voor cefepime tijdens 
continue niervervangende therapie  onderzochten we de invloed van dialysesettings op 
cefepimeconcentraties. In een simulatiestudie toonden we aan dat de kans om 
therapeutische concentraties te bereiken voor smalspectrum antibiotica in conventionele 
dosering lager is dan voor breedspectrum antibiotica in conventionele dosering, voor een 
aantal typische pathogenen waarvoor de-escalatie kan ondernomen worden.  
Een meer praktisch deel van dit onderzoek behandelde de stabiliteit van meropenem, 
amoxicilline en amoxicilline/clavulaanzuur voor hun gebruik als continu infuus. Als laatste 
rapporteren we de resultaten van een gerandomiseerde gecontroleerde studie over het 
effect van dosisadaptaties gebaseerd op dagelijkse therapeutische drug monitoring van 
meropenem en piperacilline in kritiek zieke patiënten met normale nierfunctie.  
Om te concluderen kunnen we stellen dat dit project bijgedragen heeft tot de kennis 
over de veranderde farmacokinetiek van hydrofiele antibiotica in kritiek zieke patiënten. We 
hebben ook strategieën onderzocht die dosering kunnen verbeteren. Vooraleer we echter 
volledig kunnen overgaan tot antibiotica therapie op maat van de patiënt moeten een aantal 
cruciale vragen beantwoord worden, zoals onder meer de relatie tussen 
plasmaconcentraties en concentraties ter hoogte van het geïnfecteerde weefsel, alsook de 
relatie tussen concentraties en de klinische uitkomst van de antibioticatherapie. 
Chapter One : Introduction 
1. Infections in the ICU  
1.1. Epidemiology  
Infection is an extremely important problem in critical care medicine. In a recent point 
prevalence study,  more than half of the patients were assumed to have an infection [1]. The 
mortality rate of these infected patients was found to be more than two times higher than 
the mortality rate of the non-infected patients, with infection being an independent 
predictor of mortality [1]. It is estimated that annually 135 000 patients are dying from 
sepsis in the European Union [1]. It is the leading cause of mortality in non-coronary 
intensive care unit (ICU) patients with up to 30% of patients dying within one month of 
diagnosis [1, 2] and mortality rates exceeding 50% for septic shock [3]. Despite the advances 
in modern medicine and intensive care, the incidence of sepsis is still increasing [4, 5].  
Various factors may contribute to this increased risk of infection and the associated poor 
outcomes. First of all, compared to the general hospital population, ICU patients have a 
more frail physical condition. They have more comorbidities and more severe physiologic 
derangements and are therefore less fit to fight an infection [6]. Secondly, the large use of 
indwelling catheters among critically ill patients serves as a port of entry of microorganisms 
into the body. Last but not least, multi-drug resistant microorganisms such as methicillin-
resistant Staphylococcus aureus and multi drug resistant gram negatives such as extended 
spectrum beta lactamases producing Enterobacteriaceae, Acinetobacter baumannii and 
carbapenem-resistant Pseudomonas aeruginosa are more frequently isolated in the ICU 
compared to the general wards [7, 8]. The emerging resistance to broad spectrum antibiotics 
among gram-negative microorganisms is particularly worrisome since treatment options are 
very limited, and sometimes no effective antimicrobial agent is available at all [9].  
The most common nosocomial infections in critically ill patients are device related and 
therefore the most common sites of infection are the lungs, urinary tract and blood stream 
[7].  
 
1.2. Treatment principles 
Sepsis is a major cause of mortality and morbidity. In order to maximize outcome, sepsis 
must be timely recognized and treated. 
Adequate antibiotic therapy after source control is the cornerstone of treatment. The 
mantra for antibiotics in severe sepsis is ‘hit hard, early and appropriately’, so when 
optimizing antibiotic therapy after source control, one should take three issues into account: 
spectrum, timing and dosing [10].  
1.2.1. Source control 
Source control is critical for therapeutic success as antimicrobial therapy and other 
interventions may fail if the source of infection is not properly controlled. It is defined as 
those measures that can be used to control the focus of an infection [11]. The principles of 
source control are [11]:  
1) Drainage of abscesses containing infected fluids 
2) Removal of contaminated devices or foreign bodies which serve as a reservoir of 
microorganisms (for example, a colonized intravascular catheter or infected 
prosthetic heart valve) whenever feasible 
3) Debridement of infected or necrotic tissue 
4) Correction of anatomic derangements which result in ongoing microbial 
contamination (for example perforation of the colon) 
1.2.2. Spectrum 
It is of utmost importance that the spectrum of the chosen antibiotic covers the 
causative pathogen (“adequate” antibiotic therapy). The importance of initial antimicrobial 
choice on mortality in patients with sepsis has been repeatedly shown by separate 
investigations [12-15]. Harbarth and colleagues found the 28-day mortality to be 24% for 
patients in the adequately treated group versus 39% (82/211) for patients receiving 
inappropriate initial antimicrobial therapy in a large cohort of patients with microbiologically 
confirmed severe sepsis of multiple origin [14]. It was found to be an independent predictor 
of mortality with an adjusted odds ratio of 1.8. This was also confirmed by Ibrahim et al who 
assessed the influence of inadequate antimicrobial treatment on outcome in critically ill 
patients with blood stream infections. They found the hospital mortality to be twice as high 
in patients who received inadequate antimicrobial treatment compared to those who 
received adequate therapy [13]. Multivariate analysis of these data has identified 
inadequate treatment as the most important risk factor of hospital mortality, with an 
adjusted odds ratio of 6.9 (95 % confidence interval 5.1-9.2). This has also been confirmed in 
peritonitis, where inadequate initial antibiotic therapy was an independent predictor of 
mortality with an adjusted odds ratio of 1.6. These findings have led to the widespread use 
of broad-spectrum antibiotic therapy for the empirical treatment of infections, when the 
causative microorganism is still unknown.  The situation is less clear when studying 
ventilator-associated pneumonia where some researchers have found an excess mortality 
caused by inappropriate initial therapy estimated to be 21.4%, while others have found an 
attributable mortality as low as 1 % [12, 16]. Although it seems quite clear from studies that 
the initial spectrum has a significant effect on mortality, it is apparently dependent on many 
variables such as the type of infection, and the underlying health status of the patient. 
Moreover, these studies may overestimate the effect of adequate antibiotic therapy, as it is 
not achievable in all cases, since empiric antibiotic therapy is chosen based on local 
epidemiology, but in rare cases the patient may be infected with a resistant pathogen.  
The unadjusted mortality rates for the patient groups receiving appropriate and 
inappropriate initial antibiotic therapy are graphically shown in figure 1. 
 
Fig. 1 Influence of adequate vs. inadequate antibiotic spectrum on mortality in different 
types of infections: blood stream infections (BSI)[13], peritonitis [15] and severe sepsis of 



















Sepsis is a serious medical condition with a high mortality rate if left untreated. 
However, a major challenge with complicated infections is early recognition [17]. As such, 
severe sepsis is often not immediately recognized upon admission to the emergency 
department. As a consequence, these patients may develop shock and multi-organ failure. 
These patients are then admitted to the ICU in a moribund state, and may be beyond salvage 
[18]. Many factors contribute to this, such as age, general health status, how long it took to 
reach the emergency department/intensive care unit and how long the infection has already 
been present [19].   
Based on anecdotal evidence, similar to inadequate spectrum, delay in the initiation 
of appropriate antibiotic therapy is also considered as an important risk factor for mortality.  
Kumar and colleagues retrospectively analyzed the impact of antibiotic timing on 
hospital mortality in septic shock patients and found a strong correlation between delay in 
effective therapy and mortality. They found a decrease in survival by 7.6% for each hourly 
delay over the next 6 hours after the onset of recurrent or persistent hypotension [20]. 
Another study by Gaieski and colleagues in patients with severe sepsis also examined the 
effects of time from triage to antibiotic administration on mortality. They did not find a 
correlation between delay in antibiotic therapy and survival, but they did find that patients 
who received appropriate antibiotic therapy within 1 h after triage had a significantly better 
chance of survival compared to patients that were delayed (odds ratio = 0.3 p<0.03) [21]. 
Puskarich et al performed a retrospective analysis of data collected for a multicenter 
randomized controlled trial on early sepsis resuscitation in the emergency department and 
did not find an influence of delay of antibiotic therapy on mortality up to 6 h after triage or 
after the onset of shock. However, patients who were receiving antibiotics before the 
recognition of shock had a lower mortality compared to patients that were given antibiotics 
after recognition of shock (odds ratio = 2.35) [22]. Ferrer et al performed a retrospective 
analysis from the Surviving Sepsis Campaign database (17 990 patients with severe sepsis 
and septic shock) and found an significant increase in mortality associated with the hours of 
delay in antibiotic administration following recognition of severe sepsis (significant after 1 
hour of delay) [23].  However, it is important to realize that the impact of the timing of 
antibiotic therapy can never be separated from the severity of the disease before the 
antibiotic was administered, which is not taken into account by these retrospective studies.  
Based on this available (suboptimal) evidence, timely administration and 
appropriateness of the spectrum of antibiotic therapy have been massively promoted in 
sepsis guidelines such as the Surviving Sepsis Campaign, which recommend to begin 
intravenous antibiotic as early as possible and always within the first hour of recognizing 
severe sepsis and septic shock, often called the “golden hour” [24]. Although these 
guidelines have been shown to reduce mortality from severe sepsis and septic shock [25], it 
must be mentioned that too early use of antibiotics can lead to excessive and unnecessary 
use of broad spectrum antibiotics, which may promote the emergence of resistance.  
A Cochrane review looking at the evidence on timing of administration of antibiotics 
was published in 2012 [19]. The authors concluded that they were unable to make a 
recommendation on the early or late use of broad spectrum antibiotics in adult patients with 
severe sepsis in the ED pre-ICU admission [19]. To collect better evidence on the optimal 
timing of antibiotic delivery, randomized controlled trials would be needed. However, this 
may not be feasible, as it may be ethically wrong to randomize these patients to a seemingly 
inferior treatment arm. As performing randomized controlled trials would not be ethical, 
large and highly qualitative retrospective datasets incorporating many confounding factors 
may also improve our knowledge on this issue.   
1.2.4. Dosing 
Last but not least, when antibiotics are administered, the dose should be based on 
knowledge about the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the 
drug, in order to maximize the effect and minimize concentration-related toxicity. A good 
example of the importance of knowledge on PK/PD is how dosing of aminoglycosides has 
changed over time. Traditionally, aminoglycosides were dosed twice or three times daily. 
However, when it became clear that aminoglycosides exert concentration-dependent killing 
and have an important post-antibiotic effect, it makes more sense to dose them once-daily, 
which gives rise to a higher peak concentration (more efficient killing) and lower trough 
concentrations (less nephrotoxicity). More than 30 randomized controlled trials have been 
performed comparing once versus multiple daily dosing, and all meta-analyses of these trials 
 
favored once daily dosing [26-34]. Once daily dosing for aminoglycosides is now widely 
accepted as standard of care therapy.  
2. β-lactam antibiotics 
More than 70 years after their introduction, β-lactam antibiotics remain the mainstay of 
treatment for many bacterial infections. They are given alone or in combination with β-
lactamase inhibitors. Advantages of these drugs are their broad spectrum of activity and 
their minimal intrinsic toxicity. Although toxicity occurring from these antibiotics is rare, it is 
associated with high concentrations [35].  
2.1. Physicochemical properties 
As revealed by the name, all β-lactam antibiotics share a common β-lactam group, which 
is a cyclic amide. Another common feature is the carboxylate or sulfonate.  
β-lactam antibiotics are classified into different groups depending on the chemical 
structure: penicillins, cephalosporins, monobactams and carbapenems. Penicillins all share 
the common penam group, which is a fusion of the β-lactam and thiazolidine ring. 
Cephalosporins all contain the cephem group, consisting of the β-lactam and dihydrothiazine 
ring. Monobactams only have one ring. Carbapenems are different from penicillins because 
these antibiotics have an unsaturated bond and a carbon atom replacing sulphur at position 
1 of the thiazolidine ring, which makes them highly resistant to most prevalent β-lactamases, 
which are enzymes that hydrolyze the β-lactam ring, and so deactivate the antibiotic [36]. 
 A schematic overview of the four major β-lactam antibiotic classes is given in figure 2. 
 
Fig. 2 Common core structures of four major β-lactam antibiotics. Penicillins, 
cephalosporins and carbapenems have a bicyclic core. Monobactams have a single 
central cyclic structure (copied from [37] with permission) 
2.2. Mechanism of action 
The main targets of the β-lactam antibiotics are the penicillin-binding proteins. These 
proteins play an important role in the peptidoglycan cell wall synthesis through cross-linking 
strands of peptidoglycan into a polymer surrounding the bacterial cell. β-lactam antibiotics 
resemble the natural enzyme substrate and form a stable bond between the antibiotic and 
the enzyme. The hydrolysis of this acylated protein occurs only very slowly, therefore the 
formation of this bond between antibiotic and penicillin-binding proteins results in enzyme 
inactivation and an impaired synthesis of the bacterial cell wall [38]. 
2.3. Pharmacodynamics 
For antibiotics, pharmacodynamics (PD) describe the relationship between the antibiotic 
concentration and the ability to kill or inhibit the growth of bacterial pathogens. These 
exposure-response relationships have been studied primarily using in vitro experiments, as 
well as in animals. Most commonly used are the neutropenic thigh model and pneumonia 
model in mice. In brief, neutropenia is induced in these mice by administering 
cyclophosphamide, after which they are infected by injection of bacteria. Antibiotic 
treatment is usually started 2 hours after infection and serial plasma concentrations are 
obtained, which are used to calculate exposure. The total bacterial count from the infected 
tissue is determined after a fixed time interval. Different dosing regimens result in ranges of 
exposure, from which the relationship between exposure (time above the minimum 
inhibitory concentration (MIC), concentration/MIC, area under the curve/MIC) and response 
(number of colony forming units, death , emergence of resistance, …) can be derived. 
 Antibiotics can be classified according to their PD characteristics as concentration-
dependent, time-dependent or both, as shown in figure 3.  
 
 
Fig. 3 Pharmacokinetic and pharmacodynamic parameters of antibiotics on a concentration 
vs. time curve. T>MIC—The time for which a drug’s plasma concentration remains above the 
minimum inhibitory concentration (MIC) for a dosing period; Cmax/MIC, the ratio of the 
maximum plasma antibiotic concentration (Cmax) to MIC; AUC/MIC, the ratio of the area 
under the concentration time curve during a 24-hour time period (AUC0 –24) to MIC (copied 
from [39] with permission) 
β-lactam antibiotics exhibit a time-dependent killing pattern, meaning that the 
percentage of the dosing interval for which the unbound concentration exceeds the minimal 
inhibitory concentration (fT>MIC) of the microorganism is considered the best descriptor of 
efficacy [40]. In vitro and animal models have suggested that 30 to 70% fT>MIC (depending on 
the antibiotic) is necessary to treat infections [41]. However, a number of studies have 
suggested that higher targets may be needed to maximize the effect in humans. The 
available studies that have investigated toe relationship between achievement of PK/PD 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3. Susceptibility of the microorganism 
3.1. Importance  
Only a few years after the mass production of penicillin in 1943, hospitals already 
experienced problems with resistant Staphylococcus aureus, which was thought to be 
uniformly susceptible. The importance of testing the bacterial culture for susceptibility, and 
treating the patient only with these antibiotics that were active in vitro, became increasingly 
recognized in later years [50]. 
In order to select the appropriate antibiotic for empirical therapy, it is important to have 
a good understanding of the trends in pathogen incidence and antimicrobial resistance, 
which can differ significantly between countries (northern versus southern Europe), 
between hospitals and even between departments (general hospital settings versus ICU).  
Knowing the susceptibility is crucial, as the microorganism must be sensitive to the 
chosen antibiotics, both in the empirical phase, as well as after identification, in order to 
maximize the chances of patient survival. In order to choose the right antibiotic for the 
empirical phase, it is important to have an accurate idea about the local ecology and 
susceptibility of microorganisms. Surveillance studies provide important information on this 
subject and have shown that the incidence of antimicrobial-resistant pathogens is increasing 
[51, 52]. On a more local level, hospital antibiograms provide the percentage of samples for 
a given organism together with their antibiotic sensitivity. This is used to select the 
appropriate empirical therapy, to assist in determining if coverage for multidrug resistant 
organisms in the empiric therapy are necessary and to monitor resistance rates, such as the 
incidence of methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant 
enterococci (VRE), extended spectrum beta-lactamase (ESBL) producing bacteria and 
carbapenemase-producing Enterobacteriaceae (CPE) [53].  
After identification of the causative organism, antibiotic therapy may be adapted to the 
susceptibility profile, preferably switching to narrower-spectrum antibiotics to decrease 
selective pressure and therefore to reduce the development of resistance, a process which is 
called de-escalation [54]. It is generally considered safe as most studies could not find a 
negative effect on outcome [55, 56], and some studies even showed improved outcomes 




interventional, it is possible that de-escalation was only performed in patients who were 
improving and therefore selection bias may be responsible for this effect. 
De-escalation to the most appropriate single therapy as soon as the susceptibility profile 
is known is recommended in the 2013 Surviving Sepsis Campaign guideline, be it with poor 
qualities of evidence and strengths of recommendations [59]. Therefore, it is often 
incorporated in antibiotic stewardship programs in critically ill patients [60, 61], which has 
been defined as “the optimal selection, dosage, and duration of antimicrobial treatment that 
results in the best clinical outcome for the treatment or prevention of infection, with 
minimal toxicity to the patient and minimal impact on subsequent resistance”[62]. It is 
estimated that de-escalation is applied in 13-46 % of the patients (depending on the 
definition used and the context) [58, 63-66] although in clinical practice there seem to be a 
number of obstacles to use it widely [67].  
The generally accepted principle that de-escalation is safe has been challenged by the 
results of a recent randomized controlled multicenter trial, which did not suffer from the 
above mentioned selection bias as all patients in whom de-escalation was possible were 
included in the study. Leone et al found that de-escalation to narrow spectrum antibiotics 
did not reduce patient ICU length of stay and was associated with an increased number of 
antibiotic days for patients who had been de-escalated. The authors also reported that 
superinfections were more frequent in patients who were de-escalated, with about half of 
the superinfections being caused by the same pathogens as the initial infection [68]. It is 
therefore questionable whether de-escalation is actually safe in terms of preserving 
outcome while reducing broad-spectrum antibiotic use [67].  
3.2. Susceptibility testing 
The minimum inhibitory concentration (MIC) is considered to be the gold standard for 
determination of the susceptibility of organisms to antimicrobials. It is defined as the lowest 
antibiotic concentration that inhibits visual bacterial growth. 
The reference technique to determine the MIC values is by using broth microdilution (ISO 
20776-1:2006) [69]. Basically, a standardized bacterial inoculum is applied to a standardized 
broth containing serial twofold dilutions of antibiotic. The cups are left to incubate at 




concentration for which there is no visible growth. MIC determination can be performed 
manually, automatically or semi-automatically. It is generally accepted that the test result is 
reproducible within ± 1 well in a dilution series.  
While broth dilution used to be associated with a high workload, impracticalities such as 
manual preparation of antibiotic solutions, possibilities of errors and the large amount of 
reagents and space required, this has now been miniaturized by using small microdilution 
trays which can be purchased commercially [70]. After incubation, MICs can be determined 
using automated devices for inspection of each of the panel wells for growth. The 
disadvantage of this technique is the inflexibility of antibiotics available in standard 
commercial panels [70]. A suitable alternative is the antimicrobial gradient method, where a 
strip containing the dried antibiotic in serial dilutions, is placed on the surface of a culture 
plate inoculated with the bacterial suspension. The antibiotic gradient on the strip diffuses 
from the strip to the matrix, creating the same gradient in the culture medium. After 
overnight incubation, a symmetrical inhibition ellipse centered along the strip is seen. The 
MIC value is determined as the value on the scale where the lower part of the ellipse 
intersects the test strip. This approach is shown to have a high concordance with broth 
dilution techniques and offers flexibility by being able to test only the drugs of choice. 
However it is quite expensive [71-74]. Automated systems to determine susceptibility (such 
as Vitek2® from Biomerieux, and BD Phoenix® from Becton Dickinson) are also available but 
may not be as accurate compared to the gold standard technique. Moreover they only test a 
very limited range of dilutions. Failure of these systems to detect resistance has been 
reported by several studies [75-78]. 
Another very commonly used method to determine the susceptibility is based on the 
zone distribution of the disk diffusion test. In this test, antibiotic disks impregnated with 
antibiotics are placed on a culture plate swabbed with bacteria, which is left to incubate at a 
defined temperature and environment [79]. If the antibiotic inhibits bacterial growth, there 
will be a zone of inhibition where bacterial growth is not visible. Based on the diameter, 
bacteria are classified as sensitive, intermediary resistant or resistant, which will be further 
discussed in section 3.3.  
3.3. Clinical breakpoints  
There are two important factors that determine the antimicrobial efficacy of the drug, 
which are the in vitro susceptibility of the microorganism (the MIC), and the exposure of the 
drug to the bacterium in vivo (PK), as shown in figure 4. 
Susceptibility of 
the bug (MIC)
Exposure to the 
drug (PK) 
Antimicrobial efficacy of the 
drug (microbiological cure)




Fig. 4 Relationship between the susceptibility of a microorganism, exposure of an 
antimicrobial drug and antimicrobial drug effects (adapted from [80] with permission) 
Based on the MIC (microbroth dilution or gradient diffusion test) or based on the 
diameter of the inhibition zone (in the case of disk diffusion), a microorganism is classified as 
sensitive (S), intermediary resistant (I) or resistant (R). A sensitive bacterial strain is defined 
as a strain inhibited in vitro by a concentration of an antimicrobial agent that is associated 
with a high likelihood of therapeutic success. Intermediary resistant strains are defined as 
bacterial strains inhibited in vitro by a concentration of an antimicrobial agent that is 
associated with uncertain therapeutic effect. Resistant bacterial strains are strains inhibited 
in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood 
of therapeutic failure [81].  
This clinical breakpoint is derived by performing dosing simulations using the most 
common doses and taking into account the pharmacokinetic variability between patients. 
The clinical sensitive breakpoint is then defined as the MIC that will result in attainment of 
the PK/PD target for 99 % of the patients [82]. As an example, the results of the dosing 
simulations for meropenem which are used to determine the clinical breakpoint according to 
the European Society on Antimicrobial Susceptibility testing (EUCAST) for this antibiotic are 
shown in figure 5. Administering a dose of 1 g every 8 hours results in achievement of the 





PK/PD target of 40 % fT>MIC for 99% of the patients if the MIC ≤ 2 mg/L. Therefore the MIC of 
2 mg/L is the clinical breakpoint. Unfortunately, the key PK parameters used to perform 
these dosing simulations are based on PK from healthy volunteers, which is different from 
PK in critically ill patient, and does not take into account the vast variability seen in critically 
ill patients, which will be discussed in section 4.  
 
Fig. 5 Percentage time exceeding the minimum inhibitory concentration (fT>MIC) for 
meropenem 1000 mg x 3 times daily. The following pharmacokinetic parameters were used : 
volume of distribution 20.8 L (coefficient of variation (CV) 13%), elimination half-life 1.04 h 
(CV 19%), fraction unbound 91%, infusion time 0.5 h (Rationale document EUCAST [83]) 
4. Pharmacokinetic alterations of hydrophilic antibiotics during critical illness 
Pharmacokinetics (PK) is the study of the movement of drugs into, through and out of 
the body, and describes the concentration of the drug versus the time.  
Antibiotic dosing regimens are usually determined in healthy adults with normal 
physiology. Moreover, clinical breakpoints are also determined using PK data from non-
critically ill patients. However, patients in intensive care units are distinctly different from 
those in general wards and from healthy volunteers. A recent multinational pharmacokinetic 
point prevalence study in critically ill patients has shown that β-lactam antibiotic 
concentrations vary greatly between ill patients and that the plasma concentration halfway 
through the dosing interval did not exceed the MIC (assuming a worst case scenario) in 16 % 
of the patients, who were therefore considered underdosed [84]. Both volume of 
distribution (Vd) and clearance are the key PK determinants. Unfortunately, many 




these PK determinants [39, 85, 86]. Figure 6 summarizes the possible PK alterations in 
critically ill patients.  
 
Fig. 6 Pharmacokinetic alterations in critically ill patients. CL : clearance, Vd : volume of 
distribution (adapted from [39] with permission) 
4.1. Changes in volume of distribution 
The (apparent) volume of distribution (Vd) is defined as the theoretical volume in 
which the drug would need to be distributed in order to produce the blood concentration. It 
is a constant factor that relates the plasma concentration (Cp) to the dose (equation 1) [87]. 
Dose = Cp x Vd  (1) 
β-lactam antibiotics are hydrophilic drugs and predominantly distribute into the 
intravascular and interstitial fluid. Therefore, these drugs have a small Vd, usually consistent 
with the volume of extracellular body water (approximately 0.1-0.6 L/kg), which results in 
high plasma concentrations [88].  
Critically ill patients often have a larger Vd for hydrophilic drugs compared to healthy 
adults, mainly because of a systemic inflammatory response syndrome (SIRS) [39]. This 




laboratory alterations which are due to an infectious or a non-infectious cause, such as 
trauma, pancreatitis, burn injuries, hematological derangements and surgery [6]. Sepsis is 
defined as SIRS with an infectious cause. This inflammation response triggers a capillary leak 
and fluid extravasation into the interstitial space (also called third spacing) and results in 
hypotension. In order to maintain blood pressure, large amounts of fluids are often 
administered, which also distribute into the interstitial fluid, thereby substantially increasing 
the interstitial volume. This rise in interstitial volume leads to a large increase of volume of 
distribution of hydrophilic antibiotics, resulting in lower initial drug concentrations [85]. A 
large volume of distribution in critically ill patients has been demonstrated for β-lactam 
antibiotics, aminoglycosides and vancomycin [89-96]. The volume of distribution of some -
lactam antibiotics compared to healthy volunteers is shown in figure 7. 
 
Fig. 7 Heterogeneity of volume of distribution (Vd) of β-lactam antibiotics in critically ill 
patients. Open circles: volume of distribution in healthy volunteers; filled squares: weighted 
means of volume of distribution in critically ill patients; straight lines: ranges of the means of 
volume of distribution in the studies (copied from [97] with permission).  
Figure 8 illustrates the effect of increased Vd on concentrations in plasma and tissue after a 




































Fig. 8 Concentrations in plasma (central compartment) and tissues (peripheral 
compartment) in healthy volunteers/general ward patients and critically ill patients after 
standard dosing  
4.2. Changes in clearance 
Clearance is defined as the volume of plasma cleared of drug per unit of time. The 
main route of elimination for most β-lactam antibiotics is renal excretion, and therefore the 
concentrations will be highly affected by changes in renal function. In critically ill patients, 
both a decreased as well as an increased clearance can occur.  
4.2.1. Decreased clearance 
Acute kidney injury (AKI) is generally defined as the sudden and sustained loss of 
kidney function which results in the inability to excrete nitrogenous waste and xenobiotics 
and in the dysregulation of extracellular volume and electrolytes [98].  
The lack of a standard definition for AKI has resulted in a large variation in the 
reported incidence [99]. In 2004, the Acute Dialysis Quality Initiative has published a 
consensus definition on AKI: the risk, injury, failure, loss, and end-stage renal disease 
classification (RIFLE). The classification is based on a relative increase in serum creatinine 




common sequel. The incidence of AKI (RIFLE category injury or failure) in sepsis has been 
reported to be around 40% [100, 101]. AKI will lead to a reduction in -lactam antibiotic 
clearance [102, 103], and hence a significant increase in plasma concentrations. Although 
not very common, toxicity from -lactam antibiotics may occur and is associated with high 
concentrations [35].  
4.2.2. Extracorporeal clearance  
In the case of severe AKI, initiation of renal replacement therapy may be needed. This 
may consist of continuous renal replacement therapy (CRRT), intermittent hemodialysis or a 
hybrid form, such as sustained low-efficiency dialysis. Solute removal occurs by convection 
and/or diffusion. Many factors may influence the antibiotic clearance from the circuit such 
as the filter material, blood flow rate, ultrafiltration rate, dialysate rate, location of fluid 
replacement, interruptions because of filter clotting or for therapeutic interventions [104]. 
The modality and dosage of the renal replacement therapy are unstandardized and 
individualized to the patient needs and therefore antibiotic clearance varies tremendously 
with method and settings [105].  
These extracorporeal circuits may further complicate PK, and have not been properly 
investigated because these studies are not recommended in existing US Food and Drug 
Administration (FDA) guidance documents or required for new drug approval [106]. 
Observational studies have shown a wide variability in antibiotic concentrations during 
CRRT, with many patients having low concentrations early in therapy, and accumulation 
occurring in the next days [107-109]. 
To date, there are relatively little clinical data on the removal of specific drugs by 
CRRT. Moreover, it is unclear how the specific dialysis settings influence drug 
concentrations. Current recommendations on antibiotic dosing during CRRT are based on 
studies that included a limited number of patients who received different types of CRRT and 
therefore larger and better designed studies are necessary.  
4.2.3. Augmented renal clearance  
The exact opposite phenomenon of acute kidney injury is also frequently encountered in 
critically ill patients and has been coined “augmented renal clearance” (ARC). This 




toxins, waste products and pharmaceuticals and has been defined as a creatinine clearance 
of 130 mL/min/1.73m² or higher [110].   
This hyperdynamic circulation, characterized by a high cardiac output and low systemic 
vascular resistance is a result of the SIRS which triggers cytokine release. How this influences 
renal function is still being studied. It is assumed that renal blood flow is correlated with 
cardiac output, which has been investigated by Udy et al. These researchers have shown a 
weak correlation (R= 0.346) between the cardiac index using pulse contour analysis and 
creatinine clearance in septic patients [111]. In order to normalize cardiac function, fluid 
resuscitation and vasopressors are often prescribed. These events all result in an enhanced 
blood flow to the major organs, including the kidneys which enhances glomerular filtration 
rate (GFR). Altered tubular function and recruitment of renal reserve, are also thought to 
contribute to this phenomenon [112]. This increases drug delivery to the glomerulus and 
subsequent elimination of renally cleared antibiotics, which in turn may possibly lead to 
therapeutic failure and selection of drug resistant strains [113, 114]. The potential 
physiologic mechanisms are graphically shown in figure 9, however it must be noted that  
these mechanisms are still being investigated. In order to further elucidate the 
pathophysiology, Udy et al have investigated the changes in GFR and renal tubular function 
in 20 critically ill patients at risk of augmented renal clearance (ARC), using exogenous 
marker compounds. Sinistrin was used to measure GFR, p-aminohippuric acid for assessment 
of tubular anion secretion, pindolol for cationic secetion and fluconazole for tubular 
reabsorption. They found that GFR was markedly elevated. Tubular anion secretion and 
tubular reabsorption were also elevated, was also elevated. Net tubular cationic secretion 
was impaired..  
Although ARC has been discovered a long time ago (the  first report on ARC dates from 
1978), it is being increasingly described in critically ill patients [116]. ARC typically occurs in 






Fig. 9 Mechanisms driving augmented renal clearance; GFR: glomerular filtration rate 
(adapted from [115] with permission) 
Udy et al. also found that 65% of all ICU patients without evidence of absolute renal 
impairment had evidence of ARC on at least one occasion during the first seven study days, 
and of those patients manifesting ARC,  74% did so on at least 50% of the study period (7 
days) [118].  De Waele et al. reported that at least one episode of ARC was observed in 55.8 
% of the patients, with an incidence of 36.6 episodes/100 patient days.  Moreover, 60.9 % of 
the patients manifested ARC on more than 50 % of their ICU days[119]. These data suggest 
that ARC is likely to be common. Moreover, Udy et al. have also demonstrated that up to 
82% of the patients with ARC had subtherapeutic β-lactam plasma concentrations  after 
standard dosing [120]. 
Not only is ARC very common as shown above, research has also shown that ARC is 
associated with worse outcomes: Claus et al studied 128 patients in a mixed cohort of 
surgical and medical ICU patients receiving antimicrobial therapy and found 27.3% of the 
patients with ARC had therapeutic failure (defined as an impaired clinical response and the 
need for alternate antimicrobial therapy by two investigators blind for creatinine clearance), 
versus 12.9 % in the patients without ARC (p=0.04) [117].  
4.3. Changes in protein binding 
Many drugs, including β-lactam antibiotics bind to proteins. The degree of protein 
binding greatly affects PK. The most important binding proteins are albumin and 1-acid 
glycoprotein. This binding between drug and protein must be seen as a reversible 




graphically represents a two-compartment model for a drug, including protein binding. The 
bound fraction acts as a drug-reservoir in the vascular compartment.  
 
Fig. 10 The equilibrium between unbound, bound and distributed drug in the body in a two-
compartment model. The bloodstream is the central compartment and the peripheral 
compartment represents the extravascular tissues where the drug distributes from the 
central compartment. kin corresponds to the absorption constant (in oral administration) or 
the infusion rate (in intravenous infusion), k12 corresponds to the constant that describes the 
movement of drug from the central compartment (1) to the peripheral compartment (2). k21 
describes the movement from the peripheral compartment(s) back to the central 
compartment. kb and kub describe the equilibrium between bound and unbound drug, 
respectively, and albumin in the bloodstream. kb and kub will depend on the binding affinity. 
kbʹ and kubʹ describe the equilibrium between bound and unbound drug and albumin in the 
peripheral compartment where binding can occur to extravasated albumin or to cell 
membranes (including intracellular distribution). The albumin binding equilibrium will 
displace depending on the plasma albumin concentration and the plasma drug 
concentration. kout corresponds to the elimination constant from the central compartment 
(copied from [121], with permission) 
Protein binding affects PK in two ways. First, only the unbound antibiotic is able to 
penetrate into the extravascular space and distribute into the infected tissue to exert its 
pharmacological effect. Protein binding is therefore an important determinant of the extent 
of tissue distribution and the volume of distribution. Secondly, only the free drug can be 




Hypoalbuminaemia, defined as serum albumin levels < 25 g/L by the SAFE (Saline 
versus Albumin Fluid Evaluation) study, is very common in critically ill patients (incidence 
around 40-50%), mainly caused by loss through the capillaries mediated by the inflammation 
response [122]. A lower albumin concentration gives rise to a decreased binding to albumin. 
Therefore, free concentrations in plasma will initially increase. However, this increased 
unbound fraction is also available for distribution and elimination, which leads to a higher 
volume of distribution and a faster elimination from the body and thus leading to low 
concentrations later in the dosing interval, which is unfavorable for time-dependent 
antibiotics [123].  
The importance of changes in protein binding is often not clinically relevant, since an 
increase in free fraction does not always result in an increased free concentration. A change 
in protein binding, causing a higher free fraction may initially result in higher concentrations, 
but as this concentration is available both for distribution and elimination, these processes 
which will decrease the free concentration [124].  
Because of the dynamic equilibrium between higher unbound fraction and increased 
distribution and elimination, the influence of hypoalbuminaemia is probably most relevant 
for highly bound compounds, where small changes in protein binding may result in a large 
increase of unbound fraction. An decreased protein binding from 50 to 40 % results in only 
20 % increase in free concentration while a decreased protein binding from 99 to 98 % 
results in a 100 % increase in free concentration, which may lead to toxic effects if the drug 
has a narrow therapeutic-toxic window. In the case of highly renally cleared drugs such as -
lactam antibiotics, this increased free concentration will be distributed and cleared, giving 
rise to low trough concentrations, which may impact the effect of these drugs. It has been 
shown for highly bound -lactam antibiotics, such as ertapenem that conventional dosing of 
1 g once daily, as determined in studies on healthy volunteers with normal serum albumin 
concentration, leads to suboptimal PK exposure in critically ill patients: the volume of 
distribution was found to be 4 times larger than the volume of distribution in healthy 
volunteers, and clearance 2 times higher [125-127]. Similar observations have been made for 
other highly protein bound antibacterials such as ceftriaxone, teicoplanin, cefazolin and 




4.4. Impaired tissue penetration 
In order to be effective, antibiotics need to penetrate from the plasma into the site of 
infection. Another factor complicating dosing in critically ill patients is the fact that severe 
infection may cause vascular dysfunctions, which can impair the penetration into the 
infected tissue. Although not much is known on this subject, there is some literature 
suggesting impaired tissue penetration and subsequent subtherapeutic tissue 
concentrations for many antibiotics in critically ill patients with a severe infection [133-136].  
5. Dose – optimization 
Considering that the PK of -lactam antibiotics are significantly altered in critically ill 
patients and that administering standard doses that are based on pharmacokinetic data 
from healthy volunteers may lead to both under-as well as overdosing, individually tailored 
antibiotic therapy may be a useful strategy to improve efficacy and prevent toxicity. At this 
moment, PK/PD modeling, and antibiotic therapeutic drug monitoring (TDM) are being 
explored to achieve this, together with prolonged infusion strategies, which form the 3 
components of -lactam antibiotic dose optimization.  
5.1.  Prolonged infusion time 
Prolonged infusion encompasses both terms extended (defined as a discontinuous 
infusion of 2 hours or more) and continuous infusion.  
There is compelling evidence that administration of β-lactam antibiotics by prolonged 
infusion increases the time for which the concentration exceeds the MIC of the pathogen 
(both in blood as well as in interstitial fluid), and therefore results in a better PK profile in 
critically ill patients than intermittent infusion when using the same dose, particularly for 






Fig. 11 Simulated concentration time profiles for a patient with fixed pharmacokinetic 
parameters only changing the duration of infusion (30 minute infusion, 3 hour infusion and  
continuous infusion), showing that prolonging infusion time increases the time above the 
minimal inhibitory concentration for less susceptible organisms.  
 Whether or not this results in improved outcome is still up for debate as comparative 
clinical studies between intermittent and prolonged infusion did not demonstrate significant 
differences in patient outcome. Abdul-Aziz et al explored the methodological flaws and 
inconsistencies of the published clinical studies, such as heterogeneous patient populations, 
patients with a low level of illness severity, inconsistent dosing regimens, pathogens with 
high susceptibilities and insufficient sample sizes. They concluded that continuous infusion 
of β-lactam antibiotics will not be beneficial to all patients but only to a specific subset, 
namely the critically ill with severe infections [141]. Currently, a 420 patient phase II study 
has been completed which should shed light on the benefit of bolus vs. continuous infusion. 
A proof-of-concept randomized controlled trial from this research group did already show 
that in this patient population, continuous infusion resulted in higher clinical cure rates 
[142].  
Therefore, administering antibiotics as a continuous infusion is increasingly used in 
intensive care units (ICU) around the world [49]. However, this way of administration brings 
about some practical issues such as the need for a loading dose to ensure rapid achievement 
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stability and compatibility should also be taken into account, as some -lactam antibiotics 
are not stable for 24 hours at room temperature. Most critically ill patients receive multiple 
drugs simultaneously, and often drug-drug compatibilities are not investigated, which 
requires the need for a dedicated line for continuous infusion [143]. 
5.2 Patient tailored antibiotic therapy 
 Even with the use of prolonged infusion techniques, the large PK variability between 
patients will continue to exist, and blind dosing may still lead to under-or overdosing in some 
patients. Because of this variability, individualized dosing, adapted to the physiology of the 
patient and the susceptibility of the causative pathogen may be better suited to ensure 
maximum efficiency and minimal toxicity. 
5.2.1. Population pharmacokinetics 
Population PK is the study of the variability in drug concentrations between individuals of 
a specific target population. It includes both the extent, as well as the sources and the 
correlates of this variability [144]. The major difference between population PK and 
traditional PK studies is that in traditional PK studies, the mean plasma-concentration time 
profile is the main point of interest. However, the focus of population PK is to provide 
estimates of the mean PK parameters (called population-typical values) together with the 
components of variability (called population variability values) [145]. 
Non Linear Mixed Effects Modeling is widely used as an estimation method of population 
PK. Population parameters are composed of so called fixed-effects and random-effect 
parameters, which are estimated simultaneously. Fixed effects include the population typical 
values, which define the average value for a PK parameter in the population, and the 
relationship between measureable patient characteristics (called covariates, for example 
creatinine clearance) and PK parameters. Random-effects parameters are the population-
variability values, which quantify variation. The model is defined by a structural model, a 




5.2.1.1. Building blocks of a population pharmacokinetic model  
5.2.1.1.1. Structural model 
The structural model defines the structure of the PK process. It is the PK model best 
describing the concentration data without covariates. It is part of the fixed-effects part of 
the population PK model. Most commonly used are one, two or three compartmental 
models [145].  
5.2.1.1.2. Random effect model 
 The random effect model describes the variability of the PK parameters. The random 
effects can be subdivided into 3 categories: between subject variability, residual unexplained 
variability and between occasion variability [145].  
Between subject variability measures the unexplained random differences between 
subjects (also called the inter-individual variability). It quantifies the deviation from the 
individual PK parameter to the population PK parameter. It is mostly described by the 
coefficient of variation [145]. 
 Residual unexplained variability measures the remaining unexplained variability 
when all other sources of variability have been taken into account. It includes errors in the 
analytical assay, in the drug administration, in the sample timing, etc. It can be described by 
an additive, a proportional, a combined additive-proportional or an exponential error model 
[145]. 
Between occasion variability (also called inter occasion variability) is a measure of 
unexplained random differences within the same individual on different occasions and is 
similarly to between subject variation mostly described by the coefficient of variation [147]. 
5.2.1.1.3. Covariate model 
A covariate is any measurable variable specific to an individual that may affect the 
drug PK and therefore explain part of the between subject variation. The goal of a covariate 
model is to reduce the between subject variation. Most important covariates are weight, 
renal function and age. The covariate model describes the effect of covariates on the PK 
parameters of the structural model. It is also part of the fixed-effects part of the population 
pharmacokinetic model. The decision to include a covariate in the final model should be 




 If the PK parameters can be precisely predicted based on the covariates, 
individualization of drug therapy becomes possible.  
5.2.1.2 Monte Carlo simulations  
After a well-evaluated and robust pharmacokinetic model including covariates has 
been developed in a population pharmacokinetic analysis of patient data, Monte Carlo 
simulations can be performed to make predictions about the future. A set of 
pharmacokinetic parameter values is generated for each simulated subject by random 
sampling within the predefined parameter distribution for each simulation. A concentration-
time profile can be generated for each simulated subject, which can then be used to 
evaluate the likely result of different therapeutic approaches. Examples can be: the effect of 
achieving therapeutic targets of different dosing strategies, or the effect on the 
development of resistance, drug toxicity and so on [148]. This technique is very valuable, as 
this allows researchers to ask many “what if” questions without having to perform a new 
clinical trial, which gives the possibility to maximize knowledge in absence of large studies 
[148].  
It must be noted that the appropriateness and robustness of the PK model is crucial. 
A model based on a very limited sample size will probably not be able to describe all PK 
variability likely to be encountered in the critically ill. However, Monte Carlo Simulations 
based on these small studies can still be instructive of the results of new dosing strategies, 
although the results should not be considered definitive [148]. Moreover, it is important to 
realize that Monte Carlo Simulations use a random sampling within a pre-defined 
distribution, which is often large and therefore the results will not be correct for each 
individual patient.  
5.2.2. Therapeutic drug monitoring  
If there are no population PK studies available, or if the random effects are 
considered to be too high to allow for dose individualization, then a more individualized 
approach using therapeutic drug monitoring (TDM) is likely to be a strategy that is better 
suited to optimize dosing [105].  
TDM requires direct measurement of antibiotic concentrations with timely reporting 




by comparing the concentration to a therapeutic target, or by the use of sophisticated 
software which estimates the antibiotic exposure [105].  
Components subjected to TDM are generally drugs with a narrow therapeutic index 
and with large intersubject PK variability, that cannot be easily be titrated to effect and 
which have a clear concentration-effect relationship.  
For aminoglycosides it has also been shown that individualized antibiotic therapy, with 
dosing adapted to specific pharmacokinetic targets using therapeutic drug monitoring (TDM) 
positively affects outcome [149-151]. An impressive study conducted in 1999 in the 
Netherlands found mortality to be lower in patients admitted with an infection treated with 
aminoglycosides subjected to active TDM compared to  patients admitted with an infection 
treated with aminoglycosides subjected to nonguided TDM [149]. All available studies found 
TDM to be cost effective and associated with lower nephrotoxicity [150, 151]. 
For vancomycin, the benefit of TDM remains somewhat controversial. There are 
conflicting reports whether or not vancomycin-associated nephrotoxicity is concentration 
dependent. However, a recent meta-analysis on the benefits of TDM of vancomycin 
suggested that TDM significantly improves clinical efficacy while reducing the likelihood of 
developing nephrotoxicity [152]. 
TDM has not widely been investigated for β-lactam antibiotics, and has traditionally 
been considered unnecessary because of their wide therapeutic index [153]. Currently there 
is almost no information about the effect of TDM on outcome for patients treated with -
lactam antibiotics. To date, there is only one study that investigated the influence of 
feedback dose alterations of different drugs (aminoglycosides, fluoroquinolones and -
lactam antibiotics) and found that adjustment of dose was independently associated with 
the probability of obtaining a positive clinical outcome in a multivariate analysis (p< 0.0002) 
[154].  
Unfortunately, TDM of β-lactam antibiotics is currently challenging with long 
turnaround times, expensive equipment, logistical problems related to the instability of the 
samples and the need for well-trained personnel. A detailed review on the available assays 






















Chapter Two : Research Objectives 
Despite the clinical experience with β-lactam antibiotics and high clinical cure rates for 
non-critically ill patients, outcomes in infected critically ill patients are still poor despite 
apparently appropriate and timely antibiotic therapy. In recent years, very few new 
antibiotics have become available, and the same is to be expected in the next years. With 
increasing rates of antimicrobial resistance, a rational use of antibiotics has been advocated. 
Optimized use of antibiotics to improve outcome and reduce antibiotic resistance is 
therefore the next challenge.  
In the heterogeneous population of an intensive care setting, correct antibiotic dosing is 
problematic because of highly variable and unpredictable pharmacokinetic changes in 
critically ill patients. The decreased susceptibility is an additional factor that makes dosing 
even more problematic. Considering this wide variability of antibiotic concentrations in 
critically ill patients, individually tailored antibiotic therapy may be a useful strategy to 
improve dosing. 
The aim of this thesis is to provide valuable information that can be used as a basis for 
patient tailored antibiotic therapy. For this, antibiotic concentrations need to be accurately 
measured in plasma. The first aim of this PhD is therefore to develop and validate an 
analytical method to accurately determine the plasma concentration of the most commonly 
used β-lactam antibiotics in Ghent University Hospital. As these antibiotics are considered to 
be quite unstable, we will also explore the pre-analytical stability of these antibiotics in 
plasma and whole blood in order to investigate whether labor-intensive measures taken to 
prevent degradation are really warranted. 
The second aim of this research is to gain more insight in the pharmacokinetics of these 
antibiotics, and their determinants. Therefore, we will conduct a number of pharmacokinetic 
studies in critically ill patients. In an era of emerging resistance and few new available 
antibiotics, it is necessary to use all remaining armamentarium optimally. Critical illness has 
an effect on the pharmacokinetics of both broad-as well as smaller spectrum antibiotics, and 
therefore research to optimize dosing should be focused on both broad-as well as smaller 
spectrum antibiotics.  
We will investigate the population pharmacokinetics of amoxicillin/clavulanic acid and 
cefuroxime in critically ill patients without acute kidney injury. We will also investigate the 
population pharmacokinetics of cefepime in septic shock patients during continuous renal 
replacement therapy. We will investigate the pharmacokinetics of meropenem and 
piperacillin administered as an extended infusion and compare it to bolus infusion. Another 
study will focus on the pharmacokinetic variability within the same patient over an entire 
course of treatment of piperacillin. We will also examine the adequacy of dosing of -lactam 
antibiotics when de-escalating from empirical broad spectrum antibiotics to more targeted 
narrow spectrum antibiotics by performing dosing simulations using previously published 
pharmacokinetic studies.  
The third and last aim of this thesis is to perform a number of studies focused on 
optimizing antibiotic therapy in clinical practice. Firstly, we will investigate the stability of 
drug infusions containing meropenem or amoxicillin/clavulanic acid reconstituted in 
physiologic saline, to evaluate the potential to be administered as a continuous infusion. 
Secondly, we will investigate the influence of creatinine clearance on 
pharmacokinetic/pharmacodynamic target attainment. Finally, we will analyze the effect of 
a dose-adaptation strategy based on daily therapeutic drug monitoring on target attainment 
of meropenem and piperacillin/tazobactam by performing a randomized controlled trial. 
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Chapter Four : Analytical Methods 
Performing pharmacokinetic studies requires accurate measurement of drugs in 
patient samples. This chapter summarizes the analytical work that has been performed as 
part of this thesis. 
 This first part of this chapter is a review of all currently available methods that can be 
used for TDM-purposes. An important part of this PhD consisted of developing a reliable 
method to quantify the most commonly used -lactam antibiotics in Ghent University 
Hospital, which is described in section 2. For this research, 2 analytical methods were 
developed. The first described method is able to quantify 6 -lactam antibiotics amoxicillin, 
ampicillin, piperacillin, ceftazidime, cefazolin, meropenem and 2 -lactamase inhibitors, 
clavulanic acid and tazobactam. Although this method proved to be very accurate and 
reliable, it was associated with a high workload because of the intensive sample clean-up 
procedure. Moreover, the chosen mobile phases were different from the mobile phases 
used for other routine analyses performed on the same machine. Therefore, we developed a 
new method with minimal sample preparation using the standard mobile phases that were 
also used for other methods. The last part of this chapter summarizes the pre-analytical 
research, as little is known on this subject for -lactam antibiotics. As they are generally 
considered to be quite unstable, labor intensive measures are currently often used, which 
makes routine therapeutic monitoring of these drugs even more challenging. This pre-
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Abstract 
In some patient groups - including critically patients - the pharmacokinetics of β-lactam 
antibiotics may be profoundly disturbed due to pathophysiological changes in distribution 
and elimination. Therapeutic drug monitoring (TDM) is a strategy that may be helpful to 
optimize dosing. The aim of this review was to review and analyze the published literature of 
the methods used for β-lactam quantification in TDM programs. Sixteen reports described 
methods for simultaneous determination of 3 or more β-lactam antibiotics in plasma/serum. 
Measurement of these antibiotics, due to low frequency of usage relative to some other 
tests, is generally limited to in-house chromatographic methods coupled to ultraviolet or 
mass spectrometric detection. Although many published methods state they are fit for TDM, 
they are inconvenient because of intensive sample preparation and/or long run times. 
Ideally, methods used for routine TDM should have a short turn around time (fast run-time 
and fast sample preparation), a low limit of quantification and a sufficiently high upper limit 
of quantification. The published assays included a median of 6 analytes (interquartile range 
(IQR) 4-10), with meropenem and piperacillin as most frequently measured β-lactam 
antibiotics. The median runtime was 8 minutes (IQR 5.9 - 21.3). There are also a growing 
number of methods measuring free concentrations. An assay that measures antibiotics 
without any sample preparation would be the next step toward real-time monitoring, 






Infection is a severe problem in many areas of medicine. Sepsis alone is the leading cause 
of mortality in non-cardiac intensive care units with up to 30% of patients dying within one 
month of diagnosis [2]. Timely and appropriate antibiotic therapy after source control is 
considered to be the mainstay of treatment [24]. Achieving adequate antibiotic exposure is 
equally important, however, because of pathophysiological changes in the pharmacokinetics 
of the drugs, optimal dosing remains very difficult [39, 49]. 
β-lactam antibiotics are the most commonly used antibiotics because of their broad 
spectrum of activity and wide therapeutic index. They exhibit time-dependent 
pharmacodynamics, meaning that the duration that the free antibiotic concentration 
exceeds the minimal inhibitory concentration (MIC) of the pathogen (fT>MIC) determines the 
bactericidal effect. Subtherapeutic concentrations using standard dosing have been reported 
in many patients groups, in particular, critically ill patients, [128, 140, 155-161] which in turn 
may result in clinical failure as well as development of antibiotic resistance. Toxicity of β-
lactam antibiotics is less common, but severe when it occurs, with seizures from high 
concentrations being reported previously [35, 162-165]. 
A more individualized approach using therapeutic drug monitoring (TDM) with dosing 
adapted to the altered pharmacokinetics of the individual patient is likely to be a strategy 
that can help optimize dosing [105]. TDM is mostly used for drugs with a narrow therapeutic 
index (such as aminoglycosides and glycopeptides) to maximize efficacy and minimize 
toxicity, although only aminoglycosides have supportive published outcome data [150]. TDM 
of β-lactam antibiotics is a relatively new technique, and although to date, there is no 
evidence that this leads to improved clinical outcomes, it is increasing in popularity as a 
means to optimize dosing in difficult patient populations, mostly for reasons of efficacy [49, 
166].  
However, unlike TDM of aminoglycosides and glycopeptides, no commercial assays such 
as immunoassays are available for routine monitoring of β-lactam antibiotics. A comparison 
of TDM of β-lactam antibiotics to aminoglycosides and glycopeptides is shown in figure 1.  
The aim of this review was to identify and analyze the published literature of the 
methods used for β-lactam quantification during TDM programs. In this review we describe 
 
 
and compare the available methods to determine β-lactam antibiotics in plasma/serum and 
























Fig. 1 : Comparison of therapeutic drug monitoring of β-lactam antibiotics to 
aminoglycosides and glycopeptides 
1.2 Search strategy 
1.2.1 Search terms 
Data for the present review were identified using a literature search of Pubmed from 
1951 to January 2015, as well as references from within relevant papers and the extensive 
files of the authors. The search terms included: (((Beta-lactam OR penicillin OR 
cephalosporin OR carbapenem OR monobactam)) AND ("quantification" OR "determination" 
OR "assay" OR "chromatographic" OR "immunoassay")) AND ("dosage" OR "patients" OR 
"therapeutic drug monitoring" OR "TDM" OR "clinical samples").   
1.2.2. Principles for the preferred method 
Simultaneous analysis of 3 or more β-lactam antibiotics in serum/plasma was considered 
as an inclusion criterion for a method to be included in this review (1 for alternative 
biological fluids, e.g. peritoneal fluid). The characteristics extracted from the included assays 
were runtime, precision and accuracy of the method, the calibration range, the lower limit of 
quantification (LLOQ) as well as the upper limit of quantification (ULOQ). We also listed 
 
 
whether selectivity was tested, in case photometric detection was used, and whether the 
matrix effect was tested, in the case of mass-spectrometric detection.  
1.3 Results  
A total of 588 articles were reviewed for qualitative synthesis, of which 476 titles did not 
describe assay methods for quantification of β-lactam antibiotics, but described general 
microbiological research, veterinary research, or pharmaceutical research. Seventeen 
reports described methods for simultaneous determination of 3 or more β-lactam antibiotics 
in plasma/serum: 15 chromatographic methods [167-181], and 2 non-chromatographic 
methods [182, 183]. Forty-two methods were found determining one or two β-lactam 
antibiotics, 11 of which determined at least one β-lactam antibiotic in other body fluids such 
as cerebrospinal fluid, ultrafiltrate or used an alternative sampling strategy such as dried 
blood spots [184-195]. Eleven papers reporting immunoassays were also found [196-207].  
1.3.1. Methods to measure -lactam antibiotic concentrations in plasma or serum 
1.3.1.1. Chromatographic assays 
Fourteen of the 15 chromatographic methods used reversed phase separation, coupled 
to ultraviolet (UV) (n = 9/15) or to mass spectrometric (MS) detection (n = 6/15).  There 
seemed to be no difference whether plasma or serum was used. The characteristics of these 
methods are summarized in table 1.  
Three methods did not report data on specificity, and one method only reported the 
results of one blank sample [171, 172, 175, 177]. Most of the manuscripts did not report on 
stability testing, although this is of major importance for β-lactam antibiotics, which in some 
cases are relatively unstable [208]. 
1.3.1.1.1. Analytes 
The most frequently measured β-lactam antibiotic was meropenem, which was 
included in 14 of 15 methods, followed by piperacillin (n = 11). The amount of analytes per 
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1.3.1.1.2. Calibration range 
The ideal assay should have an LLOQ that is lower than the minimal inhibitory 
concentration (MIC) of the likely causative pathogen. The LLOQ of most methods were 
indeed around MIC values for most pathogens (≤0.5 mg/L). Some methods reported a very 
high LLOQ such as 2 or 5 mg/L for meropenem (higher than the MIC breakpoint for the least 
susceptible pathogens such as Pseudomonas aeruginosa), 5 mg/L for flucloxacillin, or 10 
mg/L for piperacillin [167, 168, 174]. Using a method with a high LLOQ may result in many 
trough samples measured as undetectable concentrations potentially leading to unnecessary 
dose adjustments for infections caused by lower MIC pathogens.  
As both very high and low concentration values can be expected when performing TDM 
in ICU patients where such a wide range of organ functions is possible, and turn around time 
is strongly delayed if samples have to be re-analyzed after dilution, it is important that the 
ULOQ is sufficiently high. An ULOQ of 100 mg/L or higher should be preferred, especially for 
piperacillin, for which the most commonly used daily dosage is 12-16 g, resulting in high 
concentrations in a many patients.  However, 6 out of 10 methods that quantified 
piperacillin reported an ULOQ of < 100 mg/L [170, 171, 175, 176, 178, 180]. One method 
reported the highest calibrator to be as low as 5 mg/L, which would not be considered 
convenient for routine TDM [176].  
1.3.1.1.3. Runtime 
The median runtime per sample was 8 minutes (IQR 5.9 - 21.3).  However for routine 
TDM, shorter runtimes are desirable, as a batch with multiple calibrators and quality control 
samples can require a high number of samples to be analyzed consecutively. 
1.3.1.1.4. Sample preparation 
When developing an assay to determine the total concentration in plasma, a range of 
sample preparation procedures can be used, depending on the way the sample is pre-
treated (protein precipitation using organic solvents or using solid phase extraction) and, 
depending on optional evaporation, used to concentrate the sample. Four methods used 
protein denaturation and subsequent dilution of the supernatant [174, 176, 180, 181], only 
one used solid phase extraction and subsequent dilution [170], 2 methods used protein 
denaturation and back-extraction of acetonitrile [168, 169], 2 methods used protein 
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denaturation, evaporation of the supernatant and reconstitution of the residue [173, 179], 
and three methods used solid phase extraction, evaporation of the supernatant and 
reconstitution of the residue [171, 175, 177]. Four assays were found that determined free 
concentrations, all of which used ultrafiltration [167, 172, 178, 179]. 
1.3.1.2. Dried blood spots 
Dried blood spots are a form of biosampling where a drop of blood is collected as a spot 
on a filter paper. It is most commonly used for the screening of metabolic disorders in 
neonates, but is increasingly being used for TDM purposes as well, because of advantages 
including low volume of blood sampling, more convenient transportation, storage without 
special treatment and enhanced analyte stability, which make it very attractive for TDM 
and/or pharmacokinetic studies [209]. 
We found one method which measures ertapenem from dried blood spots for TDM in 
neonates, in whom sampling of larger volumes is not practical and 2 which measured 
piperacillin/tazobactam [184, 195, 210]. However, it must be noted that using this sampling 
strategy, it is not possible to determine free concentrations, which may be a problem for 
highly protein bound drugs like ertapenem (ca. 90% protein bound). Moreover, the drying 
process after sampling takes at least 2 h, and dried blood spots may suffer from issues 
affecting reliability of results including variations in the blood volume spotted, blood spot 
homogeneity, and haematocrit concentrations. Variability in haematocrit (the volume 
percentage of red blood cells in blood) is a widely discussed challenge, which has an 
analytical and a physiological aspect [209]. When a fixed-diameter punch is taken from these 
spots, punches with a high haematocrit will contain a higher blood volume, which results in 
overestimation [209]. Compounds that do not enter erythrocytes will display low blood to 
plasma ratios (the ratio between the concentration of a compound measured in blood and 
the concentration measured in plasma). Hence, the presence of erythrocytes may be seen as 
a dilution of the plasma fraction of whole blood [209], and therefore bridging studies in 
which both dried blood spots and plasma samples are collected in order to evaluate the 
correlation between the concentrations are needed. A bridging study has been performed 
for piperacillin and tazobactam, and found concentrations in dried blood spots to be on 
average 62 and 52 % lower compared to plasma, suggesting that piperacillin and tazobactam 
do not partition into red blood cells. A large range in the dried blood spots to plasma ratios 
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was observed [210]. Moreover, one of the biggest potential advantages of dried blood spots, 
namely stability has been shown to be insufficient to allow for transportation on room 
temperature [195].  These findings may limit its use for TDM purposes.  
1.3.1.3. Other methods to determine -lactam antibiotics in blood 
1.3.1.3.1 Thermal biosensing 
Thermal biosensing detects the heat generated by enzymatic reactions, in this case, 
the reaction of penicillinase with the β-lactam antibiotic [182]. This technique was used by 
Chen and colleagues to determine concentrations of penicillin G, penicillin V and ampicillin in 
whole blood and serum without any sample preparation.  
  Avoidance of sample preparation with this method reduces the turnaround time 
(time to which results are available) drastically and could even allow for point of care testing. 
However, there are issues that need to be resolved first. Chen et al. determined penicillin V, 
G and ampicillin, which are all susceptible to penicillinase, which is a requirement for the 
detection principle of this method. Firstly, it is unclear whether this system would be able to 
monitor meropenem, which is one of the most widely prescribed β-lactam antibiotics, 
developed to be greatly resistant to β-lactamases. Secondly, other frequently used β-lactam 
antibiotics are co-formulated with a β-lactamase inhibitor such as amoxicillin/clavulanic acid, 
piperacillin/tazobactam and ampicillin/sulbactam. Finally, similar to the dried blood spot 
analysis, bridging studies are needed to correlate the concentrations in whole blood to 
plasma concentrations. 
1.3.1.3.2. Spectrofluorimetric determination 
Some β-lactam antibiotics produce fluorescent degradation products. Therefore, the 
amount of light emitted by the degradation product after acid or alkaline degradation 
correlates with the initial concentration of the β-lactam antibiotic. Omar and colleagues 
developed a method to quantify 7 cephalosporins, which used spectrofluorimetric 
determination based on alkaline degradation. This method is inexpensive as long as a 
luminescence spectrometer is available. However, a fairly complicated sample pretreatment 
is needed with strict pH control and therefore it is not readily applicable for routine TDM 
[183].   




An immunoassay measures the concentration of an analyte in a solution using an 
antibody. Such immunoassays are commercially available for aminoglycosides and 
glycopeptides and are widely used for TDM of these compounds. Currently, no 
immunoassays are available for quantification of β-lactam antibiotics in human plasma. 
However, there are multiple assays available for trace analysis of antibiotics in milk and 
other food sources, with very fast analysis times [196-207]. Most of these immunoassays 
only give qualitative results, but some also give quantitative results, however in a 
concentration range which is far too low for TDM purposes, as these tests are designed to 
quantify in the μg/L range (which is necessary to detect antibiotic residues in these dietary 
products) while therapeutic values for these antibiotics in human plasma are 100-1000 times 
higher.  
The advantage of using an immunoassay over the previous described chromatographic 
methods is that the equipment needed to perform an immunoassay is available in all clinical 
laboratories and should be easy to use. However, immunoassays can be troubled by 
interferences and cross-reactivity from similar compounds. Taking into account that patients 
may be switched from one antibiotic to another, the presence of the previous antibiotic may 
be problematic if the immunoassay is not sufficiently specific. Moreover, many different 
immunoassays, each with specific calibrators and controls, should be available in order to 
quantify all the available β-lactam antibiotics 
1.3.1.3.4. Biosensors 
Accurate quantification of small molecules using biosensors is emerging and seems 
very promising.  Important applications of biosensing include glucose measurements in 
diabetic patients, or detecting bacterial DNA using micro-arrays. A biosensor is made out of 3 
parts, firstly a biological sensor, such as an enzyme or a cell, secondly a transducer, which 
transduces the signal to the third part, the physicochemical detector, which for example has 
an increased fluorescence intensity when the ligand is added.   Biosensors have been 
designed for some β-lactams yet they have not been properly validated and compared to a 
reference method [211, 212].  
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1.3.1.4. Free drug concentrations 
Drugs are bound to serum proteins to varying degrees. The bound fraction is in 
equilibrium with the free (unbound) fraction. There is increasing interest in measuring this 
free concentration of antibiotics, given that the free concentration is responsible for 
bacterial killing as well as toxicity.  
The two most relevant drug-binding serum proteins are albumin and α1-acid 
glycoprotein. It is often assumed that measuring free concentrations is only advisable for 
highly bound drugs (≥ 95 % protein binding). Although this may be the case for healthy 
volunteers and general ward patients, many special patient groups (such as the critically ill, 
burn patients, undernourished patients or patients with nephrotic syndrome) frequently 
suffer from hypoalbuminaemia, which may significantly alter protein binding and therefore, 
basic pharmacokinetic parameters of the free antibiotic such as volume of distribution and 
clearance [123, 213].  
Ultrafiltration is a simple method for measuring protein binding: the plasma sample is 
transferred to the upper chamber of a two-piece container separated by a molecular weight 
cutoff filter and when centrifuged separates the free fraction of drug into the lower 
chamber. However, ultrafiltration may be susceptible to non specific drug adsorption to the 
container [214] and to variations in the experimental conditions such as pH, temperature 
and centrifugal force, which has been reported for vancomycin, but also for the β-lactam 
antibiotics cefazolin and ertapenem [215-217]. Kratzer and colleagues report a free fraction 
for ertapenem of about 12.5 % at 4°C, but 20% when centrifuged at 37°C.[216] Briscoe and 
colleagues were the first to report on a method to determine free concentrations of a range 
of β-lactam antibiotics using ultrafiltration.[178] Connor and colleagues report free 
concentrations of piperacillin when centrifuged at 4°C, which may not be the ideal 
temperature to accurately measure free concentrations [185].  
Importantly, there are few comparative data between ultrafiltration and the technique 
that is considered the gold standard, equilibrium dialysis [218]. In equilibrium dialysis, two 
chambers are separated by a semipermeable membrane. These chambers are filled with 
serum/plasma and a buffer, respectively. This method needs a long time for equilibrium to 
be reached, which may pose a problem for some β-lactam antibiotics that are relatively 
unstable. 
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Wong and colleagues have compared the measured free concentration (using 
ultrafiltration) to the free concentration predicted from published protein binding values for 
seven β-lactam antibiotics using blood samples obtained from critically ill patients. 
Significant differences between measured and predicted free drug concentrations were 
found only for highly protein-bound β-lactam antibiotics, such as flucloxacillin (bias of 56.8% 
overprediction) and ceftriaxone (bias of 83.3% overprediction). No correlation between free 
and bound concentrations was found for these antibiotics, therefore direct measurement is 
considered essential for these drugs. For low to moderately protein bound antibiotics (such 
as piperacillin and meropenem), free concentrations appear to be predictable from the total 
concentrations [219]. 
1.3.2  Measuring -lactam antibiotics in alternative matrices 
Measuring β-lactam concentrations in other biological fluids may be beneficial, as these 
fluids may be more closely related to the site of infection. Only methods determining β-
lactam antibiotics in cerebrospinal fluid and ultrafiltrate were found in our review with no 
assays published for TDM in other fluids, such as ascites fluid or epithelial lining fluid.   
1.3.2.1 Cerebrospinal fluid 
Nine articles were found reporting methods that determine β-lactam antibiotics in 
cerebrospinal fluid. Two methods were found for meropenem [186, 187], 3 for cefepime 
[188-190], 2 for ceftazidime [191, 192], 1 for ceftriaxone [193] and 1 for cefotaxime [194]. 
Four out of 9 methods used protein precipitation with acetonitrile as a sample preparation 
[188, 192-194], 4 did not use any sample preparation [187, 189-191] and one used 
ultrafiltration [186]. The detection method was LC–UV in 5 cases [186, 188, 192-194] and 
micellar electrokinetic capillary chromatography in 3 cases [187, 189, 191]. Micellar 
electrokinetic chromatography has the advantage of eliminating the need for sample 
preparation, which is advantageous to improve turn-around-time. However, the migration 
time is quite long (10 minutes) and conditioning between runs is necessary [189-191]. 
1.3.2.2. Renal replacement therapy ultrafiltrate 
Connor et al. investigated the relationship between free plasma concentration of 
piperacillin and tazobactam and the concentration in dialysate in patients treated with 
continuous venovenous dialysis in 50 samples from 19 patients and concluded that dialysate 
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drug concentrations accurately predicted free plasma free drug concentrations (R² = 0.91 for 
piperacillin and 0.92 for tazobactam) [185]. However, the most evident deviation from unity 
was found in the lower-concentration piperacillin data, where dialysate concentrations 
underestimated plasma concentrations by as much as 50%. Therefore, it is unsure whether 
ultrafiltrate may replace plasma as a way to measure free concentrations although targeting 
higher concentrations with this technique may overcome this potential inadequacy.   
1.4 General comments on setting up a method for TDM purposes  
As routine TDM requires frequent runs (preferably once daily), the consequences of an 
extensive sample preparation and long runtimes for the laboratory personnel and on 
equipment occupation are important. Therefore, when developing a method, minimizing 
sample preparation is desirable, while still retaining sufficient assay sensitivity. The ideal 
method should be able to measure both low (around MIC values of most commonly 
causative pathogens), as well as high analyte concentrations without dilution. Moreover, 
turn around time should be kept to a minimum. As with all bioanalytical methods, the 
method should be thoroughly validated before it is used in clinical routine. Validation should 
include assessment of precision and accuracy, linearity, stability, interferences and matrix 
effect (in cases where mass spectrometry is used as the mechanism of detection). If one of 
the analytes is a β-lactam which is co-administered with a β-lactamase inhibitor (such as 
piperacillin/tazobactam or amoxicillin/clavulanic acid), it should be made sure that the β-
lactamase inhibitor does not interfere. It is unclear whether or not the β-lactamase inhibitor 
should also be quantified during TDM, as there is currently no pre-defined target for the β-
lactamase inhibitors and it is the βlactam antibiotic that is responsible for the antibacterial 
effect. 
 The developed assay should include all commonly used antibiotics, both small as well 
as broad spectrum agents, as only applying TDM for the broad spectrum antibiotics such as 
piperacillin and meropenem might lead to unnecessary switch from smaller spectrum 
antibiotics to these broad spectrum drugs while the reason for therapeutic failure might 
have been the altered pharmacokinetics of the smaller spectrum antibiotics, and a dose 
increase might have been enough to ensure optimal efficacy and therefore TDM of smaller 
spectrum drugs may potentially even spare the broad spectrum and more potent antibiotics. 
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If highly protein bound antibiotics are to be measured, free concentrations are preferred 
over total concentrations.  
Pre-analytical stability must be guaranteed, as β-lactam antibiotics are generally 
considered to be quite unstable. However, this limited stability should not confound 
monitoring as these compounds are still stable for an adequate amount of time. The hospital 
staff must be aware that stability is limited, and therefore samples should be sent to the lab 
as soon as the sample is taken, and the isolated plasma should be immediately frozen in the 
lab.  
1.5 Future directions 
The best of all cases would be a bedside sample collection device that requires only a 
small volume of whole blood but immobilizes the proteinaceous and cellular component of 
the specimen to isolate the free fraction, thus yielding a sample requiring minimal 
preparation and providing maximal pharmacokinetic information; unfortunately, no such 
device is currently available. 
Presently, TDM of β-lactam antibiotics requires the use of relatively expensive 
chromatographic techniques. As not all hospitals have this equipment available, easy 
transportation of the samples to a reference laboratory without the need for costly 
measures to prevent degradation would be most convenient. Therefore, more research into 
the utility of dried blood spots would be useful. Recently, two other promising sampling 
devices have been described. The first is the volumetric absorptive microsampler, which 
consists of a polymeric tip and is designed to absorb a fixed volume of blood independent of 
haematocrit [220]. The second device is a paper collection disk bearing plasma from a 
fingertip drop of blood that can be air dried in fifteen minutes and transported to the lab in a 
mailing envelope [221].  
The cost of personnel to run chromatographic assays is also likely to be higher per 
sample than for the immunoassays used to measure aminoglycosides and glycopeptides. 
Therefore, another logical step would be to develop an easy to use assay that does not 
require expensive equipment or highly trained personnel. Immunoassays are available for 
the analysis of β-lactam antibiotics in food products, so technically it should be possible, as 
milk is an equally complex matrix as plasma. Therefore, more research in this field is also 
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recommended. Liquid chromatography coupled to tandem mass spectrometric detection is a 
very powerful tool, and has many advantages, such as enhanced specificity and the ability to 
simultaneously measure multiple analytes in highly complex biological matrices, but the 
adoption for clinical use has been limited because of instrument cost, expertise, training, 
quality assurance and standardization [222]. However progress is now being made in these 
areas with new instruments that allow analysis to be performed by general medical analysts, 
and the development of more user-friendly workstations with simplified sample preparation 
procedures. Finally, the commercial availability of reagent kits eliminates method 
development [222].   
Last but not least, measuring free concentrations is an area that is in constant 
development. More research is needed about how to rapidly determine free concentrations 
to provide more accurate data.  
1.6 Conclusion 
Several methods have been developed and validated for TDM of β-lactam antibiotics. As 
quantification of these antibiotics is presently limited to in-house methods, most of the 
published methods use chromatographic separation coupled to UV or MS detection. There is 
currently no immunoassay available for TDM of β-lactam antibiotics.  
Although many publications state the method under study is fit for TDM, some may not 
be considered highly practical because of intensive sample preparation and/or long assay 
run times. In order to develop a method for routine TDM, rapid sample preparation, short 
turn around time, low limit of quantification and sufficiently high upper limit of 
quantification are vital. The antibiotics that require monitoring are dependent on the 
hospital usage. Indeed, most of the published assays monitored meropenem and piperacillin 
because they are widely used at many institutions.  
There is a growing interest in measuring concentrations in other matrices, such as 
cerebrospinal fluid, as well as measuring free concentrations. Ideally, a sample would be 
taken at bedside using a collection device that requires only a small volume of blood and can 
isolate the free fraction, which would yield a sample that requires minimal sample 
preparation and would be able to provide maximal pharmacokinetic information, 
unfortunately, no such device is currently available. 
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2. Developed analytical methods  
2.1. Quantification of seven -lactam antibiotics and two -lactamase inhibitors in 
human plasma using a validated UPLC-MS/MS method 
Authors : Mieke Carlier,  Veronique Stove, Jason A. Roberts , Eric Van de Velde, Jan J. De 
Waele, Alain G. Verstraete 
Article history : Received 3 April 2012, Accepted 30 June 2012 
Reference : International Journal of Antimicrobial Agents 40 (2012) 416–422 
Abstract 
There is an increasing interest in monitoring plasma concentrations of β-lactam antibiotics. 
The objective of this work was to develop and validate a rapid ultra-performance liquid 
chromatographic method with tandem mass spectrometric detection (UPLC-MS/MS) for 
simultaneous quantification of amoxicillin, ampicillin, cefuroxime, cefazolin, ceftazidime, 
meropenem, piperacillin, clavulanic acid and tazobactam. Sample clean-up included protein 
precipitation with acetonitrile and back-extraction of acetonitrile with dichloromethane. Six 
deuterated β-lactam antibiotics were used as internal standards. Chromatographic 
separation was performed on a Waters Acquity UPLC system using a BEH C18 column (1.7 
μm, 100 x 2.1 mm) applying a binary gradient elution of water and acetonitrile both 
containing 0.1 % formic acid. The total runtime was 5.5 minutes. The developed method was 
fully validated in terms of precision, accuracy, linearity, matrix effect and recovery. The assay 
has now been successfully used to determine concentrations of amoxicillin/clavulanic acid, 
cefuroxime and meropenem in plasma samples from intensive care patients. 










Infections are an extremely important problem in critical care medicine. Sepsis alone is 
the leading cause of mortality in non-cardiac intensive care units [1]. Adequate antibiotic 
therapy is one of the mainstays in the treatment, with the emphasis on timely 
administration and appropriateness of the spectrum [24]. The β-lactam antibiotics are 
central to the treatment of sepsis and life-threatening infections in the intensive care units. 
They are generally considered as time-dependent antibiotics, which means they exert 
optimal bactericidal effect when drug concentrations at the site of infection are maintained 
above the minimum inhibitory concentration (MIC) [40].  
Although timely administration and appropriateness of spectrum are important, 
antibiotic dosing is also highly likely to affect clinical efficacy [39]. Recent data demonstrate 
that the concentration of antibiotics in plasma and at the site of infection is highly variable 
and that standard doses of antibiotics lead to underdosing in a considerable number of 
patients [39, 93]. This is most commonly caused by pharmacokinetic changes in volume of 
distribution and increased clearance compared to non-critically ill patients and may result in 
decreased efficacy. On the other hand, overdosing is also possible, leading to toxicity 
without increased efficacy [39]. This wide spectrum of pharmacokinetics makes empiric 
dosing choices highly challenging and likely to result in sub-optimal antibiotic exposures or 
toxicity. 
Based on these considerations, monitoring antibiotic concentrations and subsequent 
dose-adaptation might offer a solution to maximize efficacy and minimize toxicity, especially 
in patients with considerable pharmacokinetic variability, such as intensive care patients 
[223, 224]. 
As current research is primarily focused on the study of broad-spectrum antibiotics, the 
pharmacokinetic study of narrower-spectrum β-lactams has received little attention. Patient-
tailored antibiotic therapy may allow reliable use of the full spectrum of antibiotics available, 
including narrow-spectrum antibiotics that are only rarely used in most intensive care units. 
If these antibiotics can be adequately monitored, physicians may be more confident to 
prescribe them in severe infections. With this in mind, we believe a method capable of the 
simultaneous quantification of both narrow- and broad-spectrum antibiotics is required. At 
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this time, the concentration-effect relationship for the β-lactamase inhibitors is poorly 
described. We decided to incorporate these compounds in this method because if this assay 
were to be used for therapeutic drug monitoring, patients could perhaps reach toxic levels of 
these compounds when increasing the penicillin compound in co-formulations. Whilst HPLC 
methodology for individual analytes and some combinations exists in the literature, no 
published method is available that simultaneously quantifies the nine drugs we are 
interested in.  
The objective of this report is to describe a newly developed UPLC-MS/MS-analysis for 
determination of drugs most frequently used in Ghent University hospital : three penicillins 
(amoxicillin, ampicillin and piperacillin), one carbapenem (meropenem), three 
cephalosporins (cefuroxime, ceftazidime and cefazolin) and two β-lactamase inhibitors 
(clavulanic acid and tazobactam). 
2.1.2. Materials and methods 
Chemicals and reagents 
High purity powder of piperacillin, amoxicillin, ampicillin, ceftazidime, cefuroxime, 
tazobactam, clavulanic acid and bovine serum were purchased from Sigma-Aldrich (Bornem, 
Belgium), meropenem and cefazolin from Molekula (München, Germany). D5-piperacillin and 
D6- ceftazidime were bought from Alsachim (Strassbourg, France). D4-amoxicillin, D5-
ampicillin, D6-meropenem and D3-cefuroxime were obtained from Toronto Research 
Chemicals (Ontario, Canada). Sodium dihydrogen orthophosphate and potassium 
orthophosphoric acid were analytical grade, acetonitrile was LC-MS grade, dichloromethane 
was HPLC grade. Pure water (CLSI type I), provided by a purification system (Elga LabWater, 
Analis, Namur, Belgium), was used throughout the study. Blank plasma was obtained from 
healthy volunteers. 
Instruments 
The UPLC-MS/MS system consisted of a Waters Acquity UPLC instrument coupled to a 
TQD triple-quadrupole mass spectrometer (Waters Corp., Milford, MA). Separations were 
performed on an Acquity UPLC BEH C18 column (100 mm x 2.1 mm) with a 1.7 μm particle 
size equipped with a 0.2 μm precolumn filter unit and a guard column (Waters Corp., 
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Milford, MA). Analytes were measured in the multiple reaction monitoring (MRM) mode. 
The flow rate was set at 0.4 mL/min. The column and autosampler tray temperature were 
set at 50°C and 4 °C respectively. Ten μL of the extract was injected into the column. The 
MS/MS instrument was operated with a capillary voltage of 1.00 kV, a source temperature of 
140°C and desolvation gas (nitrogen) at 400°C with a flow of 800 L/h. The interchannel delay 
was 20 ms. Parent and daughter ions, cone voltage and collision energy were optimized by 
automatic infusion of 1 mg/L in a mixture of 50/50 water/acetonitrile containing 0.1% formic 
acid, except for clavulanic acid and tazobactam, for which a higher (10 mg/L) concentration 
was needed. Most analytes were measured in ESI+ mode, only clavulanic acid, tazobactam 
and cefuroxime gave better signal in ESI- mode. Dwell times were adjusted individually to 
obtain an optimal amount of data points to describe the peak. For quantification of 
amoxicillin, meropenem, ceftazidime, ampicillin, cefuroxime and piperacillin, their 
deuterated analogue was used as internal standard. D4-amoxicillin was used as internal 
standard for clavulanic acid and tazobactam, D5-ampicillin was used for cefazolin. For each 
compound two transitions were followed. One transition was used for quantification (the 
quantifier), the other transition was monitored for identification (the qualifier). The 
proportion of these two peak areas is a fixed value which is used for identification. This 
should not deviate by more than 20 % from the fixed value. The optimized MRM, ratio of the 
peak areas for both transitions, cone voltage, collision energy and dwell time are listed in 
table 1. Because of the large number of mass transitions being followed, a separate channel 
was created for each compound. Breaking up the section into different channels which are 
all being measured for a specific amount of time allows more scans per analyte. The 
different channels and the time during which they are being measured is shown in figure 1. 
Data were acquired using Masslynx 4.1 software and processed using Quanlynx 4.1 software 
(Waters Corp., Milford, MA).  
Chromatographic conditions 
The mobile phase consisted of a mixture of solution A (0.1 % formic acid in water) and 
solution B (0.1 % formic acid in acetonitrile) with an initial composition of 5% solution B. The 
mobile phase composition changed linearly from 5 % B at 0.5 min to 55 % at 4.0 min, after 
which the column was rinsed with 95 % B for 0.5 min and re-equilibrated to starting 
conditions for one minute.  
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D4-amoxicillin 370.22 113.90 20 19 0.050 + 














D6-meropenem 390.22 147.00 34 18 0.021 + 







D6 -ceftazidime 553.28 167.00 28 23 0.020 + 







D5 -ampicillin 355.22 111.00 26 18 0.020 + 
Cefazolin 455.16 155.90 20 16 0.030 + 









D3 -cefuroxime 426.09 210.00 20 20 0.030 - 







D5 -piperacillin 523.28 148.10 24 20 0.030 + 
CV, cone voltage; CE, collision energy ; ESI, electron spray ionisation 




Fig. 1 Use of separate channels for all compounds measured during a specific amount of 
time increases the amount of scans per analyte 
Preparation of standards and quality controls 
Calibrators were prepared in 0.066 M aqueous phosphate buffer pH 6, as described by 
Reyns [225]. Briefly, a stock solution was prepared by weighing 10 mg of each compound 
was and dissolving these compounds altogether in 100.0 ml phosphate buffer. Aliquots were 
stored in microfuge tubes at -80°C. The calibrators were prepared freshly from the stock 
solution with the same buffer. 
Quality controls were also prepared in aqueous phosphate buffer. The highest quality 
control (QCH) was prepared by weighing 8 mg of each compound and dissolving these 
compounds altogether in 100.0 ml phosphate buffer. Aliquots were stored in microfuge 
tubes at -80°C. The medium and low concentration quality controls were prepared by 
diluting QCH with phosphate buffer and were also stored at -80°C. 
Stock solutions of the deuterated internal standards were prepared by diluting 1 mg of 
each internal standard in 10 ml of the appropriate solvent (methanol or water according to 
the certificate of analysis) and were stored at -80°C. A working solution in methanol was 
made by adding equal amounts of the stock solution in methanol, and similarly a working 
solution in water was prepared. These working solutions were also stored at -80°C. Before 
analysis, these two working solutions were added together and diluted with water to obtain 
a concentration of 11 mg/L of each internal standard.  
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Sample preparation  
To 20 μl calibrator or quality control in phosphate buffer, 15 μL internal standard and 20 
μL of bovine serum was added in a microfuge tube. Similarly, to 20 μL of sample, 15 μL of 
internal standard and 20 μL of phosphate buffer was added. The tubes were pulse-
centrifuged to collect the mixture at the bottom of the tube and were then vortexed using a 
vortex-mixer for 3 minutes at maximum intensity (1400 rounds per minute) at 4°C. 100 μL of 
acetonitrile was added to precipitate proteins and the microfuge tube vortex-mixed for 3 
minutes at 1400 rounds per minute at 4°C. Precipitated proteins were separated by 
centrifugation for 5 minutes at 16 000 g. Hundred μl of the supernatant was transferred into 
another microfuge tube containing 100 μL of water which was automatically vortex-mixed 
for 3 minutes at 1400 rounds per minute after which 100 μL of dichloromethane was added. 
The microfuge tube was vortex-mixed for 3 minutes at 1400 rpm to partition the acetonitrile 
and lipid-soluble plasma components into the dichloromethane organic phase, and 
centrifuged at 16 000 g for 2 minutes to separate the layers. An aliquot (100 μL) of the upper 
aqueous phase was transferred to an autosampler vial for chromatographic analysis, and 10 
μL was injected into the chromatographic system.  
Method validation 
Specificity and selectivity 
Selectivity was demonstrated by analyzing plasma samples from ten different healthy 
volunteers and from 25 intensive care patients not receiving any of the studied compounds. 
The absence of interference of the internal standards was checked by analyzing zero 
samples, which are blank bovine serum samples spiked with the internal standards. Similarly, 
blank samples of bovine serum each spiked with the compounds at their highest expectable 
concentration (without the internal standard) were used to check for absence of 
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Matrix effect and extraction recovery 
Matrix effect was assessed as described by Matuszewski et al [226]. This involved 
determination of the peak areas of the analytes in three different sets of samples: one 
prepared in blank matrix spiked before extraction (set A), one prepared in blank matrix 
extract and spiked after extraction (set B), and one in neat mobile phase (set C). The matrix 
effect was then calculated as a percentage of the response of set B in relation to set C 
samples. The extraction recovery was determined by the response of set B in relation to set 
A. These experiments were performed using five different sources of blank matrix from 
healthy human volunteers at two concentrations.  
Linearity  
The choice of an appropriate calibration model is necessary for reliable quantification. 
For this experiment, six calibration samples at nine concentration levels were analyzed. The 
data were tested for homoscedasticity. When the assumption of homoscedasticity was not 
met, which was the case for all analytes, a weighting factor was applied. In order to find the 
appropriate weighting factor and calibration model, the sum of the relative errors for 
different weighting factors and regression models was calculated. The method that gave the 
smallest sum of the relative errors was chosen the most appropriate calibration model [227].  
Accuracy and precision 
Accuracy is used to describe the systematic error in the sense of bias, precision is the 
closeness of agreement between a series of measurements [228]. Accuracy and precision 
were determined from the analysis of quality control samples at three concentration levels 
analyzed in duplicate during eight days. The recommended value for precision and accuracy 
is ± 15 %, except for the lower limit of quantification (LLOQ), for which a limit of ± 20 % is 
acceptable[229]. Accuracy was calculated as the percent difference between the mean of 
the analyzed quality control sample and the true value. The lower limit of quantification 
(LLOQ) was also determined from the analysis of spiked samples at a low concentration (0.5 
mg/L, 0.75 mg/L and 1 mg/L). The total precision was calculated using one-way ANOVA with 
the varied factor (day) as grouping variable as described by Peters [230].  
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To assess whether bovine serum can be used to correct the matrix of the quality controls 
which are prepared in phosphate buffer the following experiment was conducted : thirty QC 
samples were assessed using bovine serum to correct the matrix, and thirty QC samples 
were assessed in the same run using human plasma from five healthy volunteers to correct 
the matrix. These two groups were compared using a paired t-test.  
Application to biological samples 
The present method was successfully applied to construct time-concentration profiles of 
amoxicillin/clavulanic acid, cefuroxime and meropenem in plasma samples obtained from 
intensive care patients. This study was carried out according to the principles of the 
Declaration of Helsinki and was approved by the local Ethics Committee. Written informed 
consent according to local practice was obtained for every patient. Amoxicillin/clavulanic 
acid and cefuroxime were administered as an intermittent infusion over 30 minutes, 
meropenem as an extended infusion over 180 minutes. Blood samples were collected into 
heparinized plasma sampling tubes at different time intervals. These samples were 
centrifuged promptly after sampling, sent to the lab on ice and frozen at -80°C until analysis 
2.1.3. Results 
Chromatography 
The total run time was 5.5 minutes. Fig. 2 shows representative MRM chromatograms 
for all analytes obtained from human serum spiked with the seven β-lactam antibiotics and 
two β-lactamase inhibitors.  
Specificity and selectivity 
Nor the blank plasma from healthy volunteers or intensive care patients who did not 
receive any of the studied compounds, nor the zero samples were associated with any 
detectable interference. The blank samples of bovine serum that were spiked with the 
compounds at their highest expected concentrations also showed no interference of the 
analyte with the internal standard or with other (co-eluting) compounds.  
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Recovery and matrix effect 
Mean absolute recovery (AR) for all compounds (determined on 5 sources of different 
blank plasma from healthy volunteers spiked at two concentrations) ranged from 60 to 72 %, 
with a maximum relative standard deviation (RSD) less than 15 %. For all compounds, ion 
enhancement was observed. The mean matrix effect ranged from 105 % to 135 % with a 
maximum RSD of less than 15 %. Table 2 summarizes the data for absolute recovery and 
matrix effects for the nine compounds.  
Linearity  
All compounds could be quantified between 0.5 mg/L and 100 mg/L, except for 
piperacillin, which was quantified between 1.5 mg/L and 100 mg/L. Because of the wide 
calibration range, a weighting factor was found to be necessary.  
Amoxicillin and ceftazidime gave best results using linear regression and a weighting 
factor 1/x². For meropenem, cefazolin, cefuroxime, clavulanic acid and tazobactam, 
quadratic regression and weighting factor 1/x provided optimal results. The best calibration 
model for piperacillin was found to be quadratic using weighting factor 1/x².  
Table 2 
Absolute recovery (AR) and matrix effect (ME) for the analyzed compounds in order of 
retention time 
Compound AR (%) RSD (%) ME (%) RSD (%) 
clavulanic acid 68.1 14.6 117.0 9.8 
amoxicillin 61.2 11.3 131.4 11.3 
tazobactam 71.5 9.2 108.9 7.8 
ceftazidime 67.3 8.5 128.5 12.2 
meropenem 59.9 13.1 125.0 5.6 
ampicillin 65.9 6.0 114.8 7.9 
cefazolin 66.8 10.6 115.7 6.9 
cefuroxime 69.4 9.1 104.1 12.2 
piperacillin 67.2 9.7 136.2 14.7 




















Fig. 2 MRM chromatograms and retention times for a mixture of the compounds at a 
concentration of 10 mg/mL spiked to blank plasma. 
Accuracy, precision and limit of quantification 
Data on total precision are summarized in Table 3. The LLOQ of each compound was 0.5 
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level, and from 3 to 15 % at higher levels. Mean accuracy values ranged from 89.9 to 101.5 
%.  
There was no difference between the QC samples corrected with bovine serum and the 
QC samples corrected with human plasma (p > 0.05 for all nine compounds at 3 different 
concentrations). 
Application to biological samples 
The results are shown in figures 3 to 6. Fig. 3 shows plasma concentrations of 
meropenem from a patient with acute kidney injury. As β-lactam antibiotics are principally 
eliminated by the kidneys, this explains the high concentration reached in this patient. Figure 
4, 5 and 6 clearly state the pharmacokinetic variability in intensive care patients.  
  
Fig. 3 Time-concentration profile of 1 g meropenem administered as an extended infusion 
over a period of 240 minutes (n=1) 
 
Fig. 4 Time-concentration profile of 1 g amoxicillin administered as an intermittent infusion 















































Fig. 5 Time-concentration profile of 1 g cefuroxime administered as an intermittent infusion 
over a period of 30 minutes (n=1). 
 
Fig. 6 Time-concentration profile of 0.2 g clavulanic acid administered as an intermittent 
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2.1.4. Discussion  
Monitoring the concentrations of β-lactam antibiotics in plasma might be a useful tool for 
optimizing the treatment of patients, especially those with altered pharmacokinetics, such as 
critically ill patients. To enable maximal use of the full antibiotic spectrum, monitoring of 
narrow-spectrum antibiotics is likely to be valuable.  
In this study, we validated an UPLC-MS/MS method for the simultaneous quantification of 
seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma. We used 
gradient elution, which gave optimal separation within minimal time limits. Because of their 
hydrophilic behavior, clavulanic acid, amoxicillin and tazobactam show minimal retention on 
conventional reversed-phase C18 columns. The peak shape of these compounds could be 
improved by starting at a very low percentage of solution B and steeply increasing this 
percentage. However, this approach was not further used as all nine compounds eluted at 
the same time (data not shown). Other gradient curve types or other percentages did not 
solve this problem. No problems have been encountered during validation due to the 
biphasic peak shape of clavulanic acid, amoxicillin and tazobactam. Full separation of the 
nine compounds was not possible: amoxicillin and tazobactam both elute at the same time, 
the same applies for meropenem and ceftazidime. As tested in the selectivity experiments, 
this did not cause any problems because of the high selectivity of the detector. The method 
has been shown to be accurate and precise, as acceptance criteria were met for all 
compounds (accuracy between 85-115 %, precision within 15 %). 
The major advantage of our method is its speed of analysis (5.5 minutes per sample), 
which is considerably faster than other methods for multiple analytes previously reported 
[168, 171, 174, 175, 179, 231-234]. This allows high sample throughput and enables fast 
reporting of the results if this method were to be used for therapeutic drug monitoring. 
Moreover, our sensitivity was significantly better than reported by other methods [168, 171, 
174]. Our limit of quantification was 0.5 mg/L for all components, except for piperacillin (1.5 
mg/L). Sufficient sensitivity could be useful, as for many bacteria the MIC is than 1 mg/L 
[235]. An additional advantage of our method is its low sample volume as it requires only 20 
μL plasma. We have also confirmed the clinical suitability of this method and have applied it 
to the analysis of plasma samples obtained from patients. A potential drawback of this assay 
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is the fact that it only measures total antibiotic concentrations, although the unbound 
concentration is pharmacologically active. Determining the unbound concentration can be 
done using ultracentrifugation for patients where this information is deemed essential.  
Chapter 4 : Analytical Methods
 
 
2.2  Ultrafast quantification of -lactam antibiotics in human plasma using UPLC-MS/MS 
Authors : Mieke Carlier, Veronique Stove, Jan J. De Waele, Alain G. Verstraete 
Article history : Received 1 September 2014, Accepted 29 November 2014, Available online 
8 December 2014  
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Abstract 
There is an increasing interest in monitoring plasma concentrations of β-lactam antibiotics. 
The objective of this work was to develop and validate a fast ultra-performance liquid 
chromatographic method with tandem mass spectrometric detection (UPLC-MS/MS) for 
simultaneous quantification of amoxicillin, cefuroxime, ceftazidime, meropenem and 
piperacillin with minimal turn around time. Sample clean-up included protein precipitation 
with acetonitrile containing 5 deuterated internal standards, and subsequent dilution of the 
supernatant with water after centrifugation. Runtime was only 2.5 minutes. 
Chromatographic separation was performed on a Waters Acquity UPLC system using a BEH 
C18 column (1.7 μm, 100 x 2.1 mm) applying a binary gradient elution of water and methanol 
both containing 0.1 % formic acid and 2 mmol/L ammonium acetate on a Water TQD 
instrument in MRM mode. All compounds were detected in electrospray positive ion mode 
and could be quantified between 1 and 100 mg/L for amoxicillin and cefuroxime, between 
0.5 and 80 mg/L for meropenem and ceftazidime, and between 1 and 150 mg/L for 
piperacillin. The method was validated in terms of precision, accuracy, linearity, matrix effect 












There is a growing interest in monitoring plasma concentrations of β-lactam antibiotics, 
as concentrations are variable in critically ill patients with both very low and high 
concentrations occurring [236]. Low concentrations are most commonly caused by changes 
in volume of distribution and increased clearance compared to non-critically ill patients 
which may result in decreased efficacy [39]. On the other hand, overdosing is also possible in 
the presence of organ dysfunction such as acute kidney injury, leading to toxicity without 
increased efficacy [39]. Because of the wide spectrum of pathophysiological changes in 
critically ill patients, antibiotic concentrations are very difficult to predict. Furthermore, 
recent data suggest that there is a relationship between serum concentrations of β-lactams 
and clinical outcomes in the critically ill [49]. Based on these considerations, therapeutic 
drug monitoring (TDM) of antibiotic concentrations and subsequent dose-adaptations might 
offer a solution to maximize efficacy and minimize toxicity.  
TDM of β-lactam antibiotics requires an assay method with a short turn around time in 
order to allow a quick dose adaptation. However, unlike TDM of aminoglycosides and 
glycopeptides, for which immunoassays have been developed and are commercially 
available, quantification of -lactam antibiotics are generally limited to in-house developed 
methods using liquid chromatography coupled to ultraviolet detection or liquid 
chromatography coupled to mass spectrometric detection. Most methods use extensive 
sample clean up and have fairly long run times [168, 169, 171, 173, 237]. Although some of 
them state they are fit for daily TDM, the extensive sample preparation and fairly long 
runtime do not make them an ideal method, unless an instrument is dedicated to only this 
assay.  
The objective of this report is to describe a newly developed ultra performance liquid 
chromatographic tandem mass spectrometric (UPLC-MS/MS) analysis which has been 
optimized to ensure minimal turn around time for the determination of 5 frequently used β-
lactam antibiotics: two penicillins (amoxicillin and piperacillin), one carbapenem 
(meropenem), two cephalosporins (cefuroxime and ceftazidime). 
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2.2.2 Materials and methods 
Chemicals and reagents 
High purity powder of piperacillin, amoxicillin, ceftazidime, cefuroxime, meropenem and 
bovine serum were purchased from Sigma-Aldrich (Bornem, Belgium). The deuterated 
standards D5-piperacillin, D4-amoxicillin, D6-meropenem, D5-ceftazidime and D3-cefuroxime 
were obtained from Toronto Research Chemicals (Ontario, Canada). Pure water (Clinical 
Laboratory Reagent Water standard), provided by a purification system (Elga LabWater, 
Analis, Namur, Belgium), was used throughout the study. Blank plasma was obtained from 
healthy volunteers. 
Instruments 
The UPLC-MS/MS system consisted of a Waters Acquity UPLC instrument coupled to a 
TQD triple-quadrupole mass spectrometer (Waters Corp., Milford, MA). Separations were 
performed on an Acquity UPLC BEH C18 column (100 mm x 2.1 mm) with a 1.7 μm particle 
size equipped with a 0.2 μm precolumn filter unit and a guard column (Waters Corp., 
Milford, MA). Analytes were measured in the multiple reaction monitoring (MRM) mode. 
The flow rate was set at 0.4 mL/min. The column and autosampler tray temperature were 
set at 50°C and 4 °C respectively. Forty μL of the extract was injected into the column. The 
MS/MS instrument was operated with a capillary voltage of 1.00 kV, a source temperature of 
140°C and desolvation gas (nitrogen) at 400°C with a flow of 800 L/h. Parent and daughter 
ions, cone voltage and collision energy were optimized by infusion of 1 mg/L in a mixture of 
50/50 water/methanol containing 0.1% formic acid and 2 mM ammonium acetate. All 
analytes were measured in the electrospray positive (ESI+) mode. For each of the antibiotics, 
a deuterated analogue was used as internal standard. The optimized MRM, cone voltage, 
collision energy and dwell time are listed in table 1. Data were acquired using Masslynx 4.1 
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Table 1. Acquisition parameters used in the UPLC-MS/MS method on the Waters TQD 
detector 




CV (V) CE 
(eV) 
Dwell time (s) 
Amoxicillin 366.1 114.0 18 20 0.150 
D4-amoxicillin 370.2 114.0 16 20 0.150 
Meropenem  384.2 141.2 26 15 0.045 
D6-meropenem 390.2 147.0 26 15 0.045 
Ceftazidime  547.1 468.0 20 12 0.045 
D5-ceftazidime 552.0 468.0 24 12 0.045 
Cefuroxime 442.2 364.1 20 10 0.045 
D3-cefuroxime 445.1 367.1 18 9 0.045 
Piperacillin  518.2 143.1 32 17 0.045 
D5-piperacillin 523.3 148.1 32 17 0.045 
CV, cone voltage; CE, collision energy  
Chromatographic conditions 
The mobile phase consisted of a mixture of solution A (0.1 % formic acid and 2 mM 
ammonium acetate in water) and solution B (0.1 % formic acid and 2mM ammonium acetate 
in methanol) with an initial composition of 2% solution B. The mobile phase composition 
changed from 2 % B at 0.4 min to 98 % at 0.5 min, after which the column was rinsed with 98 
% B for one minute and re-equilibrated to starting conditions for another minute. Total 
runtime was 2.5 minutes. 
Preparation of standards and quality controls 
Calibrators were prepared in bovine serum. A stock solution was prepared by 
weighing 10-20 mg of each compound and dissolving these compounds altogether in 10.0 
mL water, which was then diluted 10 times in bovine serum to prepare the highest 
calibrator. The other calibrators were prepared by diluting the highest calibrator with bovine 
serum. Aliquots were stored in microfuge tubes at -80°C.  
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Quality controls were also prepared in bovine serum. A stock solution was prepared by 
weighing 8-18 mg of each compound and dissolving these compounds altogether in 10.0 mL 
water, which was then diluted 10 times in bovine serum to prepare the highest quality 
control. Aliquots were stored in microfuge tubes at -80°C. The medium and low 
concentration quality controls were prepared by diluting QCH with bovine serum and were 
also stored at -80°C. 
Stock solutions of the deuterated internal standards were prepared by diluting 1 mg of 
each internal standard in 10 ml of the appropriate solvent (methanol or water according to 
the certificate of analysis). Aliquots were stored at -80°C. A working solution was prepared 
freshly for each analysis by adding 35 μL of each stock solution to 1325 μL acetonitrile. 
Sample preparation 
To 15 μL calibrator, quality control or patient sample, 100 μL internal standard working 
solution was added in a microfuge tube. The tubes were vortexed using a vortex-mixer 
(Eppendorf, Hamburg, Germany) for 3 minutes at maximum intensity (1400 rounds per 
minute). Precipitated proteins were separated by centrifugation for 5 minutes at 16 000 g. 
Hundred μL of the supernatant was transferred into an autosampler vial which contained 
400 μL of water, which were then vortexed using a vortex-mixer for 3 minutes at maximum 
intensity, after which they were ready for chromatographic analysis. Forty μL was injected 
into the chromatographic system.  
Method validation 
Specificity and selectivity 
Selectivity was demonstrated by analyzing plasma samples from ten different healthy 
volunteers and from 10 intensive care patients not receiving any of the studied compounds. 
The absence of interference of the internal standards was checked by analyzing zero 
samples, which are blank bovine serum samples spiked with the internal standards. Similarly, 
blank samples of bovine serum each spiked with the compounds at their highest expectable 
concentration (without the internal standard) were used to check for absence of 
interference of the analyte with the internal standard.  
Matrix effect and extraction recovery 
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Matrix effect was assessed as described by Matuszewski et al [226]. This involved 
determination of the peak areas of the analytes in three different sets of samples: one 
prepared in blank matrix spiked before extraction (set A), one prepared in blank matrix 
extract and spiked after extraction (set B), and one in neat mobile phase (set C). The matrix 
effect was then calculated as a percentage of the response of set B in relation to set C 
samples. The extraction recovery was determined by the response of set B in relation to set 
A. These experiments were performed using four different sources of blank matrix from 
healthy human volunteers, and 1 source from bovine serum (analyzed four times) at a low 
(between 1.5 and 4 mg/L depending on the compound) and high (between 80 and 150 mg/L 
depending on the compound) concentration. 
Linearity  
For this experiment, six calibration samples at six concentration levels were analyzed. In 
order to find the appropriate weighting factor and calibration model, the sum of the relative 
errors for different weighting factors and regression models was calculated. The method 
that gave the smallest sum of the relative errors was chosen the most appropriate 
calibration model [227].  
 Accuracy and precision 
Accuracy and precision were determined from the analysis of quality control samples at 
4 concentration levels (lower limit of quantification (LLOQ), low quality control (QC), medium 
QC and high QC). Within-run accuracy and precision were determined by analysis of 5 
replicates in a single run for each concentration level. For assessment of the between-run 
accuracy and precision, 1 measurement of 4 samples at different concentration levels was 
performed over 8 different days. In order to pass validation, the mean concentration should 
be within 15 % of the nominal value (except for the LLOQ where 20 % is tolerated) for both 
within- as well as between run accuracy [229]. The coefficient of variation (CV) for both 
within- as well as between-run precision should not exceed 15 % (except for the LLOQ where 
20 % is tolerated) [229]. 
Carryover 
Carryover was assessed according to EMA guidelines by injection of a blank sample 
after the highest standard. The peak area of the analyte in the blank sample must be less 
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than 20% of the peak area of the LLOQ of the analyte and less than 5% of the peak of the 
internal standard [229]. This experiment was performed in triplicate. 
Stability 
 Stability of the internal standard working solution 
Stability of the internal standard working solution was assessed by comparing the 
response of the calibrators injected directly after sample preparation and the response of a 
new calibrator set extracted with an internal standard working solution which had been 
stored for 15 h at 4°C. The internal standard working solution was considered stable if there 
was no significant difference using the related samples Wilcoxon signed rank test for each of 
the antibiotics.  
Autosampler stability of the extracts 
The stability of plasma-extracts was evaluated by repeated injection after 15 h in the 
autosampler at 4°C using blank plasma from 5 different volunteers spiked at 3 
concentrations (low, medium, high). The extracts were considered stable if the confidence 
interval for the mean degradation did not include -10%. 
Freeze thaw stability 
The influence of freeze thaw cycles was investigated by analyzing plasma, taken from 5 
different volunteers, and spiked at 3 concentrations (low, medium, high) after 0, 1, 2 or 3 
freeze thaw cycles. One freeze thaw cycle consisted of thawing the 80 μL sample 15 min at 
room temperature, after which it was transferred to -80°C for one hour. The concentrations 
were compared for each concentration level using an analysis of variance (ANOVA) test, a p 
value ≤0.05 was considered significant. The samples with a p value >0.05 where considered 
stable. For the samples with a p value ≤ 0.05 , the percentage degradation was calculated. 
These samples were still considered stable if the confidence interval for the mean 
degradation did not include -10%.  
Method comparison with previously published method  
Patient samples that have previously been collected for were re-analyzed using this new 
method and using our previously published method, which has a more extensive clean-up 
and different chromatographic conditions [169]. We compared the results using Bland and 
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Altman plots. For study samples, the difference between the two values obtained should be 
within 20% of the mean for at least 67% of the repeats, as specified by the European 
Medicine Agency (EMA) [229] .  
2.2.3 Results 
Chromatography 
The total run time was 2.5 minutes. Fig. 1 shows representative MRM chromatograms 
for all analytes obtained from human plasma spiked with the 5 β-lactam antibiotics at LLOQ. 
We decided to measure all compounds in the ESI+ mode. Because cefuroxime normally 
requires ESI- mode, we measured the ammonium adduct for cefuroxime in positive mode (M 
+ 18). Because of its hydrophilicity, amoxicillin showed almost no retention on the column 
and eluted after only 0.8 minutes. Retention could be improved by injecting a smaller 
volume of sample onto the column (10 μL instead of 40 μL), however, this resulted in a 
decreased signal to noise ratio. As we used a deuterated internal standard, we were able to 
compensate for this effect.  
Validation 
 Specificity and selectivity 
No detectable interferences were found when analyzing the blank plasma from healthy 
volunteers or intensive care patients who did not receive any of the studied compounds, and 
the zero samples. The blank samples of bovine serum that were spiked with the compounds 
at their highest expected concentrations also showed no interference of the analyte with the 
internal standard or with other compounds.  
Recovery and matrix effect 
Mean absolute recovery (AR) for all compounds ranged from 67 to 100 %, with a maximum 
relative standard deviation (RSD) less than 11 %. For meropenem, ion enhancement was 
observed, while for amoxicillin, there was ion suppression. Table 2 summarizes the data for 
recovery and matrix effects, both absolute and compensated by the internal standards and 
shows that the internal standard compensates very efficiently for the ion suppression for 
amoxicillin and the ion enhancement of meropenem. 








Fig. 1 Multiple reaction monitoring chromatograms for a mixture of compounds at LLOQ spiked 




























































A linear regression curve using weighting factor 1/x provided best results for 
meropenem, piperacillin and amoxicillin, a quadratic curve using weighting factor 1/x for 
cefuroxime, and a quadratic curve using weighting factor 1/x² for ceftazidime.  
Accuracy, precision and limit of quantification 
Data on total precision are summarized in Table 3. The LLOQ of each compound was 
between 0.52 and 1.1 mg/L. For the different analytes, the between-run imprecision ranged 
from 4.8 to 16.7 % at LLOQ-level, and from 1.6 to 10.8 % at higher levels. Within-run 
imprecision ranged from 3.7 to 11.4 % at LLOQ level, and from 1.0 to 4.8 % at higher levels. 
Within-run accuracy values ranged from 92.6 to 107.6 %. Between-run accuracy ranged from 
95.8 to 109.2 %.  
Carryover 
No peak was found in the blank sample for all tested antibiotics, except for 
piperacillin. The peak found in the blank sample was only 10 % of the peak of the LLOQ of 
piperacillin. No peak was found for the internal standards. Therefore all antibiotics passed 
the acceptance criterion.  
Stability 
Stability of the internal standard working solution 
For each of the five tested antibiotics, there was no statistically significant difference 
(p= 0.916 for piperacillin, p=0.5 for meropenem, p=0.173 for cefuroxime, p=0.6 for 
ceftazidime, p=0.345 for amoxicillin) between the responses for the 6 calibrators using a 
freshly prepared internal standard working solution or using a working solution that has 
been stored at 4°C for 15 h.  
Autosampler stability of the extracts 
The confidence interval of the mean degradation did not encompass -10 % for all 
analytes.  
 




For meropenem, ceftazidime and amoxicillin, the ANOVA test showed no significant 
difference between the concentrations of the samples at each of the tested levels. For 
piperacillin, the ANOVA test revealed a difference for the low and high level control sample, 
and for cefuroxime for the medium control sample. However, the confidence interval for the 
mean degradation did not encompass -10%. Therefore, all analytes are considered stable 
during 3 freeze/thaw cycles.  
Method comparison 
The Bland and Altman plots are shown in figure 2. The mean difference ranged between -2.1 
and + 3.7 %. For meropenem, piperacillin cefuroxime and ceftazidime, none of the samples 
differed by more than 20 % of the mean. For amoxicillin, 2 out of 34 samples differed by 
more than 20 % of the mean.  





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 2. Method comparison: Bland and Altman plots  
Black line: mean difference (%) , dashed lines : SD ± 1.96 CV dif : standard deviation of the 
average difference ± 1.96 times the coefficient of variation (CV) of the average difference. 
2.2.4. Discussion  
In this study, we validated a UPLC-MS/MS method for the simultaneous quantification of 
5 frequently used β-lactam antibiotics. Bovine serum was used as a matrix for the calibrator 
and control solutions as this can be easily purchased and it has an accompanying certificate 
Mean = 3.7 % 
SD - 1.96 CV dif =  - 9.6 % 




























Average of new and previous method (mg/L) 
Meropenem (n=24) 
Mean = 0.46 % 
SD - 1.96 CV dif =  - 10.3 % 




























Average of new and previous method (mg/L) 
Piperacillin (n=15) 
Mean = 1.8 % 
SD - 1.96 CV dif =  -18.2 % 




























Average of new and previous method (mg/L) 
Cefuroxime (n=17) 
Mean = 3.4 % 
SD - 1.96 CV dif =  -13.7 % 




























Average of new and previous method (mg/L) 
Amoxicillin (n=34) 
Mean = -2.1 %  
SD - 1.96 CV dif =  -16.1 % 

































of analysis, guaranteeing a constant composition and the absence of infectious agents. As 
bovine serum is not identical to human plasma, it is of utmost importance to investigate the 
matrix effect of both human plasma and bovine serum, used for preparation of the 
calibrators and control samples. The internal standard working solution is stable for up to 15 
h when stored at 4°C, and the extracts are stable for at least 15 h in the autosampler at 4°C. 
The pre-analytical stability of the plasma samples has been investigated and reported 
separately. We found that amoxicillin, piperacillin and meropenem are stable for at least 4 h 
at room temperature followed by 4 h of storage at 4°C [169]. 
To ensure minimal turn around time, we used minimal sample preparation including 
protein precipitation and subsequent dilution. We did not focus on full chromatographic 
separation of the compounds, because the subsequent mass spectrometric detection offers 
plenty of selectivity and specificity. The method has been shown to be accurate and precise. 
Only few publications are describing a method for quantification of β-lactam antibiotics 
using deuterated standards [169, 170]. We assume this is because of the cost of deuterated 
analogues. However, because of our small sample volume, we only add 285 ng of deuterated 
standard to each sample. Consequently, one mg of deuterated standard is enough for 
analyzing 3500 samples. It is clear that the cost of this deuterated internal standard is only a 
mere fraction of the total cost, mostly consisting of the depreciation of the UPLC-MS/MS 
instrument and the personnel costs. Moreover, using a deuterated internal standard has 
significant advantages, such as ideal compensation for undesired effects. 
The major advantage of our method is its speed, as it includes minimal sample 
preparation, and a chromatographic runtime of only 2.5 minutes per sample, which is 
considerably faster than all other methods for multiple analytes previously reported. This 
allows high sample throughput and enables fast reporting of the results. Sample preparation of 
a run consisting of 6 calibrators, 3 internal quality control samples and 10 patient plasma 
samples would take up maximum of 40 minutes sample preparation (the initial centrifugation 
of the blood samples not taken into account) and less than 50 minutes chromatographic 
runtime. Therefore, the workload associated with this daily TDM of β-lactam antibiotics is low. 
Using this method, TDM of β-lactams can be easily combined with TDM of other drugs, such as 
immunosuppressive drugs, on the same instrument, which in our case also use the same 
chromatographic solvents. Hence, delays due to through priming and equilibration of solvents 




μL plasma), which is relevant in critically ill patients and in neonates. A potential drawback of 
this assay is the fact that it only measures total antibiotic concentrations, although the 
unbound concentration is pharmacologically active. However, research has shown that for low 
to moderately protein bound drugs, the free concentration can be estimated from the total 
concentration [219].  
2.2.5. Conclusion 
In this study, we validated an ultrafast UPLC-MS/MS method for the simultaneous 
quantification of 5 frequently used β-lactam antibiotics. To ensure minimal turn around time, 
we used a minimal sample preparation including protein precipitation and subsequent dilution. 
We have performed a method comparison and have shown comparable results to our previous 

















3. Exploration of the pre-analytical stability of β-lactam antibiotics in plasma and blood: 
implications for therapeutic drug monitoring and pharmacokinetic studies  
Authors : Mieke Carlier, Jan J. De Waele , Alain G. Verstraete, Veronique Stove 
Article history :  Received August 19 , 2014 ; accepted October 13 , 2014 
Reference : Clin Chem Lab Med 2014; aop DOI 10.1515/cclm-2014-0833 
Severe infection and sepsis are the most common causes of morbidity and mortality in 
non-cardiac intensive care units worldwide [1]. Research has shown that initiating 
appropriate and timely antibiotic therapy is crucial for survival [24]. However, reaching 
adequate antibiotic concentrations may also be important, as recent data suggested a 
correlation between serum concentrations of β-lactam antibiotics and clinical outcomes in 
the critically ill [49]. However, because of pathophysiological changes and treatment 
interventions, dose optimization in these patients remains difficult for the treating physician 
[39]. There is a growing interest in therapeutic drug monitoring (TDM) of plasma 
concentrations of β-lactam antibiotics, as this may maximize efficacy and minimize toxicity 
[166, 236]. However, little is known about the pre-analytical stability of these antibiotics, 
which are generally considered to be very unstable. Therefore, labor intensive measures are 
currently used such as stabilization of carbapenems using non-nucleophilic buffers, 
transportation of the blood sample on ice and immediate centrifugation and subsequent 
storage of the plasma at -80°C, which makes routine therapeutic monitoring of these drugs 
more challenging [107, 174, 238, 239].  
The objective of this study was to evaluate the pre-analytical stability of three commonly 
used β-lactam antibiotics, both in whole blood and in plasma. This study was conducted at 
the intensive care unit of Ghent University Hospital, Belgium between February and April 
2014. The trial was conducted in accordance with the Declaration of Helsinki. The study was 
approved by the Ethics Committee of Ghent University Hospital (registration number 
2012/229). Patients were invited to participate but, as no patient data were used and no 
extra blood was taken, the need to obtain written informed consent was waived. 
To evaluate the pre-analytical stability of these antibiotics, two blood tubes were drawn 
at the same time from patients treated with amoxicillin (n=8, range 4 to 45 mg/L), 




heparinized tube with (Venosafe VF-052SAHL, tube A) and one without (Venosafe VF-
052SHL, tube B) a gel separator (Terumo Europe, Leuven, Belgium). One mL of whole blood 
from tube B was removed to an Eppendorf cup and stored at 4°C (postponed centrifugation 
condition, tube C). Tube A and the remaining part of tube B were both centrifuged (8 min, 
1885 g, room temperature (RT)). Tube A (plasma in contact with the gel separator) was first 
stored at RT for 4 h and was then placed at 4°C for further storage (mimicking the worst case 
scenario in our laboratory). Tube B (plasma in contact with the blood cells) was stored at 4°C 
immediately after centrifugation. The tubes on the bench at room temperature were not 
protected from light. An aliquot of plasma was taken from tube A and B. For tube C, an 
aliquot of whole blood was transferred to a new cup which was centrifuged. The resulting 
plasma was transferred to a new cup. Collection of aliquots occurred at serial time points up 
to 72 h (0 h, 4 h, 6 h, 8 h, 24 h, 48 h and 72 h) and were stored at -80°C until analysis. The 
aliquots were analyzed in duplicate using an adapted and optimized version of an in house 
developed ultra high performance liquid chromatography tandem mass spectrometric 
method [169]. In brief, 15 μL plasma was precipitated with 100 μL acetonitrile containing the 
internal standard (a deuterated analogue of each of the antibiotics) at a concentration of 1.5 
mg/L, which was then vortexed and centrifuged. Hundred μL of the supernatant was diluted 
in 400 μL of water and 40 μL was injected onto the chromatographic column. Imprecision 
was < 10% at all concentrations. The influence of one freeze thaw cycle was investigated 
during validation and no significant degradation occurred.  
The drug was considered stable if the mean recovery was ≥ 95 % of the reference 
condition. The aliquot immediately sampled after centrifugation of tube B was considered 
the reference condition. In 5% of the samples, the analysis could not be performed because 
of too small sample volume.  
For the different storage conditions and tested β-lactam antibiotics, mean recovery and 
mean percentage degradation (+ standard deviation) are shown in Figure 1 and Table 1, 
respectively. Meropenem was stable for 8 h in whole blood or plasma in contact with cells at 
4°C, while amoxicillin and piperacillin were stable for 48 h under this condition. The tube 
containing a gel separator stored for 4 h at RT followed by storage at 4°C was stable up to 8 
h for amoxicillin, but only 6 h for meropenem and piperacillin. We first assumed that the 
limited stability of piperacillin might be caused by adsorption of piperacillin to the gel 
 
 
barrier. However, our initial experiment was not appropriate to test this, as the storage 
conditions during the first 4 hours were different (RT for samples with separator gel and 4°C 
for plasma without gel barrier) and storage at a higher temperature could possibly also 
explain the higher instability of piperacillin in tube A. Therefore, we carried out an additional 
gel-adsorption experiment and compared 6 piperacillin plasma concentrations which were 
sampled with and without gel barrier and were stored at identical conditions (4°C). The 
recovery was calculated as the ratio of the piperacillin concentration in the sample to the 
reference (concentration of piperacillin immediately sampled in the tube without gel 
separator). This recovery was compared for each time point using the related samples 
Wilcoxon signed rank test and the difference in recovery between the tube with and without 
gel separator reached statistical significance after 48 h (p=0.046) and after 72 h (p=0.028). 
The difference in recovery between gel and no gel was around 10% after 48 and 72 h. As the 
percentage recovery for the gel tube in the first experiment was much lower than the 
second after 24, 48 and 72 h, this is due to the period stored at room temperature. 
These experiments were performed using Venosafe heparin tubes from Terumo®, and 
the results are therefore only applicable on these tubes. Although only a limited number of 
samples was used in our experiment, we believe they give already a good estimation on the 
stability of the different compounds tested.  
In conclusion, this study shows that the pre-analytical stability of these selected β-lactam 
antibiotics is relatively good and is dependent on the compound. Meropenem is slightly less 
stable than amoxicillin and piperacillin. Labor-intensive measures, now often taken to 
prevent degradation, such as transportation on ice, immediate centrifugation and 
stabilization of meropenem using non-nucleophilic buffers may be unwarranted. This can 
considerably simplify storage and transportation to the laboratory and therefore facilitate 
the implementation of TDM in clinical practice. Tubes not containing a gel separator are 
preferred, as there seems to be some adsorption of piperacillin to the gel barrier if the 






Meropenem (n=7) Amoxicillin (n=8) 
Piperacillin (n=10)    
         Plasma without gel separator (4°C) 
 
         Whole blood without gel separator 
   
         Plasma in contact with gel separator (4h 
at RT then moved to 4°C) 
 
Figure 1: Mean recovery in function of time and storage conditions for meropenem, 
amoxicillin and piperacillin. Error bars : ± 1 standard deviation. Black line : limit of stability 










Table 1 : Mean recovery (%) ± standard deviation (%) 
 Condition A (mean recovery %) 
 4 h 6h 8h 24h 48h 72 h 
Amoxicillin (n=8) 95 ±5 96 ±6 97±8 91±7 87±7 85±5 
Meropenem (n=7) 96±7 95±6 93±7 93±4 81±6 75±7 
Piperacillin (n=10) 95±4 95±4 91±5 84±6 74±9 65±13 
 Condition B (mean recovery %) 
 4 h 6h 8h 24h 48h 72 h 
Amoxicillin (n=8) 98±6 95±6 97±5 96±4 95±3 94±4 
Meropenem (n=7) 98±4 96±4 97±7 89±3 83±7 76±7 
Piperacillin (n=10) 101±5 102±3 96±5 95±5 96±3 94±6 
 
 Condition C (mean recovery %) 
 4 h 6 h 8h 24h 48h 72 h 
Amoxicillin (n=8) 100±5 99±7 100±5 98±7 95±6 92±7 
Meropenem (n=7) 97±4 96±4 95±7 90±3 79±6 73±6 
Piperacillin (n=10) 100±6 101±4 96±5 95±5 95±4 92±6 
Condition A : plasma in contact with gel separator, stored for 4 h (not protected from light) 
at room temperature after which it was placed at 4°C (protected from light) ; Condition B : 
plasma without gel separator in contact with cells stored at 4°C (protected from light) ; 
Condition C : postponed centrifugation : whole blood stored at 4°C (protected from light) 
 
 
Chapter Five : Pharmacokinetic Studies 
This chapter describes 6 pharmacokinetic studies performed as part of this PhD thesis. 
Section 1 and 2 describe the population pharmacokinetics of amoxicillin/clavulanic acid and 
cefuroxime in critically ill patients without renal failure. Data were collected in Ghent 
University Hospital. The samples were analyzed using the first developed method described 
in chapter 4. Analysis of the data was performed as part of an international research stay at 
the Burns, Trauma, and Critical Care Research Centre in Brisbane, Australia. Section 3 
describes the population pharmacokinetic analysis of cefepime during continuous renal 
replacement therapy using data collected at the Erasme Hospital in Brussels. A 
pharmacokinetic analysis of meropenem and piperacillin administered as an extended 
infusion in critically ill patients, and a comparison with bolus infusion is described in section 
4. Patients treated with meropenem and piperacillin administered as an extended infusion 
were sampled in Ghent University Hospital. The pharmacokinetic data were compared with 
pharmacokinetic data from patients administered meropenem and piperacillin as a bolus 
infusion in the Royal Brisbane and Women’s hospital, Brisbane, Australia. The plasma 
samples were analysed at the Burns, Trauma and Critical Research Centre in Brisbane, 
Australia. The fifth section describes the variability in piperacillin concentrations within the 
same patient over an entire course of therapy using data that were collected as part of the 
TDM study (described in chapter 6). The last section of this chapter describes a simulation 
study investigating the pharmacokinetic target attainment of both broad spectrum and 
narrower spectrum -lactam antibiotics for a selection of microorganisms in which de-
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Abstract 
Objective: The objective of this study was to investigate the population pharmacokinetics 
and pharmacodynamics of amoxicillin and clavulanic acid in critically ill patients.  
Methods: In this observational pharmacokinetic study, multiple blood samples were taken 
over one dosing interval of intravenous amoxicillin/clavulanic acid (1000/200 mg). Blood 
samples were analysed using a validated ultra high performance liquid chromatography 
tandem mass spectrometry technique. Population pharmacokinetic analysis and dosing 
simulations were performed using non-linear mixed effects modeling. 
Results: One hundred and four blood samples were collected from 13 patients. For both 
amoxicillin and clavulanic acid, a two-compartment model with between subject variability 
on both clearance and the volume of distribution of the central compartment described the 
data adequately. For both compounds, 24 h urinary creatinine clearance was supported as a 
descriptor of drug clearance. The mean clearance of amoxicillin was 10.0 L/h and mean 
volume of distribution was 27.4 L. For clavulanic acid mean clearance was 6.8 L/h and mean 
volume of distribution was 19.2 L. Dosing simulations for amoxicillin supported use of 
standard dosing regimens (30-minute infusion of 1g 4 times daily or 2g 3 times daily) for 
most patients when using a target MIC of 8 mg/L and a pharmacodynamic target of 
50%fT>MIC, except for those with creatinine clearance > 190 mL/min. Dosing simulations for 
clavulanic acid showed little accumulation when high doses were administered to patients 
with high creatinine clearance. 
Conclusions: Although vast pharmacokinetic variability exists for both amoxicillin and 
clavulanic acid in ICU patients, current dosing regimens are appropriate for most patients, 





Infection is an important problem in critical care medicine. In a recent point prevalence 
study, 71 percent of over 13000 patients admitted to intensive care units (ICU) around the 
world received antibiotic therapy [1]. Sepsis alone is the leading cause of mortality in non-
cardiac intensive care ICU’s with up to 30% of patients dying within one month of diagnosis 
[2]. Currently, timely and appropriate antibiotic therapy after source control is considered to 
be the mainstay in treatment [24]. However, it is important that adequate concentrations 
are achieved [236]. 
Amoxicillin is a semisynthetic penicillin which has been in clinical use for decades. It is 
commonly administered with the beta-lactamase inhibitor clavulanic acid to broaden its 
antibacterial spectrum of activity. In ICU, amoxicillin/clavulanic acid is used for community 
acquired infections caused by both gram positive, and gram negative organisms inclusive of 
anaerobes [240]. Specific indications include community acquired pneumonia, intra-
abdominal, skin and soft tissue infections.  
β-lactam antibiotics exhibit a time-dependent killing pattern, meaning that the 
percentage time above the minimal inhibitory concentration (fT>MIC) of the micro-organism is 
considered the best determinant of efficacy of these antibiotics. For penicillins, 50% fT>MIC is 
considered the minimum pharmacodynamic target for maximal bacterial killing [40]. 
However, research in critically ill patients shows that higher PK/PD targets such as 100% 
fT>MIC or even 100% fT>4xMIC may be associated with better outcomes [42, 43]. 
Numerous studies have already investigated the population PK of broad-spectrum 
antibiotics in critically ill patients [148, 157-161, 238, 241, 242], all of which highlight the 
different PK of these drugs in comparison with healthy volunteers and highlight the need of 
individual dosing of these antibiotics in critically ill patients. However, if research is only 
focused on these broad spectrum antibiotics, this may encourage physicians to favor using 
these antibiotics, even when more targeted therapies could be just as effective, only 
because these broad spectrum antibiotics have been investigated in this special patient 
population. This is why data on more targeted therapies are equally relevant [128]. 
Although amoxicillin/clavulanic acid is commonly used in critically ill patients, there are 
little data to guide dosing of amoxicillin and clavulanic acid in this specific patient 
population. Therefore the aim of this study was to evaluate the population pharmacokinetics 
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of amoxicillin and clavulanic acid in ICU patients and investigate if PK/PD targets are 
achieved with current dosing strategies, as well as investigate the potential of alternative 
dosing regimens and strategies. 
1.2. Methods 
Patients 
This prospective, open-label PK study was conducted at the ICU of the Ghent University 
Hospital, Belgium between March and July 2012. The trial was conducted in accordance with 
the Declaration of Helsinki. The study was approved by the Ethics Committee of the Ghent 
University Hospital (registration number 2012/078) and was registered with the European 
Union Drug Regulating Authorities Clinical Trials (EudraCT), registration number 2011-
006107-35. Written informed consent was obtained from all patients or a legally authorized 
representative before enrolment. Patients were enrolled in the study if they were admitted 
to the ICU and were prescribed amoxicillin/clavulanic acid. The exclusion criteria included: 
<18 years of age, a hematocrit of <21% , absence of an arterial catheter or need for renal 
replacement therapy.  
Drug administration  
Amoxicillin/clavulanic acid (Augmentin®, GlaxoSmithKline, Genval, Belgium), was infused 
intravenously over 30 minutes using a syringe pump. Amoxicillin/clavulanic acid (1000 
mg/200mg) was dosed 4 times daily for patients with normal renal function, and 3 times 
daily for patients with renal impairment.  
Study procedures 
Blood samples for assay were obtained at assumed PK steady state (at least 24 hours of 
therapy) through a separate arterial catheter. Blood samples were collected just before the 
start of infusion (time 0), and after 0.25, 0.5, 0.75, 1, 2, 4, 6 or 8 hours (depending on dose 
interval) in lithium-heparinized collection tubes (Venosafe, Terumo, Leuven, Belgium). The 
blood samples were centrifuged for 10 min at 3000 g (ALC Centrifugette 4206, Analys, Gent, 
Belgium) immediately after sample collection and then frozen on dry ice and finally stored at 
-80°C (within one hour after sample collection) for maximum 4 weeks until assay. 
 
 
In order to determine 24 hour creatinine clearance, the patient’s urine was collected, 
starting at the time of initiation of the antibiotic infusion. The plasma sample at time 0 was 
also used to determine the concentration of creatinine in blood. Additional data were 
obtained from the medical record and included participant demographics, clinical details, 
measures of illness severity, microbiological results, and laboratory investigations. 
Analytical methods 
The plasma samples were analysed at the toxicology laboratory of the Department of 
Laboratory Medicine at Ghent University Hospital. The plasma concentrations of amoxicillin 
and clavulanic acid were determined by validated ultra high performance liquid 
chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). The details of this 
method have been previously described elsewhere [169]. In brief, sample preparation 
included protein precipitation with acetonitrile and back-extraction of acetonitrile with 
dichloromethane. Amoxicillin-d4 was used as an internal standard. Chromatographic 
separation was performed on a Waters Acquity UPLC system using a BEH C18 column (1.7 
μm, 100 x 2.1 mm) applying a binary gradient elution of water and acetonitrile both 
containing 0.1 % formic acid. The total runtime was 5.5 minutes. The lower limit of 
quantification was 0.5 mg/L and imprecision was < 15 % at all levels. Observed 
concentrations for amoxicillin were corrected for protein binding (17 %) [240]. 
Creatinine was measured in both plasma and urine using the rate blanked, compensated 
and uncompensated Jaffe technique, respectively (Modular P and Cobas 6000, Roche 
Diagnostics GmbH, Mannheim, Germany). The creatinine clearance was calculated as follows 
: 24 hour creatinine clearance = Vu x Ucr/( 1440 x Scr ), where Vu is the urinary volume (mL), 
Ucr the urinary creatinine concentration (μmol/L) and Scr the serum creatinine concentration 
(μmol/L).  
Pharmacokinetic analysis 
The concentration-time data were analysed using non-Linear mixed-effects modeling 
(NONMEM version 6.1, Globomax LLC, Hanover, USA). A Digital Fortran compiler was used 
and the runs were executed using Wings for NONMEM (http://wfn.sourceforge.net). The 
first-order conditional estimation (FOCE) method with interaction was used throughout the 
model building.  
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For the population PK analysis, the plasma amoxicillin concentrations were fitted to one-, 
two-, or three-compartment linear models using subroutines from the NONMEM library.  
Between subject variability (BSV) 
BSV was evaluated using an exponential variability model. Various models for residual 
unexplained variability (RUV) were also tested. 
Model diagnostics 
Visual inspection of diagnostic scatter plots and the NONMEM objective function value 
(OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was 
undertaken in the NONMEM program using log-likelihood ratios, which are assumed to be 
chi square distributed. On the basis of a χ2 test of the difference in OFV, a decrease in the 
OFV of 3.84 units (p < 0.05) for one degree of freedom was considered statistically 
significant. Decreases in BSV of one of the parameters of at least 10% were also accepted for 
inclusion of a more complicated model.  
Covariate screening 
Covariate model building was performed in a stepwise fashion with forward inclusion 
and backward deletion based upon the aforementioned model selection criteria. Creatinine 
clearance, age, sex, weight, Acute Physiology and Chronic Health Evaluation (APACHE) II 
score and Sequential Organ Failure Assessment (SOFA) score were evaluated as covariates.  
Bootstrap 
A nonparametric bootstrap method (n= 1000) was used to study the uncertainty of the 
pharmacokinetic parameter estimates in the final model. From the bootstrap empirical 
posterior distribution, we have been able to obtain the 95 % confidence interval (2.5 to 97.5 
% percentile) for the parameters, as described previously [243].  
Dosing simulations 
As creatinine clearance was the only covariate retained in the final model, only the 
effects of different creatinine clearances were simulated. The creatinine clearances 
simulated were 10 ml/min, 30 mL/min, 50 mL/min, 100 mL/min, 130 mL/min, 150 mL/min 





Table 1 : simulated dosages for amoxicillin 
intermittent extended Continuous 
No loading dose No loading dose Loading dose : 1 g over 0.5 h 
Infusion time 0.5 h Infusion time = half of dosing 
interval 
Constant infusion over 24 
hours 
0.5 g q4h 0.5 g q4h  
0.5 g q6h 0.5 g q6h  
0.5 g q8h 0.5 g q8h  
1 g q4h 1 g q4h 6 g q24h 
1 g q6h 1 g q6h 4 g q24h 
1 g q8h 1 g q8h 3 g q24h  
2 g q6h 2 g q6h 8 g q24h 
2 g q8h 2 g q8h  
 3 g q6h 12g q24h 
q4h : every 4 h, q6h : every 6 h, q8h : every 8 h, q24h : every 24 h  
The ability of each dosing regimen to achieve predefined pharmacodynamic targets (50 
% fT> MIC) was then assessed. The target MIC was the highest MIC for which the antibiotic is 
used according to EUCAST breakpoints, which is 8 mg/L, the EUCAST breakpoint for 
Enterobacter spp., Klebsiella spp., Citrobacter spp and Escherichia coli.  
Performing dosing simulations for clavulanic acid to evaluate efficacy was not 
undertaken as the pharmacodynamic target is not clear. Therefore, simulations for clavulanic 
acid could only be undertaken to investigate whether accumulation of clavulanic acid occurs 
if the dose or frequency of amoxicillin/clavulanic acid administration is increased. Dosing 
simulations were performed for creatinine clearances of 30, 50, 130 and 190 mL/min for 
both a low and high dose of amoxicillin/clavulanic acid (table 2). 
Validation of the model 
The model for amoxicillin was validated using data from 14 independent patients 
enrolled as part of another pharmacokinetic study [84]. Two concentrations were available 
per patient. Validation was performed by comparing the observed versus predicted 
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High dose amoxicillin/clavulanic acid 
(mg) 
Low dose amoxicillin/clavulanic acid 
(mg) 
30 2000/400 q8h 500/100 q8h 
50 2000/400 q6h 500/100 q6h 
130 2000/400 q4h 500/100 q4h 
190 2000/400 q4h 500/100 q4h 
CrCl : creatinine clearance , q4h : every 4 h, q6h : every 6 h, q8h : every 8 h, q24h : every 24 h  
1.3. Results 
Patient characteristics 
A total of 104 blood samples and 13 creatinine clearances were analysed from 13 
patients enrolled in this study. Demographic and general clinical characteristics are shown in 
table 3. The most frequent reason for the antibiotic therapy was a pulmonary infection.  
Table 3 : patient characteristics. Values are displayed as median (interquartile range) 
Patient characteristic Value  
Age (years) 62 (58-72) 
Weight (kg) 75 (70-79) 
BMI 24 (21-25) 
Sex (% M-F) 85% - 15% 
Apache II score on ICU admission 25 (18-29) 
SOFA score on ICU admission 9 (5-12) 
SOFA score following dose administration 6 (4-12) 
Creatinine clearance (mL/min) 102 (50-157) 
BMI : body mass index, Apache : Acute Physiology and Chronic Health Evaluation; SOFA: 
Sequential Organ Failure 
Pharmacokinetic analysis 
For both compounds, the best base model consisted of a two-compartment linear model 
with zero order input with exponential residual unknown variability for amoxicillin, and 
combined additive-exponential residual unknown variability for clavulanic acid. Between-
subject variability was included for both clearance and for volume of distribution of the 
central compartment for both compounds.  
The typical value of clearance (TVCL) was calculated as a function of creatinine clearance, 
normalized to the population’s median creatinine clearance, 102 mL/min (equation 1 for 
amoxicillin, equation 2 for clavulanic acid) , where θ1a is the typical value of amoxicillin 
 
 
clearance (TVCLa) in the population and θ1c is the typical value of clavulanic acid clearance 
(TVCLc) in the population. 
TVCLa= θ1a*(CrCl/102)   (equation 1) 
TVCLc= θ1c*(CrCl/102)    (equation 2) 
The addition of creatinine clearance as a covariate greatly improved model fit, for both 
compounds. None of the other covariates statistically significantly improved the model, and 
therefore, they could not be included. 
Figure 1 displays the goodness-of-fit plots for the final model for both compounds. Of the 
104 samples included in the analysis, only 5 samples had a concentration greater than 2 
standard deviations outside that predicted by the model for amoxicillin, and only 2 samples 
had a concentration greater than 2 standard deviations outside that predicted by the model 
for clavulanic acid, which we considered acceptable given the level of sickness severity and 
likely pharmacokinetic heterogeneity of the patient cohort. All other visual predictive checks 
were acceptable and confirmed the goodness of fit of the model. The plots in Fig. 1 show 
that the final PK model describes the measured concentrations adequately. All subsequent 
dosing simulations were then based on this model. 
The values of the parameters for the final models are given in Table 4 and include the 
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Fig 1. Diagnostic plots for the final population pharmacokinetic covariate model. (a) 
population predicted amoxicillin concentrations versus observed amoxicillin concentrations 
(R² 0.87). (b) individual predicted amoxicillin concentrations versus observed amoxicillin 
concentrations (R² 0.96). (c) population predicted clavulanic acid concentrations versus 
observed clavulanic acid concentrations (R² 0.44). (d) individual predicted clavulanic acid 
concentrations versus observed clavulanic acid concentrations (R² 0.98). The nonlinear 
regression line of fit is shown by the solid black line, and the line of xy is the gray dotted line. 
Table 4 : Bootstrap parameter estimates of the final covariate model 
Parameter Amoxicillin Clavulanic acid 
 Model Bootstrap Model  Bootstrap  
 Mean  Mean  95 % confidence 
interval  
Mean  Mean  95 % confidence 
interval  
   2.5 % 97.5 %   2.5 % 97.5 % 
Fixed effects         
Cl (L/h) 10.0 10.3 8.6 12.6 6.8 9.4 6.3 12.9 
Vc (L) 13.7 13.5 10.2 17.7 7.6 8.1 6.8 9.9 
Vp (L) 13.7 14.1 11.7 27.7 11.6 14.7 8.4 63.1 
Q (L/h) 15.6 15.7 12.2 19.6 10.4 10.0 8.6 11.5 
Random effects 
 BSV (% CV) 
        
Cl (L/h)  39.9 25.3 53.6  57.8 31.1 85.5 
Vc (L)  38.7 4.0  67.1 
 
 34.7 22.8 44.8 
Random error         
RUV (% CV)  22.0 10.1 32.9     
RUV (SD, mg/L)      1.2 0.7 1.7 
Cl = Clearance, Vc = Volume of distribution of the central compartment ; Vp = Volume of 
distribution of the peripheral compartment; Q = Intercompartmental clearance; BSV = 
between subject variability; RUV = residual unexplained variability; CV = coefficient of 







































































The results of the dosing simulations for amoxicillin are summarised in Table 5, which 
shows whether the target of 50 % or 100 % fT>MIC will be achieved for different values for 
creatinine clearance and different dosing strategies.  
The standard dose of 1 g q6h or 2 g q8h amoxicillin results in adequate exposure for both 
low and normal creatinine clearances. However, dependent on the chosen target, standard 
dosing will not suffice for patients with high creatinine clearance infected with a micro 
organism with a high MIC90 (8mg/L). Patients with a creatinine clearance of 190 mL/min do 
not even achieve 50% f>TMIC, which is considered the minimal PK target needed for bacterial 
killing, if standard dosing regimens are used.  
The results of the dosing simulations for clavulanic acid are shown in figure 2 a-d, which 
shows the concentrations of amoxicillin and clavulanic acid over a 7 day course for both a 
low and high dose for different values of creatinine clearance. These figures show that little 
accumulation of clavulanic acid occurs if higher doses of amoxicillin/clavulanic acid are 
administered to the patients with normal-high creatinine clearance.  
Validation 
Similar to the characteristics of the patients used to build the model, the main indication 
for antibiotic therapy was also treatment of a pulmonary infection. Median creatinine 
clearance was 97.5 (IQR 44-125) mL/min, which was comparable to the creatinine clearance 
of the patients in the present study, for whom the median creatinine clearance was 102 (IQR 
50-157) mL/min (p= 0.685).  
The results of the external validation are graphically shown in Figure 3. The coefficient of 
determination was 0.75 and was found to be statistically significant (p<0.0001).  
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Fig. 3 – Observed amoxicillin concentrations versus predicted concentrations for 28 samples 
from 14 independent patients 
  
  
Fig. 2. Dosing simulations for amoxicillin and clavulanic acid in high and low dose for 
different creatinine clearances. (a) Concentration vs time for a patient with creatinine 
clearance 30 mL/min ; Low dose : 500mg/100mg amoxicillin/clavulanic acid q8h ; High dose : 
2000 mg/400 mg amoxicillin/clavulanic acid q8h. (b) Concentration vs time for a patient with 
creatinine clearance 50 mL/min ; Low dose : 500mg/100mg amoxicillin/clavulanic acid q6h ; 
High dose : 2000 mg/400 mg amoxicillin/clavulanic acid q6h. (c) Concentration vs time for a 
patient with creatinine clearance 130 mL/min ; Low dose : 500mg/100mg 
amoxicillin/clavulanic acid q4h ; High dose : 2000 mg/400 mg amoxicillin/clavulanic acid q4h. 
(d) Concentration vs time for a patient with creatinine clearance 190 mL/min ; Low dose : 
500mg/100mg amoxicillin/clavulanic acid q4h ; High dose : 2000 mg/400 mg 
amoxicillin/clavulanic acid q4h. Legend : Amoxicillin low dose : black dotted line; Clavulanic 
acid low dose : black solid line; Amoxicillin high dose : grey dotted line; Clavulanic acid high 











































































1.4. Discussion  
Although amoxicillin/clavulanic acid is frequently used to treat severe infections in 
critically ill patients, this is the first paper to investigate its population pharmacokinetics in 
ICU patients. We found that both amoxicillin and clavulanic acid clearance were proportional 
to creatinine clearance, with important variability between patients for antibiotic clearance. 
Current dosing schemes are adequate for patients without increased creatinine clearances 
when minimal PK/PD targets are used. 
Table 5: The effect of creatinine clearances and different dosing strategies on the probability 
of target attainment for amoxicillin (50% fT> MIC and 100% fT> MIC) 
Creatinine clearance 30 mL/min 
        MIC      
Dose    
<4 mg/l 8 mg/l 16 mg/l 
50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 
II 0.5 g q6h + + + + + - 
II 0.5g q8h + + + + + - 
II 1 g q8h + + + + + + 
II 1 g q6h + + + + + + 
Creatinine clearance 50 mL/min 
        MIC    
Dose 
<4 mg/l 8 mg/l 16 mg/l 
50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 
II 0.5g q6h + + + + + - 
II 1g q8h + + + + + - 
EI 1g q8h + + + + + + 
II 1g q6h + + + + + + 
CI 4g q24h + + + + + + 
Creatinine clearance 130 mL/min 
       MIC    
Dose 
<4 mg/l 8 mg/l 16 mg/l 
50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 
II 1g q8h + - - - - - 
II 1g q6h + + + - - - 
EI 1g q6h + + + - + - 
CI 4g q24h + + + + - - 
II 1g q4h + + + + + - 






Chapter 5 : Pharmacokinetic Studies
 
 
Creatinine clearance 190 mL/min 
        MIC    
Dose 
<4 mg/l 8 mg/l 16 mg/l 
50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 50%fT>MIC 100%fT>MIC 
II 1gq6h + - - - - - 
EI 1g q6h + + + - - - 
CI 4g q24h + + + - - - 
II 1g q4h + + + - - - 
CI 6g q24h + + + + + - 
EI 2g q6h + + + - + - 
CI 8g q24h + + + + + + 
EI 3g q6h + + + + + - 
II : intermittent infusion, EI : extended infusion, CI : continuous infusion, + : target attained, - 
: target not attained 
 
Clearance appears to be an important factor in the variability described. This 
pharmacokinetic variability is typical for ICU patients and has been shown for other beta-
lactams as well. The available pharmacokinetic studies in healthy volunteers show for 
amoxicillin a mean clearance of about 12.5 L/h with a CV (coefficient of variation) around 20 
% [244-246]. This is in contrast to our findings of a mean clearance of 10.0 L/h with a CV of 
more than 80 % in the 13 patients included in this study, which highlights the importance of 
studying this specific patient population. The values observed for volume of distribution (IQR 
24.7-30.7 L) seem to be comparable with those found in literature for healthy volunteers 
[244-246]. As there are no population pharmacokinetic studies published for clavulanic acid, 
it was not possible to compare our results to the results previously described in the 
literature.  
The EUCAST breakpoint for amoxicillin for common respiratory pathogens such as 
staphylococcus aureus (2 mg/L) and streptococcus pneumonia (0.064 mg/L) is low. However, 
this breakpoint MIC is far higher for other species, such as Enterobacter spp., Escherichia coli 
and Klebsiella spp. , for which the breakpoint MIC is 8 mg/L, which are potential 
considerations with community acquired intra-abdominal infection[235].By performing 
dosing simulations for amoxicillin and investigating the probability of target attainment we 
have demonstrated that intermittent infusion of amoxicillin 1 g q6h or 2 g q8h will ensure 
plasma free concentrations exceeding this breakpoint MIC for at least 50% fT>MIC -which is 
considered the minimum PK/PD target to achieve bacterial killing- for patients with low and 
normal kidney function. However, using the same dosing strategy, patients with very high 
 
 
creatinine clearances (190 mL/min) will not reach this target. In order to achieve sufficient 
exposure, these patients need more frequent antibiotic administration (1g 6 times daily) or 
need to be treated with alternate dosing strategies. This means that standard dosing should 
lead to sufficient PK/PD exposure when treating an infection caused by an organism with a 
low MIC (in the case of a respiratory tract infection), but may fail to achieve sufficient PK/PD 
exposure when treating an infection caused by an organism with a high MIC (in the case of 
an intra-abdominal infection), when the creatinine clearance is > 190 mL/min. It is important 
to state that estimations of GFR such as the cockroft gault equation and the modified diet in 
case of renal disease (MDRD) are not reliable in ICU patients, and 8 or 24 hour urinary 
creatinine clearance should be preferred in these patients [247-249].  
Moreover, research in critically ill patients shows that higher PK/PD targets may be 
associated with better outcomes [42, 43]. If one aims to achieve these higher targets such as 
100% T>MIC or even 100% T>4xMIC more frequent dosing or administration by prolonged 
infusion is necessary for patients with normal to high renal function. Amoxicillin is stable for 
up to 24 h for a concentration range from 20-40 g/L [250]. However, stability of clavulanic 
acid when used as a prolonged infusion is unknown. In addition, more frequent dosing or 
alternate dosing strategies could also be a way to treat more resistant microorganisms, 
which would otherwise be classified as not sensitive to this antibiotic, which may be very 
valuable in this era of increasing resistance. The advantage of using extended or continuous 
infusion on PK/PD target attainment has already been shown for other -lactams as well 
[133, 140, 251].  
As for clavulanic acid, dosing simulations were only performed to evaluate accumulation, 
since the pharmacodynamic target for efficacy is unknown. We have shown that there is 
little accumulation of clavulanic acid in patients with high creatinine clearance treated for 7 
days with a high dose amoxicillin/clavulanic acid. 
This paper has a number of limitations. First, we have not investigated free 
concentrations or concentrations at the site of infection. Instead, we have measured total 
drug concentrations with correction for protein binding based on literature. This is an 
oversimplification, but our (unpublished) data show that this approach is acceptable for low 
protein bound drugs such as amoxicillin (17% protein binding), although it is not accurate for 
more highly protein bound drugs. Moreover, we have only included 13 patients in this study, 
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which may not be sufficient to describe the variability present in ICU patients. However, this 
small study still provides important guidance for dosing this drug in the ICU given that the 
data is presently not available [148].  
1.5.  Conclusion 
We found great variability in antibiotic clearance, which is not found in healthy 
volunteers, which points out the importance of individual dosing in ICU patients. We have 
shown that current dosing regimens of 1000/200 mg 4 times daily or 2000/400 mg 3 times 
daily for patients with low to normal creatinine clearance lead to sufficient pharmacokinetic 
exposure. However, patients with very high creatinine clearance need more frequent dosing 
or alternate dosing strategies to achieve the minimal PD target of 50 % T> MIC (8mg/L), with 
little accumulation of clavulanic acid. To achieve higher targets such as 100% fT>MIC in 
patients with high creatinine clearance, administration of higher doses as a prolonged 
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Abstract:  
Objective: The objective of this study was to investigate the population pharmacokinetics of 
cefuroxime in critically ill patients.  
Methods: In this observational pharmacokinetic study, multiple blood samples were taken 
over one dosing interval of intravenous cefuroxime. Blood samples were analysed using a 
validated ultra high performance liquid chromatography tandem mass spectrometry 
technique. Population pharmacokinetic analysis and dosing simulations were performed 
using non-linear mixed effects modeling. 
Results: One hundred and sixty blood samples were collected from 20 patients. Creatinine 
clearance ranged between 10 and 304 mL/min. A two-compartment model with between-
subject variability on clearance, volume of distribution of the central compartment and 
volume of distribution of the peripheral compartment described the data adequately. 
Twenty-four hour urinary creatinine clearance was supported as a descriptor of drug 
clearance. The population model for clearance was , where  is the typical of 
cefuroxime clearance in the population, which is 9.0 L/h. The mean volume of distribution 
was 22.5 L. Dosing simulations showed failure to achieve the 
pharmacokinetic/pharmacodynamic (PK/PD) target of 65%fT>MIC for an MIC of 8 mg/L with 
standard dosing regimens for patients with creatinine clearance ≥ 50 mL/min.  
Conclusions: Administration of standard doses by intermittent bolus is likely to result in 
underdosing for many critically ill patients. Continuous infusion of higher than normal doses 
after a loading dose is more likely to achieve pharmacokinetic/pharmacodynamic targets. 
However, even continuous infusion of high doses (up to 9 g per day) does not guarantee 
adequate levels for all patients with a creatinine clearance of 300 mL/min or higher if the 
MIC is 8 mg/L. 




Cefuroxime is a second-generation cephalosporin that has been in clinical use for over 
two decades.  
Like other β-lactam antibiotics, cefuroxime is a time-dependent antibiotic, which means 
antibacterial activity is related to the time for which the unbound concentration is 
maintained above the MIC during a dosing interval (fT>MIC). The fT>MIC required for optimal 
bactericidal activity for cefuroxime has been reported to be somewhere between 40 and 70 
% from in vitro animal models.[252] Although this may be adequate for minor infections, for 
treatment of serious infection in critically ill patients, higher 
pharmacokinetic/pharmacodynamic (PK/PD) targets such as 100% fT>MIC or even 100% 
fT>4xMIC have been associated with better outcomes, both clinical and microbiological [42, 
43].  
Research has shown that the pharmacokinetics of hydrophilic antibiotics in critically ill 
patients may differ from healthy volunteers and from non-critically ill patients. 
Subtherapeutic concentrations using standard dosing have been reported for many 
antibiotics [128, 140, 155-161]. This shows that pharmacokinetic data from healthy 
volunteers cannot just be extrapolated to critically ill patients and that population 
pharmacokinetic studies are needed to define robust drug doses for this specific patient 
population.  
To date, there are little data to guide dosing of cefuroxime in critically ill patients, which 
may preclude the use of cefuroxime in this setting. Although cefuroxime is not commonly 
used as empirical therapy in critically ill patients, because it has a relatively narrow spectrum 
and does not cover most nosocomial pathogens. However, it may have a role in de-
escalation when the pathogens are found to be susceptible to the drug. Therefore 
knowledge about the pharmacokinetics in the critically ill is important to use the drug 
appropriately.  
Therefore the aim of this study was to evaluate the population pharmacokinetics of 
cefuroxime in critically ill patients and investigate if PK/PD targets are achieved with current 






This prospective, open-label pharmacokinetic study was conducted at the ICU of Ghent 
University Hospital, Belgium between March 2012 and January 2014. The trial was 
conducted in accordance with the Declaration of Helsinki. The study was approved by the 
Ethics Committee of Ghent University Hospital (registration number 2012/078) and was 
registered with the European Union Drug Regulating Authorities Clinical Trials (EudraCT), 
registration number 2011-006107-35. Written informed consent was obtained from all 
patients or a legally authorised representative before enrolment. Patients were enrolled in 
the study if they were admitted to the ICU and were prescribed cefuroxime. The exclusion 
criteria included: <18 years of age, a haematocrit of <21% , absence of an arterial catheter or 
need for renal replacement therapy.  
Drug administration  
Cefuroxime (Zinacef®, GlaxoSmithKline, Genval, Belgium), was infused intravenously over 
30 minutes using a syringe pump. The dose was 1500 mg every 8 hours for all patients 
except for those with renal impairment (defined as a creatinine clearance < 20 mL/min), for 
whom the dose was reduced to 750 mg every 8 hours. 
Study procedures 
Blood samples for assay were obtained after at least 24 hours of therapy through a 
separate arterial catheter. Blood samples were collected just before the start of infusion 
(time 0), and after 0.25, 0.5, 0.75, 1, 2, 4, and 8 hours in lithium-heparinised collection tubes 
(Venosafe, Terumo, Leuven, Belgium). The blood samples were centrifuged for 10 min at 
3000 g (ALC Centrifugette 4206, Analis, Gent, Belgium) immediately after sample collection 
and then frozen on dry ice and finally stored at -80°C (within one hour after sample 
collection) for maximum 4 weeks until assay. 
In order to determine 24-hour creatinine clearance, the patient’s urine was collected, 
starting at the time of initiation of the antibiotic infusion. The plasma sample at time 0 was 
also used to determine the concentration of creatinine in blood. Additional data were 
obtained from the medical record and included participant demographics, clinical details, 
measures of illness severity, microbiological results, and laboratory investigations. 




The plasma concentrations of cefuroxime were determined by a validated ultra high 
performance liquid chromatography method coupled to tandem mass spectrometry (UPLC-
MS/MS). The details of this method have been previously described elsewhere [169]. 
Observed concentrations for cefuroxime were corrected for protein binding (33 %) [240, 
253]. 
Creatinine was measured in both plasma and urine using the rate blanked, compensated 
and uncompensated Jaffe technique, respectively (Modular P and Cobas 8000, Roche 
Diagnostics GmbH, Mannheim, Germany).  
Pharmacokinetic analysis 
The concentration-time data were analysed using non-linear mixed-effects modeling 
(NONMEM version 7.3, Globomax LLC, Hanover, USA). A Digital Fortran compiler was used 
and the runs were executed using Wings for NONMEM (http://wfn.sourceforge.net). The 
first-order conditional estimation (FOCE) method with interaction was used throughout the 
model building.  
Model development 
For the population pharmacokinetic analysis, the plasma cefuroxime concentrations 
were fitted to one-, two-, or three-compartment linear models using subroutines from the 
NONMEM library. BSV was evaluated using an exponential variability model. Various models 
for residual unexplained variability (RUV) were also tested. 
Model diagnostics 
Visual inspection of diagnostic scatter plots and the NONMEM objective function value 
(OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was 
undertaken in the NONMEM program on the basis of a χ2 test of the difference in OFV. A 
decrease in the OFV of 3.84 units (p < 0.05) was considered statistically significant for 1 
degree of freedom. Decreases in BSV of one of the parameters of at least 10% were also 
accepted for inclusion of a more complicated model.  
Covariate screening 
Covariate model building was performed in a stepwise fashion with forward inclusion 
based upon the aforementioned model selection criteria for those clinical parameters which 
showed significant correlation with one of the pharmacokinetic parameters. Creatinine 
 
 
clearance, serum albumin concentration, age, sex, weight, Acute Physiology and Chronic 
Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score 
were evaluated as covariates.  
Bootstrap 
A nonparametric bootstrap method (n= 1000) using NONMEM was used to study the 
uncertainty of the pharmacokinetic parameter estimates in the final model. From the 
bootstrap empirical posterior distribution, we obtained the 95 % confidence interval (2.5 to 
97.5 % percentile) for the parameters, as described previously [243]. 
Dosing simulations 
Different dosing regimens were simulated using Monte Carlo simulations. The creatinine 
clearances simulated were 50, 100, 200 and 300 mL/min. Five hundreds subjects were 
simulated per dosing strategy and per creatinine clearance. The simulated dosages are 
summarised in table 1. Each Monte Carlo Simulation generated concentration time profiles 
for 500 subjects per dosing regimen using the parameters from the final covariate model. 
From this data, the fT>MIC was calculated for each simulated subject using linear 
interpolation. The PTA was obtained by counting the subjects who achieved 65 % fT>MIC. The 
target MIC’s were 0.5, 1, 2, 4, 8 and 16 mg/L.  
Table 1: Simulated dosages 
Intermittent Extended Continuous 
No loading dose No loading dose Loading dose: 750 mg over 
0.5 h 
Infusion time 0.5 h Infusion time = half of dosing 
interval 
Constant infusion over 24 
hours 
1.5 g q8h 1.5 g q8h 4.5 g q24h 
 1.5 g q6h 6.0 g q24h 
  7.5 g q24h 
  9.0 g q24h 
q8h : every 8 hours ; q6h : every 6 hours, q24h : over 24 hours 
2.3. Results 
Patient characteristics 
A total of 160 blood samples and 20 creatinine clearances were analysed from 20 
patients enrolled in this study. Demographic and general clinical characteristics from the 
patients used for model building are shown in table 2. Eighteen patients received antibiotic 
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therapy for treatment of a pulmonary infection, and 2 for prevention of a pulmonary 
infection after aspiration. Twelve causative microorganisms were cultured from nine 
patients which are described in table 3. 
Table 2: Patient characteristics. Values are displayed as median (range) 
 
Patient characteristic  
Age (years) 69 (26-85) 
Weight (kg) 80 (65-100) 
Number of doses between start of therapy and start of study 3 (3-5) 
BMI 28 (22.6-35) 
Sex (% M-F) 73% /- 27% 
Apache II score on ICU admission 19 (13-32) 
SOFA score on ICU admission 9 (3-13) 
SOFA score on day of sampling 7 (1-12) 
Creatinine clearance (mL/min) 57 (10-304) 
Albumin concentration (g/L) 28.5 (17-42) 
BMI = Body Mass Index; M = male; F = female; ICU = intensive care unit; APACHE = Acute 
Physiology and Chronic Health Evaluation; SOFA = Sequential Organ Failure Assessment 
Table 3 : Isolated micro-organisms and their susceptibility  
Micro-organism Number of positive cultures Breakpoint MIC* 
Escherichia coli 4/12 8 
Staphylococcus aureus 2/12 4 
Haemophilus influenza 1/12 2 
Klebsiella oxytoca 1/12 8 
Raoultella ornithinolytica 1/12 ND 
Proteus mirabilis 1/12 ND 
Streptococcus pneumoniae 1/12 1 
Morganella morganii 1/12 ND 
*As described by EUCAST ;[235] ND = not determined  
Pharmacokinetic analysis 
The best base model consisted of a two-compartment linear model with zero order input 
(ADVAN3 TRANS4 subroutine) with combined additive-proportional residual unknown 
variability. Between-subject variability was supported on clearance, for volume of 
distribution of the central compartment and for volume of distribution of the peripheral 
compartment.  
 The only covariate that statistically improved the base model was creatinine 
clearance, normalized to the population’s mean creatinine clearance, 100 mL/min, which 
decreased the objective function value by 37.9 points and decreased BSV on clearance from 
 
 
0.94 to 0.29. All other covariates showed no correlation with any of the PK parameters and 
were therefore not further investigated. The final model is represented as: TVCL= 
θ1*(CrCl/100) 
The typical value of clearance (TVCL) was calculated as a function of creatinine clearance, 
normalized to the population’s mean creatinine clearance, 100 mL/min where θ1 is the 
typical value of cefuroxime clearance in the population. 
Figure 1 displays the goodness-of-fit plots for the final covariate model. The fit of the 
model was acceptable in terms of visual or statistical biases for the prediction. The plots in 
figure 1 show that the final PK model describes the measured concentrations adequately. All 
subsequent dosing simulations were then based on this model. 
The values of the parameters for the final models are given in table 4 and include the 
95% confidence intervals for the parameters computed from all bootstrap runs.  
Dosing simulations 
The probability of target attainment for different dosing regimens and different 
creatinine clearances are shown in figure 2.  
The standard dose of 1.5 g cefuroxime 3 times daily results in inadequate target 
attainment for patients with a creatinine clearance ≥ 50 mL/min. This standard dose leads to 
a 87 % probability of target attainment for patients with a creatinine clearance of 50 mL/min 
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Fig. 1. Diagnostic plots for the final population pharmacokinetic covariate model. (a) 
population predicted cefuroxime concentrations versus observed concentrations (R² 0.86). 
(b) individual predicted cefuroxime concentrations versus observed concentrations (R² 
0.99). The nonlinear regression line of fit is shown by the solid black line, and the line of 
identity xy is the gray dotted line. (c) visual predictive check generated from a monte carlo 
simulation (n=1500) and showing that the estimated population pharmacokinetic model 
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Table 4: Bootstrap parameter estimates of the final covariate model 
 Model Bootstrap  
 Median  median  95 % confidence interval  
   2.5 % 97.5 % 
Fixed effects     
Cl (L/h) 9.0 9.0 8.0 10.1 
Vc (L) 10.5 10.5 8.8 12.9 
Vp (L) 12.0 12.0 9.3 14.6 
Q (L/h) 18.7 18.4 11.8 23.8 
Random effects 
 BSV (% CV) 
    
Cl (L/h) 28.0 27.1 19.0 34.6 
Vc (L) 23.7 22.0 3.3 33.0 
Vp (L) 29.5 26.0 4.8 43.6 
Random error     
Proportional (% CV) 10.3 10.4 7.3 13.9 
Additive (SD, mg/L) 0.46 0.43 0.01 0.7 
Cl = Clearance; Vc = Volume of distribution of the central compartment; Vp = Volume of 
distribution of the peripheral compartment; Q = Intercompartmental clearance; BSV = 
between subject variability; CV = coefficient of variation, SD = standard deviation 
 
2.4. Discussion  
This is the first paper to investigate the population pharmacokinetics of cefuroxime in 
critically ill patients. We found that antibiotic clearance was proportional to creatinine 
clearance, with important variability between patients for antibiotic clearance. Current 
dosing schemes are not adequate for critically ill patients with a creatinine clearance ≥ 50 
mL/min when conservative PK/PD targets are used. 
Two pharmacokinetic studies in ambulatory and general ward patients who were treated 
with cefuroxime have been published before. The first study evaluated patients with a 
creatinine clearance between 60 and 120 mL/min and reported a mean Vd, of 16.5 L and a 
clearance of 7.4 L/h [254]. Another study in general ward patients found a typical population 
value for clearance of 6.0 L/h and also a Vd of 16.5 L [255]. This value for clearance is slightly 
lower than our findings, most likely because of their study population, which had a lower 
creatinine clearance than our study population. The values observed for volume of 
distribution from these studies are lower than the value reported in our study (23.2 L). A 
larger than normal volume of distribution is one of the typical pathophysiological changes in 
critically ill patients, a finding reported by multiple pharmacokinetic studies in critically ill 
patients [93, 140, 157, 256]. These differences from healthy volunteers highlight once again 
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the importance of performing population pharmacokinetic studies and dosing simulations in 
our specific patient population. 
By performing dosing simulations and investigating the probability of target attainment 
we have demonstrated that intermittent infusion of 1.5 g cefuroxime 8 hourly will not 
ensure 90 % probability of target attainment (plasma free concentrations > MIC for at least 
65% of the dosing interval) for MIC 8 - The EUCAST breakpoint for cefuroxime for Escherichia 
coli - for patients with a creatinine clearance ≥ 50 mL/min.[235] This problem is exacerbated 
in patients with higher creatinine clearances such as 100, 200 or even 300 mL/min. These 
patients have a high probability of underdosing, even for lower and frequently encountered 
MIC values such as 4, 2 and 1 mg/L. 
It is important to point out that there may be other covariates which may also influence 
plasma concentrations, such as body weight on volume of distribution, or SOFA score. 
However, only creatinine clearance could be retained in the final covariate model, as none of 
the other patient characteristics statistically significantly improved the model, and therefore, 
they could not be included. The reason for this is most likely the relatively small sample size 
of this study. 
Previous research has already demonstrated that patients with augmented renal 
clearance have a low probability of target attainment[120, 156, 257]. In our study population 
of 20 patients, 8 patients had a creatinine clearance >150 mL/min, 4 of which were higher 
than 200 mL/min. Research in critically ill patients shows that higher PK/PD targets may be 
associated with better outcomes [42, 43]. If one aims to achieve these higher targets such as 
100% fT>MIC or even 100% fT>4xMIC other strategies are necessary for all patients without renal 
dysfunction.  
In order to achieve sufficient exposure for an MIC of 8 mg/L, patients with a creatinine 
clearance ≥ 50 mL/min should be treated with alternate dosing strategies, such as extended 
or continuous infusion. Patients with creatinine clearances ≥100 mL/min need higher 
dosages and/or alternate dosing strategies such as extended and continuous infusion. Some 
patients with very high creatinine clearances (≥ 300 mL) need up to 9 g as a continuous 
infusion in order to achieve adequate concentrations. However, the clinical superiority of 
continuous infusions of high doses cefuroxime compared to standard intermittent dosing 
has yet to be demonstrated. It should also be noted that continuous infusion of high doses 
 
 
does not guarantee adequate concentrations for all patients with a creatinine clearance of 
300 mL/min if the MIC of the micro-organism is 8 mg/L. 
This paper has a number of limitations. First, we have not investigated free 
concentrations or concentrations at the site of infection. Instead, we have measured total 
drug concentrations with correction for protein binding based on literature [240, 253]. This is 
an oversimplification, but research has shown that this approach is acceptable for low to 
moderately protein bound drugs such as cefuroxime although it is not accurate for more 
highly protein bound drugs [219]. Also, the small cohort of 20 patients could be considered a 
limitation of this study, given the variability of patient sickness severity. This small cohort 
may have also prevented other covariates from being shown to be significant and predictive 
of the variability of pharmacokinetic parameters, such as body weight on volume of 
distribution. Due to the inclusion criteria of the study, the dose recommendations derived 
from the data analysis cannot be extrapolated to other critically ill patient populations such 
as patients with renal replacement therapy or that are obese.  
2.5. Conclusion 
In this study in critically ill patients treated with cefuroxime, we found important 
variability in antibiotic clearance and a larger than normal volume of distribution compared 
to general ward patients. The results of the dosing simulations show that current dosing 
regimens of 1.5 g cefuroxime administered 8-hourly as a bolus infusion leads to underdosing 
for many patients, whereas continuous infusion of higher than normal doses after a loading 
dose is more likely to achieve pharmacokinetic/pharmacodynamic targets. However, even 
continuous infusion of high doses (up to 9 g per day) does not guarantee adequate 
concentrations for all patients with a creatinine clearance of 300 mL/min or higher if the MIC 
is 8 mg/L.  
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Abstract 
Purpose: The aim of this study was to describe the population pharmacokinetics of cefepime 
in septic shock patients requiring continuous renal replacement therapy and determine 
whether current, or alternative dosing regimens can achieve 
pharmacokinetic/pharmacodynamic (PK/PD) targets. 
Methods: In this observational PK study, 62 samples from 13 patients were analyzed using 
non-linear mixed-effects modeling. Different dosing regimens were evaluated using Monte 
Carlo simulations with ultrafiltration flow rates (UFR) of 1000, 1500 and 2000 mL/h. The 
probability of target attainment calculated against a conservative (60 % T>MIC) and a higher 
PK/PD targets (100 % T>MIC against a minimum inhibitory concentration (MIC) of 8 mg/L, 
which is the clinical susceptibility breakpoint for Pseudomonas aeruginosa.  
Results: A one-compartment model with between-subject variability (BSV) on clearance and 
volume of distribution described the data adequately. Ultrafiltration rate was supported as a 
covariate on both parameters. The typical values for clearance and volume of distribution 
were 4.4 L/h (BSV  37%) and 40.9 (BSV 20%) L respectively. Dosing simulations showed 
failure to achieve both a conservative and a higher  PK/PD target using a dose of 1g q12h for 
patients treated with a high UFR (≥1500 mL/h). The dose of 2g q8h or 1g q6h leads to an 
optimal target attainment for high UFR. One g q8h is optimal for low UFR (≤1000 mL/h). 
 Conclusions: We found important variability in PK parameters. The dosing simulations show 
that a dose of 2g q8h or 1g q6h is needed to ensure rapid achievement of adequate levels if 
the UFR ≥1500 mL/h, and 1 g q8h for low UFR (UFR ≤ 1000 mL/h).  
3.1. Introduction 
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Septic shock is a leading cause of mortality and morbidity in intensive care units with 
hospital mortality as high as 40% [258]. Timely and adequate antibiotic therapy is then 
essential to maximize survival and is therefore highly recommended in the Surviving Sepsis 
guidelines [23, 59, 259].  
-lactam antibiotics are used as first-line therapy in this setting because of their potent 
bactericidal activity and wide therapeutic window. These antibiotics are considered to be 
time-dependent, which means the duration of the dosing interval for which the 
concentration exceeds the minimum inhibitory concentration (MIC) of the pathogen is the 
best descriptor of the bacterial killing. In vitro and animal pharmacodynamics (PD) models 
have shown that for cephalosporins, 60-70 % of the time that drug concentrations are above 
the MIC (%T>MIC) between two administrations was associated with maximal killing [260], 
while retrospective studies in critically ill patients suggest higher targets such as 100% T>MIC 
might be needed to treat life-threatening infections [42, 43, 46]. However, several studies 
have shown that the pharmacokinetic (PK) behavior of these hydrophilic antibiotics is 
profoundly disturbed in critically patients, due to different pathophysiological changes [39]. 
A higher volume of distribution and either an increased or decreased clearance compared to 
healthy volunteers has been shown in numerous studies. As such, low concentrations have 
been reported in sepsis, and may lead to treatment failure and development of antimicrobial 
resistance [93].  
Acute kidney injury is a common complication of sepsis and may lead to accumulation of 
hydrophilic drugs, which are mainly renally excreted.  Although not very common, toxicity 
from -lactam antibiotics may occur and is associated with high concentrations [107]. 
Extracorporeal circuits such as those used for continuous renal replacement therapy (CRRT) 
may further complicate PK. Indeed, recent studies showed a wide variability in antibiotic 
concentrations during CRRT, with many patients having low concentrations early in therapy, 
and accumulation occurring in the next days [107-109]. Unfortunately, there is relatively 
little clinical data on the drug removal by CRRT; moreover, it is unclear how the specific CRRT 
settings, such as ultrafiltration flow rate (UFR) and dialysis flow rate influence drug 
concentrations. Current recommendations on antibiotic dosing during CRRT are based on 
studies that included a limited sample size of patients who received different types of CRRT 
[261].  
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Cefepime is a fourth-generation cephalosporin with a broad spectrum of activity against 
both gram-positive and gram-negative pathogens including P. aeruginosa. Cefepime is 
commonly used as empirical or directed therapy for a variety of infections in critically ill 
patients. Adequacy of cefepime dosing during CRRT has previously been evaluated in studies 
with small cohorts of patients; however, a population PK approach for analysis was not used 
[262, 263], and therefore these studies could not adequately describe the influence of CRRT 
settings on cefepime PK. Moreover, these studies sampled after having reached assumed 
steady state and therefore could not evaluate cefepime PK during the early phase of 
treatment, where the risk of underdosing is the greatest. Therefore the aim of this study was 
to describe the population PK of cefepime in septic shock patients requiring CRRT and 
investigate if pharmacokinetic/pharmacodynamic (PK/PD) targets are achieved with current 




In this study, we pooled data from two previously published PK studies, the details of which 
have been described elsewhere [107, 108]. The first study was a PK study with blood 
sampling on multiple occasions [108]. The study was conducted according to the principles 
of the Helsinki Declaration for human research, and was approved by the local ethics 
committee. An informed consent was obtained from the patient if possible or from a legally 
authorized representative. The second study reviewed data that had been collected as part 
of routine treatment. Therefore, the ethics committee waived the need for informed 
consent because of its retrospective nature [107]. The inclusion criteria of the first study 
were as follows: age > 18 years; diagnosis of severe sepsis or septic shock according to 
standard criteria; acute renal failure treated with CRRT; and receiving cefepime. Exclusion 
criteria were pregnancy, burns and cystic fibrosis. For the second study, there were 
additional inclusion criteria, namely a residual creatinine clearance (CrCl) <30 mL/minute 
and at least one therapeutic drug monitoring (TDM) sample taken during the CRRT 
treatment. An additional exclusion criterion was the use of extracorporeal membrane 
oxygenation (ECMO) therapy.  
Drug administration 
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The patients received 2 g every 8 or 12 h, based on guidelines for antibiotic dosing in 
critically ill patients receiving CRRT [261]. The dose was administered as a 30-minute 
intravenous infusion. 
Continuous renal replacement therapy 
CRRT was performed according to local practice by insertion of a double-lumen catheter into 
the subclavian, femoral or internal jugular vein. Continuous veno-venous haemodiafiltration 
(CVVHDF) or continuous veno-venous haemofiltration (CVVHF) were performed using 
standard equipment (Prisma or Prismaflex, Gambro Hospal, Bologna, Italy) with a 
polyacrilonitrile cylinder (AN 69 – Hospal, Meysizeu, France) haemofilter without special 
coating. Anticoagulation was performed using systemic heparin or citrate within the circuit.  
Blood flow rate was set around 130 to 150 mL/minute and the ultrafiltration flow rate was 
adjusted to provide at least 15 to 20 mL/kg/h [107, 108]. CRRT intensity was calculated as 
dialysate flow rate (mL/kg/h) + ultrafiltration flow rate (mL/kg/h). 
Study procedures 
In the first study, blood samples were drawn from the arterial line on the day of inclusion, 
and then every second day during CRRT treatment whenever possible [108]. On each 
sampling day, blood samples were drawn immediately before antibiotic administration (0 
hours), and then 1, 2, 5, and 6 or 12 hours (depending on the antibiotic regimen) after the 
start of the infusion. The exact sampling times were recorded. In the second study, two 
blood samples were drawn during the antibiotic elimination phase: 2 h after the end of 
infusion and just before the next dose administration[107]. 
Samples were immediately put on ice and sent to the clinical chemistry laboratory, where 
they were centrifuged at 3000 rpm at 4°C for 10 minutes; the supernatant was then 
removed and analyzed using a validated high-performance liquid chromatographic 
technique, as described elsewhere [108].  
Additional data were obtained from the medical record and included participant 
demographics, clinical details, measures of illness severity and CRRT settings.  
Pharmacokinetic analysis 
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 The concentration-time data were analyzed using non-linear mixed-effects modeling 
(NONMEM version 7.3, Globomax LLC, Hanover, USA). A Digital Fortran compiler was used 
and the runs were executed using Wings for NONMEM (http://wfn.sourceforge.net). The 
first-order conditional estimation (FOCE) method with interaction was used throughout the 
model building.  
Model development 
 For the population PK analysis, the plasma concentrations were fitted to one-, two-, or 
three-compartment linear models using subroutines from the NONMEM library. Between 
subject variability (BSV) was evaluated using an exponential variability model. Various 
models for residual unexplained variability (RUV) were also tested. 
Model diagnostics 
 Visual inspection of diagnostic scatter plots and the NONMEM objective function value 
(OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was 
undertaken in the NONMEM program on the basis of a χ2 test of the difference in OFV. A 
decrease in the OFV of 3.84 units (p < 0.05) was considered statistically significant for 1 
degree of freedom. Decreases in BSV of one of the parameters of at least 10% were also 
accepted for inclusion of a more complicated model.  
Covariate screening 
Covariate model building was performed in a stepwise fashion with forward inclusion based 
upon the aforementioned model selection criteria for those clinical parameters, which 
showed correlation with one of the PK parameters. Age, sex, weight, body mass index (BMI), 
Sequential Organ Failure Assessment (SOFA) score and CRRT settings (blood flow rate, 
ultrafiltration flow rate, dialysis flow rate and CRRT intensity) were evaluated as covariates. 
In the case two or more parameters (for example weight and BMI, or ultrafiltration flow rate 
and CRRT intensity) both improved OFV, the decision to choose one covariate over another 
was based on the decrease in OFV, comparative improvement in the goodness of fit plots 
and biological plausibility.  
Bootstrap 
A non-parametric bootstrap method (n=1000) using NONMEM was used to study the 
uncertainty of the pharmacokinetic parameter estimates in the final model. From the 
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bootstrap empirical posterior distribution, we obtained the 95% CI (2.5%–97.5% percentile) 
for the parameters as described previously [243]. 
Dosing simulations 
Different dosing regimens were evaluated using Monte Carlo simulations of the final 
covariate model. The ultrafiltration flow rates simulated were 1000, 1500 and 2000 mL/h. 
One thousand subjects were simulated per dosing strategy and per ultrafiltration flow rate. 
The simulated dosages were: 1 g every 12 h, 2 g every 12 h, 2 g every 8 h, 1 g every 8 h and 1 
g every 6 h. All simulated dosages were intermittent infusions.  
For each simulation, the T>MIC was calculated for each simulated subject using linear 
interpolation. The probability of target attainment (PTA) was obtained by counting the 
subjects who achieved the PK/PD target against an MIC of 8 mg/L, which is the susceptibility 
breakpoint of cefepime against Pseudomonas aeruginosa [235]. We also calculated the PTA 
against an MIC of 16 mg/L for the high dose regimens, to evaluate the potential adequacy of 
dosing against less susceptible strains. Both a conservative PK/PD target, 60 % T>MIC and a 
higher PK/PD target, 100 % T>MIC were evaluated.  
We also determined the probability of subjects achieving a toxic concentration which was 
defined as a trough concentration exceeding 70 mg/L after 1 week of therapy based on a 
previous case report which also reviewed the relevant literature [162]. 
3.3. Results 
Patient characteristics 
A total of 62 blood samples from 13 patients were used. Eight patients were enrolled in the 
first study [108]. A second round of sampling was performed in 3 patients. The median 
number of doses before sampling was one (range 0-3). Five patients were enrolled in the 
second study [107]. One patient contributed data on 3 occasions. The median number of 
doses before sampling was 6 (range 0 – 15).  Demographic and general clinical characteristics 
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Table 1: Patient characteristics. Data are reported as median (interquartile range) [range] 
Age (years) 59 (43-70) [19-77] 
Male sex – no (%) 7 (54 %)  
Weight (kg) 70 (65-75) [60-110] 
BMI (kg/m²) 24.5 (23.9-27.2) [20.5-29.4] 
Mechanically ventilated – no (%) 11 (85 %) 
Vasopressors – no (%) 10 (77 %) 
SOFA score at the start of study 10 (9-14) [4-19] 
APACHE II score on admission 20 (14-21) [11-24] 
Blood flow rate (mL/min) 150 (140-150) [100-180] 
Ultrafiltration rate (mL/h) 1750 (1500-2000) [1000-2000] 
CRRT intensity (mL/kg/h) 36 (25-46) [10.5-57.1] 
Anticoagulation  
       Heparin – no (%) 
       Citrate – no (%) 
 
9 (69 %) 
4 (31 %) 
BMI : body mass index, SOFA : sequential organ failure assessment, APACHE : Acute 
Physiology and Chronic Health Evaluation, CRRT : continuous renal replacement therapy 
Pharmacokinetic analysis 
 The best base model consisted of a one-compartment linear model with zero order 
with combined additive-proportional residual unknown variability. Between-subject 
variability was supported on clearance and on volume of distribution. Only RRT intensity and 
ultrafiltration rate improved the baseline model, but ultrafiltration rate caused the greatest 
decrease in objective function and we therefore opted to include ultrafiltration rate as a 
covariate. The model could not be further improved by adding between occasion variability, 
as the decrease in objective function was not sufficient (2.349). As there was no correlation 
between weight (ranging between 60 and 110 kg) and volume of distribution (R² = 0.0068) 
we found no justification to incorporate weight as a covariate on volume of distribution. 
The only covariate supported for addition to the baseline model was ultrafiltration flow rate, 
normalized to the population’s median value of 1750 mL/h.  
The final model is represented as:  
TVCL= θ1*(UFR/1750)  (1)  
TVV= θ2*(UFR/1750)  (2) 
The typical value of clearance (TVCL) was calculated as a function of ultrafiltration flow 
rate, normalized to the population’s median value of 1750 mL/h. The typical value of volume 
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of distribution (TVV) was calculated as a function of ultrafiltration flow rate, also normalized 
to the population’s median value of 1750 mL/h. 
The typical value for clearance was 4.4 L/h (37 % BSV) and for volume of distribution 40.9 
L (20 % BSV). On a L/kg basis, the median value for volume of distribution was 0.66 
(interquartile range 0.48-0.73). The coefficient of variation of the exponential residual 
unexplained variability was 30 % and the standard deviation of the additive residual 
unexplained variability was 3.4 mg/L.  
Figure 1 displays goodness of fit plots and the visual predictive check for the final 
covariate model and  shows that the model describes the measured concentrations 
adequately. All subsequent dosing simulations were then based on this model.  
The values of the parameters for the final models are given in table 2 and include the 
95% confidence intervals  for the parameters computed from all bootstrap runs. 
Dosing simulations 
The PTA for an MIC of 8 mg/L and the probability of achieving a toxic concentration 
for different dosing regimens and different ultrafiltration flow rates are shown in table 3. 
The PTA against an MIC of 16 mg/L for the high dose regimens is summarized in table 4. 
When considering the conservative target of 60 % T>MIC, 1 g of cefepime every 12 h 
will result in adequate concentrations for almost all patients with an UFR of 1000 mL/h, 
however, this is not the case for patients treated with an UFR of 1500 mL/h and 2000 mL/h 
(PTA 80 % and 49% respectively). When aiming for 100 % T>MIC, this dose does not lead to 
sufficient PTA for all ultrafiltration flow rates. There is no accumulation to toxic 
concentrations after one week of treatment, as illustrated in figure 2a and b. 
Two g of cefepime every 12 h results in a high PTA when aiming for the conservative 
target, but still suboptimal when aiming for 100 % T>MIC (PTA 82 % for an UFR of 1500 mL/h 
and 73 % for an UFR of 2000 mL/h). Moreover, it leads to toxic concentrations in 5% of the 
patients treated with an UFR of 1000 mL/h.  
Two g of cefepime every 8 h results in optimal target attainment for both the 
conservative, as well as the high target for all ultrafiltration flow rates, however it leads to a 
significant proportion of patients achieving toxic levels after one week of treatment (up to 
30 % for patients treated with an UFR of 1000 mL/h, as shown in figure 2c). One g every 8 h 
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ensures optimal target attainment for an UFR of 1000 mL/h while minimizing toxicity (figure 
2e). However, this dose results in a PTA of only 79 % for patients with an UFR of 2000 mL/h 
when aiming for 100 % T>MIC. One g every 6 h leads to optimal PTA for patients treated with 
an UFR of 1500 and 2000 mL/h (97 % and 93 % respectively for the target of 100 % T>MIC), 








Diagnostic plots for the final population pharmacokinetic covariate model. (a) population 
predicted cefepime concentrations versus observed concentrations (R²=0.41). (b) Individual 
predicted cefepime concentrations versus observed concentrations (R²=0.87). The non-linear 
regression line of fit is shown by the black continuous line and the line of identity xy is shown 
by the grey dotted line. (c) Visual predictive check generated from a Monte Carlo simulation 
(n=1000) and showing that the population pharmacokinetic model has adequate 
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Table 2 : Bootstrap parameter estimates of the final covariate model 
 Model  Bootstrap  
 Mean   Mean  95 % confidence 
interval  
   2.5 % 97.5 % 
Fixed effects     
Cl (L/h) 4.5 4.5 3.6 5.6 
V (L) 40.8 40.6 33.4 48.7 
Random effects 
 BSV (% CV) 
    
Cl (L/h) 37.7 35.9 17.1 49.5 
V (L) 21.2 19.9 0.2 26.8 
Random error     
RUV (% CV) 20.4 19.9 10.9 27.3 
RUV (SD, mg/L) 3.3 3.3 0.03 5.8 
Cl = Clearance, V = Volume of distribution ; BSV = between subject variability; RUV = residual 















































































































































































































































































































































































































































































































































































































































Figure 2: Dosing simulations for cefepime different doses for different ultrafiltration flow 
rates. Legend: black line : 50 % percentile, grey lines : 2.5 and 97.7 % percentiles. (a) 
cefepime 1 g every 12 hours ultrafiltration flow rate 1000 mL/h. (b) cefepime 1 g every 12 
hours ultrafiltration flow rate 2000 mL/h. (c) cefepime 2 g every 8 hours ultrafiltration 
flow rate 1000 mL/h. (d) cefepime 2 g every 8 hours ultrafiltration flow rate 2000 mL/h. (e) 
cefepime 1 g every 8 hours, ultrafiltration flow rate 1000 mL/h. (f) cefepime 1 g every 6 
hours, ultrafiltration flow rate 2000 mL/h. UFR : ultrafiltration rate; q12h : every 12 hours; 
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This is the first paper to investigate the population PK of cefepime in septic shock patients 
requiring CRRT. We found that antibiotic clearance was proportional to ultrafiltration flow 
rate, with important variability between patients for both clearance and volume of 
distribution. The typical values we found for clearance (4.4 L/h) closely resembled the value 
for clearance found in a previous study (4.0 L/h) in patients treated with CRRT [263]. The 
same applies for the volume of distribution, where previous study found a volume of 
distribution of 0.71 L/kg, and we found a mean value for volume of distribution of 0.64 L/kg 
[263].  
Another study has also been published, which investigated the PK separately for patients 
treated with CVVH and CVVHDF, found a smaller volume of distribution of 0.46 L/kg for the 
patients treated with CVVH (which removes solute by convection, and therefore no dialysate 
is used), and a clearance of only 2.1 L/h [262]. In the patients treated with CVVHDF (which 
removes solute both by diffusion and convection, and uses both ultrafiltration and dialysis), 
the mean volume of distribution was 0.34 L/kg and a clearance of 2.8 L/h [262]. However, 
the mean ultrafiltration flow rate was 960 mL/h in the case of CVVH and 1020 mL/h in the 
case of CVVHDF. In our study the mean ultrafiltration flow rate of 1673 mL/h was 
significantly higher than the ultrafiltration flow rates used in this previous study. As 
ultrafiltration flow rate is a covariate on both volume of distribution and clearance, this may 
explain the higher typical values for volume of distribution and clearance in our study.  
Multiple studies have already investigated cefepime concentrations during CRRT, although 
not specifically in patients requiring vasopressor support. Two studies report that 1–2 g 
every 12 h is sufficient to maintain adequate plasma concentrations [262, 263]. One study 
reported low concentrations during high blood and dialysate flow rate in CVVH [264]. We 
have found that a dose of 1 g every 12 h, as suggested by a previous PK study, will not 
achieve 60 % T>MIC exposures for 20 % of the patients treated with an ultrafiltration flow rate 
of 1500 mL/h (69 % when aiming for 100 % T>MIC) when the MIC is 8 mg/L, and up to 50 % 
when the ultrafiltration flow rate is 2000 mL/h (91 % of the patients when aiming for the 
higher PK/PD target of 100 % T>MIC) [262].  
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When aiming for the minimum PK/PD target of 60 % T>MIC, the recommended dose of 2 g 
every 12 h will still result in inadequate exposure in 5 % of the patients treated with a high 
flow ultrafiltration flow rate of 2000 mL/h, and 27 % of the patients when aiming for the 
higher PK/PD target of 100 % T>MIC  [261].   
Because of our population PK approach, we were able to investigate the effect of CRRT 
settings on the cefepime PK and have found that a dose of 2 g every 8 h or 1 g every 6 h 
leads to an optimal target attainment (100 % fT>MIC) whilst minimizing the probability of 
reaching toxic trough concentrations for patients treated with a high ultrafiltration flow rate 
(1500 – 2000 mL/min). However, the optimal dose for patients treated with lower 
ultrafiltration flow rates  (1000 mL/h or less) when aiming for the high target was 1g every 8 
h. However, even when the dose is adapted to the ultrafiltration flow rate, there is still a 
huge variability in concentrations between patients, as shown in figure 2, which supports a 
potential role for therapeutic drug monitoring.  
There are a number of limitations of the current analysis we would like to discuss. First, we 
only investigated total concentrations in blood, while the unbound antibiotic is responsible 
for the pharmacological effect. However, protein binding for cefepime is low, and therefore 
the potential effect of changes in protein binding is expected to be limited. Secondly, we 
only sampled blood, and did not investigate concentrations in the fluids pre and post filter, 
so we are unable to be more mechanistic with our description of altered pharmacokinetics. 
Moreover, the study designs of the 2 studies which contributed the data for this population 
pharmacokinetic model are different and are associated with different limitations. Most of 
the blood samples from the second study were sampled comparatively late in the antibiotic 
course and are likely to represent an apparent steady state, while the blood samples from 
the PK study were sampled much earlier, most likely before steady state was reached. This 
problem should be overcome through use of the non linear mixed effects modeling used 
here. However, a potential problem is that the performance of the filter may change over 
time, something which cannot be taken into account in this retrospective pharmacokinetic 
analysis because of a lack of data on filter age. Also, the type of filter may affect the 
pharmacokinetics. This study was conducted using a polyacrylonitrile membrane hemofilter, 
and as such, our findings apply for this kind of filter only, and not for filters made from other 
materials, such  as polysulfone. Although none of the patients were taken off CRRT during 
Chapter 5 : Pharmacokinetic Studies
 
 
sampling, it is possible that this happened during the previous days, which may result in 
some drug accumulation. We did not investigate cefepime associated toxicity in this study. A 
study on the toxicity of -lactam antibiotics in critically ill patients found around 30 % 
neuroworsening in patients treated with cephalosporins, which was similar to those treated 
with penicillins or carbapenems [35]. However, there was no correlation between 
cephalosporins concentrations and the risk of neuroworsening while this was found for 
other -lactam antibiotics. It is clear that the study of toxicity is difficult, with many 
confounders, and that setting a specific concentration threshold is also difficult. The 
threshold we used for toxicity (trough concentration > 70 mg/L after 1 week of treatment) 
has been synthesized from published reports in the literature. There is limited evidence 
between concentrations and neurological toxicity, although there is strong biological 
plausibility. From the available literature it is apparent that cefepime is associated with 
seizures and this effect is concentration-dependent. The majority of published case reports 
on cefepime associated toxicity report concentrations around 70 mg/L although 
concentrations as low as 22 mg/L have been described [265]. A more specific threshold may 
be defined in the future, but since this is not available now, we set the toxicity threshold at 
70 mg/L. Finally, we did not measure residual creatinine clearance, which may also influence 
antibiotic clearance.  
Therefore, larger and better designed studies are needed. However, in absence of these 
studies, we believe that the findings of this study are relevant as this is the first study 
reporting on the influence of CRRT settings on cefepime concentrations.  
3.5. Conclusion 
In this study in septic shock patients needing CRRT treated with cefepime, we found 
important PK variability in antibiotic clearance and volume distribution. The results of the 
dosing simulations show that a high dose of 2 g every 8 h or 1 g every 6 h  is needed when 
the ultrafiltration rate is 1500 mL/h or more. A lower dose of 1 g every 8 h is optimal when 
the ultrafiltration rate is 1000 mL/h or less. 
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Abstract  
Background: Extended infusion of beta-lactam antibiotics has been advocated as a method 
for optimizing antibiotic exposure in critically ill patients. The objective of this study was to 
compare the pharmacokinetics/pharmacodynamics of extended infusion versus bolus 
infusion of piperacillin and meropenem in critically ill patients with normal renal function. 
Methods: A prospective study of 3-h extended infusion of meropenem and piperacillin in 
critically ill patients without renal dysfunction. Results from the extended infusion cohort 
were compared to previously published bolus infusion data in critically ill patients. 
Results. Twenty extended infusion patients (15 piperacillin, 5 meropenem) were compared 
with 13 bolus infusion patients (8 piperacillin, 5 meropenem). The demographic and clinical 
characteristics between both groups were not statistically different. Significant 
pharmacokinetic differences were observed in median (interquartile range) Cmax for both 
meropenem (extended infusion 17.0 (12.6-21.9) vs. bolus 85.2 (66.7-140.3); p=0.01) and 
piperacillin (extended infusion 76.2 (57.7-92.6) vs. bolus 240.2 (168.5-275.4); p=0.001). 
Considerable pharmacokinetic variability existed in each group for both drugs. Compared to 
bolus infusion, fT>MIC using extended infusion was higher for both drugs: 96% (IQR 71-100%) 
compared to 77% (IQR 41-93%) for piperacillin (p=0.05) and 82% (IQR 63-89%) compared to 
51% (IQR 48-63%) for meropenem (p=0.095); assuming an MIC of 16mg/L and 2mg/L 
respectively.  
Conclusion. This study confirms that extended infusion in critically ill patients result in 
advantageous pharmacokinetic profiles by increasing the fT>MIC for piperacillin and 
meropenem. In a significant subpopulation of critically ill patients with normal renal 
function, a 100% fT>MIC target is not reached, even with 3-hour extended infusions. 
  




Broad-spectrum beta-lactam antibiotics are effective against a wide range of pathogens 
isolated from infected intensive care unit (ICU) patients, and are essential for effective 
empirical antibiotic therapy of various infections. From a pharmacodynamic point of view, 
these are time-dependent antibiotics, which means that the time during which the unbound 
antibiotic concentration exceeds the minimal inhibitory concentration (fT>MIC) of the 
pathogen, determines bacterial killing.  
In critically ill patients, pharmacokinetics of beta-lactam antibiotics may differ from 
healthy volunteers [97]. Lower than expected concentrations have been reported for 
meropenem, piperacillin, amoxicillin, as well as for cephalosporins [39, 49]. Increased 
elimination from the circulation, most often due to increased renal clearance and changes in 
the volume of distribution are often cited as the main causes for this [39]. These lower 
antibiotic concentrations may lead to a reduction of the fT>MIC in patients treated with beta-
lactam antibiotics, increasing the risk of clinical failure of the antibiotic therapy. 
To overcome this problem, continuous and extended infusion of beta-lactam antibiotics 
have been advocated as a method for optimizing beta-lactam antibiotic exposures in 
critically ill patients [266]. Whilst pharmacokinetic simulation data exist [140, 157, 242, 267-
270], actual concentration-time data from critically ill patients supporting use of extended 
infusions are lacking. The objective of this study was to compare the 
pharmacokinetics/pharmacodynamics of extended infusion versus bolus infusion of 
piperacillin and meropenem targeting different fT>MIC targets (100% fT>MIC , 50% fT>MIC and 
100% fT>4xMIC ) in critically ill patients with normal renal function. 
4.2. Materials and methods. 
Data for the pharmacokinetics of extended infusion piperacillin and meropenem were 
collected in a prospective pharmacokinetic study performed in the medical and surgical ICU 
of the Ghent University Hospital, a tertiary care hospital with a total of 50 adult ICU beds. 
Patients receiving either meropenem (Meronem®, AstraZeneca) or piperacillin/tazobactam 
(Tazocin®, Pfizer) were included if they did not meet exclusion criteria which included renal 
dysfunction (defined as an estimated glomerular filtration rate (eGFR) assessed by the 
Modification of Diet in Renal Disease (MDRD) equation of <80mL/min/1.73 m2), age<18 
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years, absence of an arterial catheter or absence of informed consent from the patient or 
the legal representative of the patient. 
In the patients receiving extended infusion, the antibiotics were administered according 
to the extended infusion protocol used at Ghent University Hospital: patients receive a 
loading dose (1g meropenem or 4g piperacillin) administered over 30 minutes, followed 
immediately by the first extended infusion dose of either antibiotic (1g meropenem or 4g 
piperacillin) every 6h for piperacillin and every 8 hours for meropenem. Extended infusion 
doses are administered over 3 hours using a syringe pump. All antibiotics were administered 
via a central venous catheter.  
Data collected at baseline included demographic data, severity of illness at admission 
(APACHE-II [271] and SOFA [272] score), and severity of organ dysfunction at study inclusion 
(SOFA score).  
Serial plasma concentrations were obtained between 24-48 hours after the start of 
therapy at baseline (T0, just prior to initiation of the extended infusion) and after 60 (T1), 
120 (T2), 180 (T3), 210 (T4), 240 (T5), 270 (T6), 360 (T7) and 480 (T8) minutes for 
meropenem; at baseline (T0, just prior to initiation of the extended infusion) and after 60 
(T1), 120 (T2), 180 (T3), 210 (T4), 240 (T5), 270 (T6), 300 (T7) and 360 (T8) minutes for 
piperacillin.  
For each sample, 5mL of blood was collected in anticoagulant tubes without separator 
gel, via the arterial catheter. Specimens were centrifuged at 3000 rpm for 10 min within 
30minutes of sampling, and then frozen at minus 80°C. They were shipped to the Burns, 
Trauma, & Critical Care Research Centre of the University of Queensland, Australia for 
analysis through a specialized carrier.  
Kidney function was described using serum creatinine concentrations and measured 24-h 
urinary creatinine clearance. 
Assuming an MIC90 of 16mg/L (piperacillin) and 2mg/L (meropenem) [235], fT>MIC was 
calculated and a 100% fT>MIC was considered the desired 
pharmacokinetic/pharmacodynamic target. Secondary PK targets were 50% fT>MIC and 100% 
fT>4xMIC. 
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Comparison with bolus infusion 
Pharmacokinetic results were compared to data from bolus infusion obtained in previous 
prospective pharmacokinetic studies [140, 157]. 
Assay 
Samples for both the extended infusion and the previously conducted bolus infusion studies 
were both analyzed at the Burns Trauma and Critical Care Research Centre, The University of 
Queensland. The plasma concentrations of meropenem and piperacillin were determined by 
validated High Performance Liquid Chromatography (HPLC) methods based on a published 
procedure that has been optimized for each drug [168]. Sample preparation was by protein 
precipitation with acetonitrile and a wash step with dichloromethane. Separations were 
performed on a Waters X-bridge C18 column (2.1 x 30 mm, 2.5 nm) with an 
acetonitrile:phosphate buffer mobile phase (pH 2.5 for meropenem, pH 3 for piperacillin). 
Detection was by UV at 304 nm (meropenem) or 210 nm (piperacillin). The meropenem 
assay was linear from 0.2 to 100 mg/L with a precision and accuracy <7% at high, medium 
and low concentrations. The piperacillin assay was linear from 0.5 to 500 mg/L with a 
precision and accuracy <10% at high, medium and low concentrations. 
Pharmacokinetic analysis 
The pharmacokinetic values were calculated using non-compartmental methods. The 
area under the concentration time curve from 0-8 hours (AUC0-8) was calculated using the 
linear trapezoidal rule. The AUC from 0 to infinity (AUC0-∞) was calculated using AUC0-8 and 
the apparent terminal elimination rate constant ( z) which was determined from log-linear 
least squares regression analysis of concentrations from 2-8 hours (meropenem) or 2-6 
hours (piperacillin). Total body clearance (CLtot) was calculated as dose/AUC0-∞. The area 
under the moment curve from 0-8 hours (AUMC0-8) was calculated using the linear 
trapezoidal rule and AUMC from 0-∞ (AUC0-∞) and z. Mean residence time (MRT) was 
calculated as AUMC0-∞/AUC0-∞. The maximum concentration for the dosing period (Cmax) and 
the minimum concentration for the dosing period (Cmin) were the observed values; the 
apparent volume of distribution during terminal phase (Vz) = CL/ z; the half life (T1/2) = 
ln(2)/ z .  
 




The f T>MIC was calculated by observing the time during the dosing interval that the log-
linear least squares regression analysis of concentrations in the elimination phase 
intersected the target MICs (16 mg/L for piperacillin and 2 mg/L for meropenem based on 
EUCAST breakpoints available at www.eucast.org). Observed concentrations were corrected 
for protein binding (piperacillin 30%; meropenem 2%) [273]. 
Statistical analysis 
The statistical analysis was performed using the statistical software package SPSS 19.0 
(SPSS Inc. Chicago, USA). Categorical variables were compared with the Fisher’s exact test; 
continuous variables were analyzed using the Mann Whitney-U test. Data are expressed as 
median values with interquartile ranges (IQR) for continuous variables, numbers and 
percentages for categorical variables. All tests were two-tailed, and P<0.05 was considered 
statistically significant. 
Ethics 
The study was approved by the Ethics Committee of the Ghent University Hospital 
(registration number 2009/543) and registered with the European Union Drug Regulating 
Authorities Clinical Trials (registration number 2008/006825-15). The bolus infusion studies 
were previously approved by the Ethics Committee of the Royal Brisbane and Women’s 
Hospital, Brisbane, Australia (registration numbers 2005/072 and 2005/028). Written 
informed consent was obtained from the patient or his/her legal representative. 
4.3. Results. 
Patient characteristics. 
Twenty patients receiving extended infusion (15 piperacillin/tazobactam and 5 
meropenem) were compared to 13 patients receiving bolus infusion. Extended and bolus 
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Table 1. Patient characteristics from extended infusion and bolus infusion groups (data are 
presented as median (interquartile range). 
 Meropenem Piperacillin 













Age (year) 54 (51-60) 55 (48-61) 0.84 60 (52-73) 41 (22-65) 0.19 









Weight (kg) 90 (85-90) 80 (75-85) 0.55 78 (70-82) 83 (75-86) 0.24 
SeCr 
(μmol/L) 
44 (43-54) 73 (55-
101) 
0.10 59 (45-64) 57 (49-69) 0.73 
SOFA 5 (3-10) 3 (3-4) 0.22 7 (4-9) 3 (3-5) 0.07 
Legend: SOFA – Sequential Organ Failure Assessment; SeCr – Serum creatinine 
All patients but one received the standard dose, either 1g meropenem or 4g 
pipieracillin/tazobactam. One patient received high dose meropenem (2g/8h) according to 
the same scheme for a central nervous system infection, but this was accounted for in the 
pharmacokinetic analyses.  
Pharmacokinetics results. 
Extended infusion patients had significantly lower Cmax and higher Cmin values; the area 
under the concentration-time curve during 8-hour dosing period and mean residence time 
were also longer in extended infusion patients (table 2). Volume of distribution, the 
elimination rate constant and total drug clearance were comparable for both meropenem 
and piperacillin.  
Considerable variability was found in both bolus and extended infusion, as illustrated by the 
wide IQR for all pharmacokinetic variables.  
Target attainment 
Compared to bolus infusion, fT>MIC was higher using extended infusion for both 
antibiotics: 96% (IQR 71-100%) compared to 77% (IQR 41-93%) for piperacillin (p = 0.05) , 
and 82% (IQR 63-89 %) compared to 51 % (IQR 48 – 63 %) for meropenem (p = 0.02) (Figure 
1 and 2). 
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All patients receiving piperacillin as an extended infusion achieved the minimum 
pharmacokinetic target of 50% fT>MIC, whilst only 62.5 % of the patients receiving piperacillin 
as a bolus infusion achieved this target (p=0.007). This was not statistically significant for 
meropenem (100 % vs. 60 %, p = 0.4). Only half of the patients on piperacillin as an extended 
infusion achieved the target of 100% fT>4xMIC , versus none of the patients receiving 
piperacillin as a bolus infusion (p= 0.013). None of the patients receiving meropenem 
achieved 100% fT>4xMIC, regardless of infusion strategy.  
 




Fig. 2. Median piperacillin concentrations in patients treated with extended and bolus 
infusion 



























































































































































































































































































































































































































































































































































































































































































































































































In this study, we observed considerable variability in pharmacokinetics of extended 
infusion piperacillin and meropenem in critically ill patients that is similar to the variability 
observed in bolus infusion studies. Although this is one of the first reports of actual 
concentration-time data of extended infusion in critically ill patients, our findings are in line 
with earlier reports that have looked at different administration modalities of these 
antibiotics [140, 157]. This pharmacokinetic variability also translated to PD variability from 
variable PK/PD target attainment rates. These results suggest that even 3-hour extended 
infusion TID or QID may not be sufficient to reach a predefined PK/PD target of 100% fT>MIC 
in the majority of patients.  
A previous study by Shea et al., studying 13 hospitalized patients who received a 4-hour 
extended infusion of piperacillin/tazobactam [269], reported that Cmax and Cmin were 
considerably higher than in the current study. Despite the longer infusion duration, mean 
Cmax was 108.2 mg/L and Cmin 27.6 mg/L, levels that were only reached in less than 25% of 
the patients in our study. This illustrates that pharmacokinetics in critically ill patients with a 
median SOFA score of 7 at the moment of sampling, may still be significantly different from 
hospitalized patients, probably due to the pathophysiological changes of critical illness [274]. 
Compared to bolus infusion, extended infusion resulted in better PK/PD target 
attainment rates. fT>MIC was higher for both antibiotics, reaching 82 % fT>MIC for meropenem, 
and 96 % for piperacillin. Obviously, target attainment rates will be much lower for higher 
targets such as fT>4xMIC, and extended infusion alone may not be sufficient to reach these 
higher targets. Increasing the dosing frequency or using continuous infusion may be a 
solution to increase target attainment, but also standard dosages for these antibiotics may 
be inadequate. It is striking that current dosing schemes do not always result in adequate 
antibiotic concentrations, which may be explained by the fact that dosing commonly is based 
on PK data from healthy volunteers or non-critically ill patients. Therefore increasing the 
dose administered over 24h may also be necessary, irrespective of the infusion strategy 
chosen. 
We also found that increased creatinine clearance is a frequent phenomenon in patients 
treated with antibiotics. Although the exclusion of kidney dysfunction is an obvious bias, the 
problem of augmented renal clearance (ARC) cannot be underestimated [110, 275]. Studies 
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in selected patients such as severe closed head injury have reported incidences of ARC as 
high as 85% [276]. Using a cut-off of 130mL/min, we have previously reported that 51.6% of 
patients with apparent normal renal function receiving antibiotic therapy have increased 
creatinine clearance, and that this was associated with worse clinical outcome [117]. 
Although renal elimination is by no means the sole determinant of low antibiotic 
concentrations, it is associated with higher drug clearance and has been associated with low 
trough concentrations [120, 156, 277]. Because it can be easily measured in clinical practice, 
it provides an appropriate method to predict those patients at risk of sub-therapeutic 
antibiotic exposures who are probably at the highest risk of clinical failure. Efforts should be 
done to more rapidly identify these patients, either using clinical characteristics or 
biomarkers. 
The question remains however if efforts should not concentrate on developing analytical 
methods for rapid determination of antibiotic concentrations. Currently, HPLC or similar 
methods are labor intensive, and turnaround times are at least 4h; moreover, laboratories 
performing these analyses usually do a limited number of runs per week, which limits 
practical use of therapeutic drug monitoring of beta-lactam antibiotics [168, 169, 178, 224]. 
Extended infusion of antibiotics is easy to apply in critically ill patients. Most patients 
have multi-lumen central venous catheters, and the equipment needed (syringes and a 
syringe pump) is readily available in most ICUs. We prefer the use of syringe pump as 
infusion pumps require special tubing sets which have high priming volumes, which may 
result in incomplete or interrupted administration of the antibiotic [278].  
Strategies aimed at improving the use of currently available antibiotics are highly 
relevant, since few new antibiotics are being developed, especially for Gram-negative 
infections. From this study it can be concluded that antibiotics are used suboptimally in 
some patients. Although we focused on piperacillin and meropenem, it can be assumed that 
the same concepts apply for all beta lactam antibiotics. These agents are widely used in ICUs 
around the world. With the advent of more resistant (or less susceptible) microorganisms 
this could become even more relevant in the future. Increasing the fT>MIC through extended 
infusion may therefore be a strategy to counter a gradual increase in MIC. Also, micro-
organisms that are borderline resistant could still be treated with beta-lactam antibiotics 
provided a safe as well as effective concentration of the drug can be reached. Similarly, 
Chapter 5 : Pharmacokinetic Studies
 
 
applying these strategies may have potential value by decreasing the emergence of 
antimicrobial resistance. 
This study has a number of limitations. First of all, only patients with apparent normal 
renal function were included, which limits extrapolation of these finding to all ICU patients. 
Second, the number of patients included in the meropenem group was low, which may 
explain the lack of statistical significance in the meropenem target attainment rates despite 
the numerical differences observed. Also, the analysis has been done after 1 to 2 days since 
initiation of antibiotic therapy, which may miss the problem of insufficient drug 
concentrations in the very early phase of therapy. Finally, the results of extended infusion 
were compared to historical control patients treated with bolus infusion at the Burns, 
Trauma and Critical Care Research Centre in Brisbane, Australia although these patients 
were part of a prospective intensive pharmacokinetic study enabling suitable comparison to 
the extended infusion cohort. The extended infusion protocol was implemented at the ICUs 
of the Ghent University Hospital in 2007 and both the investigators and the clinicians found 
it unethical to randomize patients between bolus and extended infusion, although this 
remains a controversial issue and other clinicians may disagree on this topic. The 
pharmacokinetic characteristics such as clearance and elimination rates were comparable 
between the patient groups, suggesting that comparison is not inappropriate. 
4.5. Conclusions 
In conclusion, this study found that pharmacokinetics of piperacillin and meropenem is 
variable in critically ill patients. Although extended infusion of beta-lactam antibiotics 
increases the fT>MIC, and improves target attainment, a 100% fT>MIC target is not reached in a 
significant part of critically ill patients. In the future, once patients at risk can be easily 
identified, other strategies such as extended infusion or continuous infusion based on 
therapeutic drug monitoring should be used to optimize antibiotic exposure in this subgroup 
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Abstract 
Introduction: Piperacillin plasma concentrations are known to vary between critically ill 
patients. However, there are no comprehensive data on the variability of antibiotic 
concentrations within the same patient. The purpose of this study was to investigate the 
adequacy of dosing during an entire antibiotic course of 7 days and secondly, to investigate 
the variability in antibiotic trough concentrations, both between, as well as within the same 
patient.  
Methods: In critically ill patients with normal renal function, piperacillin trough 
concentrations were measured daily. Drug assay was performed using ultra high 
performance liquid chromatography tandem mass spectrometry. The 
pharmacokinetic/pharmacodynamic (PK/PD) target was 100% fT>MIC of the Pseudomonas 
aeruginosa EUCAST breakpoint. The within- and between-patient variability was calculated 
as % coefficient of variation (CV). 
Results: Eleven patients, treated for pneumonia, were included in this nested prospective 
observational cohort study; median (range) age was 67 (18-79) years, median (range) weight 
was 75 (57-90) kg and median BMI 23.5 (22.3-26.4). The median (range) creatinine clearance 
on day 1 of antibiotic treatment was 102 (62-154) mL/min. Trough concentrations were 
variable, ranging from 4.9 to 98.0 mg/L. We found a median CV of 40 % for within-patient 
variability, and a CV of 57% for the between-patient variability. The within-patient variability 
was inversely correlated with SOFA score (R=0.65, p=0.027) and APACHE II score on 
admission (R=0.73, p=0.009).  
Conclusions: Piperacillin concentrations varied widely both between as well as within the 
same patient. Within patient variability was inversely correlated with severity of disease. 
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Consistent dosing of piperacillin/tazobactam does not result in consistent piperacillin 
concentrations throughout the entire treatment period. 
5.1. Introduction:  
Infection is a well-recognized but persisting problem in critical care medicine. 
Antimicrobial therapy is a crucial element in the treatment of severe infections. Currently, 
timely and appropriate antibiotic therapy plus source control is considered to be the 
mainstay of treatment [59].  
Optimizing antibiotic exposure is important as well, but this is proving to be a 
considerable challenge with recent data showing that antibiotic concentrations in critically ill 
patients are highly variable, unpredictable and often sub-optimal, because of the 
pathophysiological changes in these patients [39, 93, 120]. Administration of the antibiotic 
as a prolonged or continuous infusion has been proposed as a way to optimize 
pharmacokinetics and improve patient outcome. However, we have previously shown that 
even if the antibiotic is administered as an extended infusion, patients with a creatinine 
clearance > 130 mL/min are still at risk for target non attainment [156].  
As creatinine clearance and other pharmacokinetic (PK) determinants may change 
over time, it can be assumed that antibiotic concentrations are not stable during an entire 
antibiotic treatment course. To date, there are no comprehensive data available on the 
variability of antibiotic concentrations during antibiotic treatment within the same patient.  
The purpose of this study was therefore to investigate the adequacy of dosing during 
an entire antibiotic course of 7 days when the antibiotic is administered as an extended 
infusion and secondly, to investigate the variability in antibiotic trough concentrations, both 
between patients, as well as within the same patient.  
5.2. Methods 
Patients 
This nested prospective observational cohort study was conducted in the intensive 
care unit (ICU) of Ghent University Hospital, Belgium, between April 2011 and February 
2012. This analysis was done using samples from a randomized controlled trial, which was 
approved by the Belgian regulatory agency (B67021020250). The trial was conducted in 
accordance with the Declaration of Helsinki. The study was approved by the Ethics 
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Committee of Ghent University Hospital (registration number 2010/814). Written informed 
consent was obtained from the patient or his/her legal representative. Criteria for inclusion 
were the need for antibiotic treatment with piperacillin/tazobactam, age of 18 years or older 
and the presence of an arterial catheter. Patients were excluded in case of pregnancy and/or 
lactation, allergy to the administered medication, impaired renal function (estimated 
glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation <80 mL/min), hemoglobin < 7g/dL, do-not–resuscitate orders or if the patient 
was expected not to survive the first 48h.  
The purpose of this study was to investigate the adequacy of dosing during an entire 
antibiotic course of 7 days when the antibiotic is administered as an extended infusion and 
secondly, to investigate the variability in antibiotic trough concentrations, both between 
patients, as well as within the same patient.  
For the current analysis we included patients in whom antibiotic concentrations were 
available for at least 4 consecutive days. 
Antibiotic administration 
Patients received a loading dose of 4 g/0.5 g piperacillin/tazobactam (Tazocin®, 
Pfizer), administered over 30 minutes, followed immediately by the first extended infusion 
dose of 4 g/0.5 g piperacillin/tazobactam every 6h. Extended infusion doses were 
administered over 3 hours using a syringe pump via a central venous catheter. 
Study procedures 
The first blood sample was obtained after administration of at least 3 doses, at 
apparent pharmacokinetic steady-state. One trough sample was taken per day for 7 
consecutive days, immediately before administration of the next dose. Nurses were well 
aware of the importance of accurate sample timing, and timing of this trough sample was 
very reliable. For each sample, 5 mL of blood was collected in heparin anticoagulant tubes 
without separator gel, via the arterial catheter. The samples were then sent to the core 
laboratory, where they were centrifuged and frozen immediately upon arrival at -20°C and 
were analyzed on the same day. Additional data were obtained from the medical records 
and included participant demographics, clinical details, measures of illness severity such as 
the sequential organ failure assessment (SOFA) and the acute physiology and chronic health 
evaluation II (APACHE II) score, microbiological results and laboratory investigations. 




The plasma concentrations of piperacillin were determined by a validated technique 
using ultra high performance liquid chromatography coupled to tandem mass spectrometry 
(UPLC-MS/MS) [279]. Samples were deproteinized using acetonitrile. After centrifugation, a 
portion of the supernatant was diluted and injected on a Waters BEH C18 column (1.7 μm, 
100 mm x 2.1 mm) kept at 50°C. The mobile phase consisted of a gradient elution of water 
and acetonitrile, both containing 0.1 % formic acid. Compounds were detected with a 
Waters Acquity TQD mass spectrometer operating in positive electrospray ionization using a 
compound specific method in the multiple reaction monitoring mode. The assay was linear 
from 4 to 250 mg/L with an inaccuracy < 8 % and a between-run imprecision < 10 % at high, 
medium and low concentrations. The measured total concentrations were corrected for 
protein binding, assuming 30 % protein binding of piperacillin. Creatinine was measured in 
both serum/plasma and urine using the rate blanked, compensated and uncompensated 
Jaffe technique, respectively (Modular P and Cobas 6000, Roche Diagnostics GmbH, 
Mannheim, Germany). 
Calculations 
The concentrations were inspected for outliers for each individual patient, defined as 
one value outside 3 times the interquartile range. 
The total variance was calculated by dividing the standard deviation of all available 
samples by the mean of all available trough concentrations. This total variance is the sum of 
the within-patient variance and the between-patient variance. The within-patient variance 
was calculated as the mean of all individual variances.  
Between-patient standard deviation (SD) can thus be calculated as follows: 
 
 
The within-patient variability coefficient of variation (CV) was calculated by dividing the 
individual standard deviation (SD) by the mean of this patient’s trough concentrations. 
Correlations between the within-patient CV and clinical parameters were analyzed 
using the Pearson correlation coefficient using IBM® SPSS® Statistics 20.0. A P value ≤ 0.05 
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was considered to be significant. The predefined pharmacokinetic/pharmacodynamic 
(PK/PD) target was 100% fT>MIC of Pseudomonas aeruginosa according to the EUCAST 
breakpoint (16 mg/L) [235].  
5.3. Results 
Eleven patients, all treated for pneumonia, were included in the study, and a total of 
70 blood samples were used for the current analysis. The median time between hospital 
admission and start of antibiotic therapy was 8 days (IQR 4-19). 
The median (interquartile range, IQR) age was 67 (51-75) years, 82% of the patients 
were male, with a median (IQR) weight of 75 (67-83) kg, and median BMI of 23.5 (22.3-26.4). 
The median (IQR) creatinine clearance on day 1 of antibiotic treatment was 93 (88-99) 
mL/min. The median (IQR) creatinine clearance throughout the study period was 100 (89-
136) mL/min. Median (IQR) value for SOFA score on day 1 of the study was 3 (4-6), and 24 
(18-30) for APACHE II score on admission.  
For 2 patients, only 6 concentrations were available, for one patient 5, and for one 
patient 4. Antibiotic concentrations varied considerably, both between patients as well as 
within the same patient. Trough concentrations over the treatment course ranged from 4.9 
to 98.0 mg/L.The median (IQR) trough concentration during the first day of treatment was 
33.6 (25.5-49.4) mg/L, and during the entire antibiotic treatment 27.0 (15.6-45.3) mg/L.  
The boxplot of antibiotic concentrations per day over the 7-day course is shown in 
figure 1. The black line depicts the PK/PD target of 100 % fT>MIC of P. aeruginosa according to 
EUCAST breakpoints (16 mg/L). 
 
Fig. 1. Box plot of piperacillin concentrations for each day, also showing the individual 
concentrations (□, individual values). The horizontal black line represents the target 
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minimum inhibitory concentration (MIC) of Pseudomonas aeruginosa according to the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint (16 mg/L). 
The variability within the same patient and between patients is visually depicted in 
figure 2. The black line depicts the PK/PD target of 100 % fT>MIC 16 mg/L. As shown in this 
graph, a significant portion of patients (6 out of 11) failed to achieve this predefined PK/PD 
target at least once throughout the entire 7-day antibiotic course. 
One outlier was removed for calculation of the coefficient of variation (CV). The 
median within-patient CV was 40 %, ranging from 20 to 60%. The between-patient CV was 
57 %. The influence of the analytical method (inaccuracy < 8 % and between-run imprecision 
<10 % at all levels) is negligible. 
We found a significant inverse correlation between the within-patient CV and SOFA 
score on day 1 of study (R=0.65, p=0.027) and between the within patient CV and APACHE II 
score on admission (R=0.73, p=0.009), indicating that the patients with higher individual 
variability are the patients who tend to be less severely ill with lower SOFA scores and lower 
APACHE II scores (figure 3a and 3b). There was no significant correlation between the within-
patient CV and weight, age, median creatinine clearance and CV in creatinine clearance. 
Individual concentrations were significantly correlated with creatinine clearance (p < 0.001), 
a finding reported in other studies as well [120, 156]. 
 
Fig. 2. Box plot of individual patient piperacillin concentrations, also showing the individual 
concentrations [□, individual values; ●, extreme outlier (outside three times the interquartile 
range)]. The horizontal black line represents the target minimum inhibitory 
concentration(MIC) of Pseudomonas aeruginosa according to the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) breakpoint (16 mg/L). 




Fig. 3. (a) Coefficient of variation (CV) of individual piperacillin concentrations versus 
Sequential Organ Failure Assessment (SOFA) score on Day 1 of antibiotic therapy 
(R = 0.65, P = 0.027). (b) CV of individual piperacillin concentrations versus Acute Physiology 
and Chronic Health Evaluation (APACHE) II score on admission (R = 0.73, P = 0.009). 
5.4. Discussion 
To the best of our knowledge, this report is the first to describe antibiotic 
concentrations over an entire antibiotic treatment period. 
The primary aim of our study was to investigate the adequacy of dosing during an 
entire antibiotic course of 7 days when the antibiotic is administered as an extended 
infusion. We have found that many patients (6 out of 11) failed to achieve the PK target of 
100 % fT>MIC of P. aeruginosa at least once during the entire treatment course. This PK target 
is high, but in this population 8 out of 11 patients had a prolonged hospital stay of 5 days or 
more before the start of antibiotic therapy. Therefore these pneumonias were considered to 
be nosocomial and could be caused by a Pseudomonas infection. In case of absence of a 
causative micro-organism and its sensitivity to the antibiotic, the least sensitive strain should 
still be covered by the antibiotic dosing regimen. 
The second aim of our study was to investigate the variability in antibiotic trough 
concentrations, both between patients, as well as within-patient. In spite of our strict 
inclusion criteria (eGFR > 80 mL/min), and relatively narrow range in creatinine clearance 
(IQR 89-136 mL/min), which should result in a rather homogenous group of patients, we still 
observed important variability in antibiotic concentrations, both between patients, as well as 
within-patient. The patients with lower baseline SOFA scores and lower baseline APACHE II 
scores display the largest within-patient variability. 
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Our study highlights once again the unpredictability of antibiotic concentrations, 
which is mostly caused by the altered PK due to pathophysiological changes that occur in 
critically ill patients as well as therapeutic interventions. More specifically, larger than 
normal values for volume of distribution and large variations in antibiotic clearance β-lactam 
antibiotics have been described frequently in critically ill patients, leading to very variable 
and unpredictable serum concentrations [236, 280, 281]. The finding that the more sick 
patients had relatively lower variability seems counterintuitive, as it would be expected that 
less sick patients (with lower SOFA scores) would have less PK variability, and more critically 
ill patients more variability, because of fluid shifts with third-spacing etc. This is not the first 
time an association has been made between pharmacokinetic findings and severity of illness 
scores. Udy et al have found that a modified SOFA score ≤4, is a significant risk factor for 
developing augmented renal clearance [111]. The reason for this is also not clear.  
Because of this variability and unpredictability, therapeutic drug monitoring (TDM) is 
emerging as a promising tool to guide antibiotic dosing. Roberts et al. demonstrated that 
74% out of 236 patients treated with β -lactam antibiotics did not achieve target 
concentrations [236]. Moreover, several case reports have shown that in difficult situations, 
such as in patients displaying a complex physiology or with an infection with a 
microorganism displaying increased resistance, TDM may be useful to guide therapy [256, 
275, 282]. However, the literature on TDM for β-lactam dosing is still limited and the exact 
role of TDM in clinical practice is yet to be determined.  
This report is the first to explore the variability of antibiotic concentrations in the 
same patient over multiple consecutive days. This study suggests that single individual 
concentrations are not sufficient to predict subsequent concentrations and that more 
intensive, preferably daily, TDM may be necessary. 
This study has a number of limitations. First, we have only included 11 patients in this 
study, which may not be sufficient to describe the variability present in all ICU patients. 
Furthermore, given the small sample size of this study, we could not investigate the clinical 
relevance of target non attainment. Also, this single center study only included patients with 
normal renal function, which limits extrapolation of these findings to all ICU patients. Finally, 
we did not investigate free concentrations or concentrations at the site of infection. Instead, 
we measured total drug concentrations with correction for protein binding based on the 
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literature. However, research has shown that this is a valid approach for low to moderately 
protein-bound antibiotics [219].  
5.5. Conclusion 
In this small group of studied patients with normal kidney function, there was 
considerable variability in piperacillin concentrations, both between patients, but also within 
the same patient. Antibiotic concentrations were significantly inversely correlated with 
creatinine clearance. Patients with lower baseline SOFA and APACHE II scores tended to 
have greater within-patient variability in antibiotic concentrations. Moreover, many patients 
with a normal renal function did not achieve the PK/PD target of 100 % fT>MIC of P. 
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6.  Lack of PK/PD target attainment in de-escalated antibiotic therapy in critically ill 
patients: Less is not always more 
Authors : Mieke Carlier, Jason A. Roberts,Veronique Stove,  Alain G. Verstraete, Jeffrey 
Lipman, Jan J. De Waele 
Article history : Submitted 16th February 2015, accepted 20th May 2015 
Status : Antimicrobial Agents and Chemotherapy, 2015 (in press) 
Abstract: 
Introduction: De-escalation of empirical antibiotic therapy is often included in antimicrobial 
stewardship programs in critically ill patients, but differences in target attainment when 
switching antibiotics are rarely considered. The primary objective of this study was to 
compare the fractional target attainment of contemporary dosing of empirical broad-
spectrum β-lactam antibiotics and narrower spectrum antibiotics for a number pathogens 
for which de-escalation may be considered. The secondary objective was to determine 
whether alternative dosing strategies improve target attainment. 
Methods:  We performed a simulation study using published population pharmacokinetic 
(PK) studies in critically ill patients for a number of broad-spectrum β-lactam antibiotics and 
narrower spectrum antibiotics. Simulations were undertaken using a dataset obtained from 
critically ill patients with sepsis without absolute renal failure (n=49). The probability of 
target attainment of antibiotic therapy for different micro-organisms for which de-escalation 
is applied was analyzed. EUCAST MIC distribution data were used to calculate fractional 
target attainment.  
Results: The probability to achieve therapeutic exposure was lower for the narrower 
spectrum antibiotics in conventional dosing compared to the broad spectrum alternatives, 
which could drastically be improved when higher dosages and different modes of 
administrations are used.   
Conclusions: For a selection of microorganisms the probability to achieve therapeutic 
exposure was overall lower for the narrower spectrum antibiotics using conventional dosing 
compared to the broad-spectrum antibiotics. 
 




Provision of antibiotic therapy that is timely and of an appropriate spectrum is one of the 
mainstays of treatment [12, 20]. This has led to the widespread use of broad-spectrum 
antibiotic therapy for the empirical treatment of infections. After identification of the 
causative microorganism, antibiotic therapy is typically adapted to the susceptibility profile 
of the microorganism, with a preference to change therapy to narrower-spectrum agents in 
order to decrease selective pressure for resistant pathogens. This process is called antibiotic 
de-escalation, and considered an important element in antibiotic stewardship programs [54, 
283, 284]. 
Although timing and adequacy of the antibiotic therapy remains crucial, recent data hint at 
the importance of antibiotic dosing and exposure on clinical outcome [49]. Changes in the 
physiology of the critically ill alter the pharmacokinetics of β-lactam antibiotics, with many 
patients being at risk of underdosing [39, 285]. Attainment of 
pharmacokinetic/pharmacodynamic (PK/PD) targets associated with efficacy is also 
dependent on the susceptibility of the pathogen and varies across antibiotic classes - an 
element that is rarely considered [285]. 
Although de-escalation of antibiotic therapy is a key element in many antibiotic stewardship 
programs, the possible change in PKPD target attainment in de-escalation has not yet been 
considered. De-escalation has been associated with improved outcome in many 
observational (non-randomized) studies, however, these findings may be due to selection 
bias as de-escalation may be mainly performed in patients who are improving [57, 286] . A 
recent randomized controlled study performed by Leone et al. found that de-escalation to 
narrow spectrum antibiotics did not reduce patient intensive care unit (ICU) length of stay 
and was associated with an increased number of antibiotic days in patients who had been 
de-escalated. The authors also reported that superinfections were more frequent in patients 
who were de-escalated, with about half of the superinfections being caused by the same 
pathogens as the initial infection [68]. 
Based on these observations, we hypothesized that PK/PD target attainment after de-
escalation may be lower than with empiric therapy, even when the pathogen is reported to 
be susceptible to the de-escalation antibiotic. The primary objective of this study was to 
compare the probability of achieving PK/PD targets for conventional dosing of empirical 
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broad-spectrum antibiotics and narrower spectrum antibiotics for a number of pathogens 
for which de-escalation may occur. The secondary objective was to determine whether 
PK/PD target attainment could be improved with alternative dosing strategies for both types 
of antibiotics. 
6.2. Methods 
We performed an in silico (computer)simulation study using published population 
pharmacokinetic studies in critically ill patients for a number of broad-spectrum β-lactam 
antibiotics (meropenem and piperacillin/tazobactam) and narrower spectrum antibiotics 
often used in de-escalation as reported in recent studies (amoxicillin/clavulanic acid, 
cefuroxime ,  flucloxacillin, cefazolin and cefepime) [128, 140, 155, 287-290]. Protein binding 
was assumed to be 17% for amoxicillin, 33% for cefuroxime and 10 % for cefepime [240]. 
Protein binding for meropenem is negligible, and the model for piperacillin, flucloxacillin and 
cefazolin were based on measured free concentrations, so no correction was necessary.  
We simulated 30-minute infusions for all antibiotics as intermittent infusion remains the 
most common method of administration in ICUs [49]. The broad-spectrum empirical 
antibiotics were also simulated as extended and continuous infusions as these 
administration techniques are becoming more common as a way to maximize PK/PD target 
attainment [291]. For amoxicillin/clavulanic acid and piperacillin/tazobactam, doses for the 
amoxicillin or piperacillin component only were simulated because the PK/PD targets for the 
β-lactamase inhibitors in these combinations remain unclear. The simulated dosages were 
derived from the package inserts and are summarized in table 1. PK/PD target attainment of 
higher dosages and alternative dosing strategies were also investigated for the narrower 
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Table 1: Simulated intravenous dosages of antibiotics  
Antibiotic  Dosage simulation  
Meropenem 1 g every 8 h as an intermittent infusion 
1 g every 8 h as a 4h extended infusion  
3 g/day as a continuous infusion  
Piperacillin 4 g every 8 h as an intermittent infusion  
4 g every 8 h as a 4h extended infusion  
12 g/day as a continuous infusion 
4 g every 6 h as an intermittent infusion 
4 g every 6 h as a 3h extended infusion  
16 g/day as a continuous infusion 
Cefepime 1 g every 12 h as an intermittent infusion 
2 g every 12 h as an intermittent infusion for S. aureus infections  
Amoxicillin 1 g every 6 h as an intermittent infusion 
Cefuroxime 1.5 g every 8 h as an intermittent infusion 
Flucloxacillin  1 g every 6 h as an intermittent infusion 
Cefazolin 1 g every 8 h as an intermittent infusion 
Table 2: Simulated dosages for the de-escalation antibiotics using higher dosages and 
alternative dosing strategies 
Antibiotic  Dosage simulation  
Amoxicillin 1 g every 4 h as an intermittent infusion 
 1 g every 4 h as a 2h extended infusion 
 6 g/day as continuous infusion 
Cefuroxime 1.5 g every 6 h as an intermittent infusion 
 1.5 g every 6 h as a 3h extended infusion 
 6 g/day as a continuous infusion 
Flucloxacillin  2 g every 6 h as an intermittent infusion 
 2 g every 6 h as a 3h extended infusion 
 8 g/day as a continuous infusion 
Cefazolin 1 g every 6 h as an intermittent infusion 
 1 g every 6 h as a 3h extended infusion 
 4 g/day as a continuous infusion 
Cefepime 2 g every 8 h as an intermittent infusion 
 1 g every 4 h as an intermittent infusion 
 4 g/day as a continuous infusion 
 
The simulations were performed using NONMEM (version 7.3.0, Globomax LLX, Hanover, 
USA). A digital FORTRAN complier was used and the runs were executed using Wings for 
NONMEM (http://wfn.sourceforge.net). For each antibiotic, 1000 Monte Carlo simulations 
were undertaken using a patient dataset (n=49) with varying creatinine clearances (range 22 
- 230 mL/min) using the parameters from the published covariate model. This dataset was 
obtained from a previous study conducted in a tertiary referral ICU [292]. Patients were 
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eligible for enrolment if they were between 18-80 years of age and were receiving 
piperacillin/tazobactam for treatment of sepsis (defined as a presumed or confirmed 
infection, while manifesting a systemic inflammatory response syndrome). Patients were 
excluded if they did not have an intra-arterial line, had significant renal impairment (defined 
by a plasma creatinine concentration > 171 μmol/L or the need for renal replacement 
therapy); or had a history of allergy to piperacillin or iodine. This therefore represents a 
convenience sample of critically ill septic patients, without significant renal impairment. The 
patient characteristics are summarized in table 3.  
Table 3: Patient characteristics. Data are reported as median (interquartile range) 
Male / female  (N) 27/22 
Age (years) 46 (33-64) 
Height (m) 1.70 (1.63-1.80) 
Weight (kg) 84 (73-95) 
BMI (kg/m²) 29.4 (25.1-33.3) 
Creatinine clearance (mL/min) 105 (74-143) 
APACHE II score  17 (14-25) 
SOFA score  6 (5-9) 
Serum urea concentration (mmol/L) 6.2 (3.9-8.7) 
Serum creatinine concentration (μmol/L) 73 (55-97) 
Serum albumin concentration (g/L) 21 (20-24) 
8 hour creatinine clearance (mL/min) 112 (76-142) 
Mechanically ventilated (%) 93.4   
BMI: body mass index ; APACHE II: Acute Physiology and Chronic Health Evaluation ; SOFA: 
Sequential Organ Failure Assessment  
Using the simulated concentration-time profiles, the time for which the free antibiotic 
concentration exceeds the minimal inhibitory concentration (fT>MIC) was calculated for each 
simulated subject using linear interpolation. The PK/PD target was set at 40% fT>MIC for 
carbapenems, 50 % fT>MIC for penicillins, and 65 % fT>MIC for cephalosporins, and this was 
defined as the conservative PK/PD target, which is the target found to be associated with 
maximal effect in animal models  [41]. There are almost no data on which targets are 
needed to treat infections in critically ill patients, however, there are some retrospective 
studies that have found that higher targets may be needed to treat serious infections in this 
patient population. Therefore we performed an additional simulation with a higher target of 
100 % fT>MIC for all antibiotics [42, 43].  
The micro-organisms used in this simulation study were Escherichia coli, Staphylococcus 
aureus and Streptococcus spp, Klebsiella pneumoniae, Haemophilus influenzae, Citrobacter 
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freundii, Morganella morganii and Proteus mirabilis, as these are micro-organisms for which 
de-escalation is more commonly performed [55-57, 68, 293].  
MIC distribution data for the above pathogens were obtained for each antibiotic from the 
European Committee for Antimicrobial Susceptibility and Testing (EUCAST) to determine 
fractional target attainment (FTA) [235]. This identifies the likely success of treatment by 
comparing the achievement of the PK/PD target against an MIC distribution. Microorganisms 
with an MIC above the clinical susceptible breakpoint were not included in the FTA 
calculation because ongoing prescription would not be supported by the susceptibility 
testing upon which the de-escalation is based.  
6.3. Results 
Probability of attainment for the conservative PK/PD target 
The results of the simulations for the conservative target are shown in table 4. The FTA for 
the conservative target for the broad-spectrum antibiotics administered as an intermittent 
infusion in high doses (piperacillin/tazobactam 4 g every 6 h and meropenem 1 g every 8 h) 
was > 95 % for all simulations, reaching 100 % when administered as an extended or 
continuous infusion. The FTA for piperacillin/tazobactam at a lower dose (4 g every 8 h) was 
slightly lower, with the lowest FTA being 89 % for K. pneumoniae, although this increased to 
100 % when administered as a continuous or extended infusion. 
For the narrower spectrum antibiotics in conventional dosing, the FTA was lower than for 
the broad-spectrum antibiotics. As shown in table 4, the FTA for amoxicillin/clavulanic acid 
(1 g every 6 h) ranged from 85 % (E. coli) to 100 % depending on the micro-organism. The 
lowest FTA for cefuroxime (1.5 g every 8 h) was 65 % for E. coli. Flucloxacillin (1 g every 6 h), 
cefepime (2 g every 12 h) and cefazolin (1 g every 8 h) had a FTA of respectively 74, 88 and 
90 %  against oxacillin-susceptible S. aureus.   
 Probability of target attainment for the higher 100 % fT>MIC target   
The FTA for the higher target of 100 % fT>MIC are shown in table 4. For the broad-spectrum 
antibiotics, only continuous infusion of meropenem and piperacillin/tazobactam (piperacillin 
doses of 12 and 16 g/day) reached 100% FTA for all studied micro-organisms. 
The FTA for meropenem (1 g every 8 h)  administered as a 30-minute infusion ranged 
between 100 % (Streptococcus spp.) and 64 % (oxacillin susceptible S. aureus), which 
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increased to 87 % when administered as a 4 h infusion and to 100 % when administered as a 
continuous infusion.   
Similarly, for piperacillin/tazobactam increasing infusion time improved FTA. When 
administering 4 g every 6 hours, the lowest FTA was 76 % for K. pneumoniae. It was 87 % for 
the 3 h infusion and increased to 100 % for the continuous infusion. In the lower dose, FTA 
was only 62 % for K. pneumoniae, 77 % when administered as a 4 h extended infusion and 
100 % as a continuous infusion. 
For the de-escalation antibiotics, the FTA was also lower than for the conservative target. 
The lowest FTA for amoxicillin/clavulanic acid (1 g every 6 h) was 66 % for E. coli, and 45 % 
for cefuroxime using the standard dose of 1.5 g every 8 h (E. coli).  The FTA against oxacillin 
susceptible S. aureus for flucloxacillin (1 g every 6 h) and cefepime (2 g every 12 h)  was 
similarly poor with an FTA of  36 % and 69 %, but slightly better for cefazolin (1 g every 8 h) 
with an FTA of 77 % . 
Fractional target attainment when administering higher dosages/alternative modes of 
administration for the narrower spectrum antibiotics 
The FTA using the conservative targets for the higher dosages/ alternative modes of 
administration are shown in table 4. Increasing the dose for amoxicillin/clavulanic acid from 
1 g every 6 h to 1 g every 4 h increased the FTA using the conservative target for E. coli from 
85 % to 92 %, and to 100 % when an extended or continuous infusion of 6 g was used. 
Similarly, for cefuroxime, increasing the dose and increasing infusion time improved the FTA 
from 65 % for E.coli (conventional dose of 1.5 g every 8h) to 98 % when administered as a 
continuous infusion of 6 g.  For flucloxacillin, increasing the dose from 1 g every 6 h to 2 g 
every 6 h as an extended or continuous infusion increased the FTA for oxacillin susceptible S. 
aureus from 74 to 100 %. For cefazolin and cefepime, a continuous infusion of 4 g increased 
the FTA against oxacillin susceptible S. aureus from 88 %  (cefepime 2 g every 12 h) and 90 % 
(cefazolin 1 g every 8 h) to 100 % for both antibiotics .  
When using the higher target of 100 % fT>MIC, there are large differences in FTA between the 
broad and narrow spectrum antibiotics (table 4). However, changing the intermittent 
infusion to a higher dose continuous infusion improved the FTA dramatically. For 
amoxicillin/clavulanic acid, this improved FTA from 66 % (1 g every 6 h) to 98 % (6 g 
continuously) for E. coli, for cefuroxime from 45 % (1.5 g every 8 h) for E. coli to 98 % (6 g 
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continuously). For flucloxacillin, in order to obtain a high FTA for oxacillin susceptible S. 
aureus,  the dose needed to be increased from 1 g every 6 h (FTA 36 %) to 8 g as a 
continuous infusion (FTA 100 %), and for cefepime and cefazolin respectively from 2 g every 
12 h (FTA 69 %) and  1 g every 8 h to 4 g continuously.  
 
 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.4. Discussion  
De-escalation of antibiotic therapy, or changing empirical antibiotic therapy to a 
narrower spectrum antibiotic, is often advocated to reduce use of broad-spectrum 
antibiotics in the hospitalized patient [54, 294]. It is generally considered safe and has been 
associated with improved outcomes in several observational studies  and is recommended in 
the 2013 Surviving Sepsis Campaign guidelines [57, 59, 286]. As such it is often incorporated 
in antibiotic stewardship programs in critically ill patients, [60, 61] although in clinical 
practice there seem to be a number of obstacles to use it widely [67]. In observational 
studies, empirical antibiotics are de-escalated in roughly 15-50% of the patients, depending 
on the definition used [55, 57, 67, 295]. 
In this study we have found that for a number of pathogens, the fractional target 
attainment (FTA) for the empirical broad-spectrum antibiotics meropenem and 
piperacillin/tazobactam was higher than for the narrower spectrum antibiotics 
amoxicillin/clavulanic acid, cefuroxime, flucloxacillin, cefazolin and cefepime using 
conventional dosing. Given that the probability to achieve the PK/PD target for some 
microorganism/antibiotic combinations is lower for the narrower spectrum alternative, de-
escalation, with standard dosing may predispose selected patients to clinical failure and 
recurrent infection. To the best of our knowledge, this is the first study of its kind that 
compares the achievement of therapeutic exposure of empiric antibiotic therapy versus de-
escalation based on population PK models from critically ill patients. Although there is 
currently no evidence that subtherapeutic dosing of -lactam antibiotics leads to treatment 
failure or to a  higher incidence of resistance, this has been shown for other antibiotics. For 
tobramycin for example, it has been shown that although peak concentration/MIC is 
associated with effect, for the same area under the curve/MIC value, once daily dosing (with 
subsequent lower trough concentrations) leads to higher MIC values after 2 weeks of 
treatment than three times daily dosing [296].  
The FTA is dependent on a number of factors and recent insights in PK/PD characteristic 
in critically ill patients may help us to explain these findings. Because of pathophysiological 
changes in critically ill patients, such as an increased volume of distribution and augmented 
renal clearance, standard dosing may not always lead to optimal target attainment [120, 
156]. Moreover, it is also dependent on the PK/PD target (40% fT>MIC for carbapenems versus 
65% fT>MIC for cephalosporins). Next, the susceptibility of the microorganism plays an 




important role. Susceptibility of the same microorganism may vary for different antibiotics, 
and similarly, the potency of certain antibiotics against different microorganisms may be 
different, even though all are reported to be susceptible [297].  Moreover, the PK/PD target 
is currently considered to be fixed, however it has never been investigated if the PK/PD 
target changes over time. A changing PK/PD target over time, not taken into account by 
dosing, could also result in treatment failure and emergence of resistance. Finally, an 
increasing proportion of ICUs are administering meropenem and piperacillin/tazobactam as 
an extended or continuous infusion, as a way to increase PK/PD target attainment [49, 291]. 
However, these alternative modes of administration are not used for the narrower spectrum 
antibiotics, which are still being administered as short infusions with standard doses [49]. 
This contrasting approach could further increase the gap in PK/PD target attainment 
between empirical and de-escalation antibiotics.  
The findings of our study may partly explain the findings of a recent de-escalation study 
that could not confirm non-inferiority when comparing de-escalation to continuation of the 
empirical therapy [68]. Leone et al. found in a non-blinded randomized controlled trial that 
antibiotic use was higher in de-escalated patients due to an increased number of 
superinfections, about half of them caused by the same pathogen as the primary infection. 
This suggests that the antibiotics used in de-escalation arm were less effective in eradicating 
the infection than the broad-spectrum antibiotics in the comparative arm. In this study, no 
details regarding dosing were reported [68]. 
Of the most recent de-escalation studies, only one has mentioned dose and mode of 
administration of the initial broad-spectrum regimen, but it did not mention these data 
about the de-escalated antibiotics [55, 56, 68, 293]. Another study mentioned that “the dose 
and pattern of administration were in accordance with current medical standards” [57]. 
Dosing may be the key to improve patient outcome, as recent data have demonstrated that 
there is a correlation between blood concentrations of β-lactam antibiotics and clinical 
outcome [49]. Future de-escalation studies should ensure that dosing and mode of 
administration of the narrower spectrum antibiotics are likely to achieve appropriate PK/PD 
targets.  
We could also demonstrate that PK/PD target attainment is drastically improved when 
higher dosages and different modes of administrations of the de-escalation antibiotics are 
used. However, it must also be highlighted that blindly increasing the dose in all patients 




may give rise to needlessly high concentrations in some of them. Although toxicity of β-
lactams is not common, it is severe when it occurs, with seizures from high concentrations 
being reported previously [162-164]. This wide pharmacokinetic variability suggests that the 
principle of “one dose fits all” is unlikely to be appropriate in this patient population [35]. 
There are a number of limitations of the current analysis we would like to discuss. These 
results are not based on measured concentrations from actual patients. However we have 
simulated concentrations using population pharmacokinetic models and relevant covariates 
in critically ill patients. As such the accuracy of the results can be assumed to be acceptable 
given the same approach was used for simulations with the empiric and de-escalation 
antibiotic. The patient population simulated were patients who had normal renal function 
(serum creatinine concentration <171 μmol/L) and did not include patients with acute 
kidney injury, and therefore these conclusions are only relevant to this patient group. Also, 
there is little knowledge on which PK/PD target should be aimed for in critically ill patients, 
as the targets are derived from animal models on day 1 or 2 of antibiotic therapy. Whether 
or not this PK/PD target changes over time as a result of the changing susceptibility or the 
adaptive resistance of the pathogen is also a remaining question. Moreover, there is no time 
dependency of the data. In clinical practice, de-escalation is generally performed when the 
patient is improving (and therefore the pharmacokinetic issues associated with critical illness 
may be partly normalized), and with a lower bacterial burden. This cannot be accounted for 
in the modeling. Finally, only 7 antibiotics were simulated, due to the unavailability of 
population pharmacokinetic models of other β-lactam antibiotics in critically ill patients, 
although these are all commonly used agents making these data of significant interest to 
many ICU clinicians. 
6.5. Conclusion 
For a selection of micro-organisms in which de-escalation may be considered, the results 
of this simulation study show that the probability to achieve the PK/PD target was lower for 
the narrower spectrum antibiotics amoxicillin/clavulanic acid, cefuroxime, flucloxacillin, 
cefazolin and cefepime using conventional dosing compared to the broad spectrum 
antibiotics meropenem and piperacillin/tazobactam. As this may impact clinical outcome 
parameters, studies that report on the results of de-escalation strategies should accurately 
report dosing of antibiotics used. Future research should not only be focused on correct 
dosing of broad-spectrum antibiotics, but also of narrower spectrum antibiotics, where 




higher dosages and alternative modes of administration may be needed for patients at risk 
of not achieving PK/PD targets.  







Chapter Six : Optimizing Antibiotic 
Therapy in Clinical Practice  
The sixth chapter of this work summarizes the somewhat more practical studies. The first 
section discusses 2 stability studies, one for meropenem and another one for 
amoxicillin/clavulanic, which investigated their stability and potential to be used as a 
continuous infusion. Section 2 investigates the influence of augmented renal clearance on 
PK/PD target attainment in critically ill patients treated with meropenem or 
piperacillin/tazobactam administered as an extended infusion. These data were also 
collected as part of our TDM study.  The last section summarizes the results of our TDM 
study, performed between April 2011-February 2012, which looked at the effect of TDM-













1. Stability of commonly used antibiotics in the ICU for use as continuous infusion 
1.1 Stability of generic brands of meropenem reconstituted in isotonic 
saline  
Authors : Mieke Carlier, Veronique Stove, Alain G. Verstraete, Jan J. De Waele 
History : received 11 march 2014, accepted 6 June 2014 
Reference : Minerva Anestesiol. 2015 Mar;81(3):283-7 
Abstract 
Background : Meropenem is a relatively unstable compound when dissolved. Currently all 
available data have been derived from tests on the original product from Astrazeneca, and it 
is unsure if these data can be extrapolated to the stability of other commercially available 
vials. The aim of this study was therefore to assess the stability of four different brands of 
meropenem for use as a prolonged or continuous infusion.  
Methods : Commercially available meropenem vials were reconstituted and mixed with 0.9 
% sodium chloride to produce solutions with concentrations of 10,20 and 40 mg/mL in 
polypropylene syringes, which were kept at 25°C. Samples were taken immediately after 
preparation and up to 12 hours. Solutions retaining >90% of the initial concentration were 
considered stable.  
Results : The stability was concentration dependent. At 25°C, all 10 and 20 mg/mL solutions 
were stable for 12 hours in 0.9% sodium chloride, while the 40 mg/mL solutions were stable 
for a maximum of 8 hours. Stability of the different vials of meropenem was comparable for 
the time period tested (related samples Friedman’s two way of analysis of variance by ranks, 
p=0.282).  
Conclusion : All tested commercially available vials of meropenem in a concentration of 10 
and 20 mg/mL were stable for 12 hours at 25°C when diluted in 0.9% sodium chloride. The 
40 mg/mL solutions were stable for a maximum of 8 hours. This report is the first to show 






Administration of -lactam antibiotics as a continuous infusion is gaining popularity as a 
way to optimize pharmacodynamics, as their activity depends on the time the concentration 
exceeds the minimal inhibitory concentration, with evidence suggesting improved outcomes 
for critically ill patients. [142, 298, 299] 
The poor stability of meropenem has been reported repeatedly when using concentrated 
solutions at room temperature or at elevated temperatures (≥37°C), which is why 
continuous infusion over 24 hours has been considered an unacceptable choice for delivery 
of meropenem. [300-302] However, storage at lower temperature and using less 
concentrated solutions may be a way to overcome this limitation and may be a viable 
alternative to administer meropenem as a continuous infusion. [301-305] 
Currently almost all available data have been derived from tests on the original product 
from Astrazeneca, and it is unsure if these data can be extrapolated to the stability of other 
commercially available vials. In some settings there is a concern how active these generics 
are, as only bioequivalence tests are necessary in order to be marketed. There has been a 
report on a stability issue of a cefuroxime generic brand which was discovered because of a 
significantly increased incidence of post-operative infections in the hospital after switching 
to the generic cefuroxime. In this case, the generic cefuroxime was not stable and 
hydrolyzed after only 8 minutes [306] .  
Therefore, the aim of this study was to investigate whether the stability of 4 worldwide 
commercially available vials of meropenem are equivalent.   
1.1.2. Materials and methods 
Meropenem was obtained as the commercial powder preparation for injection from four 
different brands worldwide available (Meronem Astrazeneca®, Meropenem Sandoz®, 
Meropenem Fresenius Kabi® and Meropenem Hospira®). According to the leaflets, the only 
excipient in all 4 products was sodium carbonate. One gram of Meropenem for Injection I.V. 
vial delivers 1 g of meropenem and 90.2 mg of sodium as sodium carbonate (3.92 mEq). 
 
 




Preparation of meropenem solutions 
The antibiotic was dissolved as a 10, 20 and 40 mg/mL sterile solution in isotonic saline 
(Fresenius Kabi, Germany). These concentrations represent the currently approved dose of 
0.5 g in 50 mL, 1 g in 50 mL and 2 g in 50 mL of diluents.  
Five hundred mg of meropenem was reconstituted with 20 mL of 0.9 % sodium chloride 
injection according to local practice and was then mixed with 30 mL 0.9% sodium chloride 
solution in a polypropylene syringe (Becton, Dickinson and Company ®) in order to reach a 
10 mg/mL solution.  
One gram of meropenem was reconstituted with 20 mL of 0.9 % sodium chloride 
injection according to local practice and was then mixed with 30 mL 0.9% sodium chloride 
solution in a polypropylene syringe in order to reach a 20 mg/mL solution. 
One gram was reconstituted with 20 mL of 0.9 % sodium chloride injection according to 
local practice and was then mixed with 5 mL 0.9% sodium chloride solution in a 
polypropylene syringe in order to reach a 40 mg/mL solution. 
One polypropylene syringe was made for each combination of meropenem 
concentration and brand. To minimize analytical imprecision, all samples of the same 
concentration were analysed in duplicate in the same chromatographic run on 2 separate 
occasions.  
The polypropylene syringes were stored at 25°C. Each solution was sampled immediately 
after preparation and at 1,3,6,8 and 12 hours.  
Sampling procedure 
At each sampling time, the syringes were softly shaken before duplicate 200 μL samples 
were removed from each syringe and immediately frozen at -80°C to await concentration 
determination (within 2 weeks after collection). Color and clarity were assessed by visual 
inspection.  
Analytical assay 
Meropenem concentrations were determined using a high performance liquid 
chromatography coupled to tandem mass spectrometry operating in the multiple reaction 
monitoring mode [169]. 
 
 
Because of the high specificity of this detector, there is no influence from degradation 
products and is therefore stability-indicating.  
Chromatographic separation was performed on a Waters Acquity UPLC system using a 
BEH C18 column (1.7 μm, 100 x 2.1 mm) applying a binary gradient elution of water and 
acetonitrile both containing 0.1 % formic acid. The total runtime was 5.5 minutes.  
The extraction procedure was modified, since meropenem was diluted in 0.9% sodium 
chloride in the current analysis as opposed to serum as noted in the published assay. [169] 
The total precision for this assay of meropenem in serum was 10.3 % (within run precision 
6.2 %, between run precision 8.2 %). 
Chromatographic analysis was carried out after diluting the samples to 50 mg/L in water 
containing meropenem-d6, in order to reach the linear range of the assay (0.5 – 100 mg/L). 
Two meropenem samples taken at each timepoint were independently assayed in 
duplicate in order to minimize the imprecision, and the average of these concentrations was 
used for data analysis.  
Data analysis 
Drug potency was determined at each sampling time as the percentage of the initial 
meropenem concentration remaining. The solution was considered stable if the percentage 
of intact meropenem was ≥ 90%. 
Related samples Friedman’s two way of analysis of variance by ranks was (IBM, Chicago, 
IL) was used to compare the rate of meropenem degradation between different brands. A p 
value of ≤ 0.05 was considered statistically significant.  
1.1.3.  Results 
After 12 hours storage at room temperature, all tested brands attained the stability 
criterion of 90 % intact molecule when meropenem was dissolved as a 10 or 20 mg/mL 
solution in 0.9% sodium chloride. However, when higher concentrations were used, stability 
decreased and fell below 90% after 8 hours storage at room temperature, as the percentage 
intact molecule after 12 hours was 86.5 %. Throughout sampling, solutions were clear and 
ranged from colorless to slightly yellow. 




The results are shown in figures 1 a-c which show the percentage of intact molecule for all 
tested brands over time for 10, 20 and 40 mg/mL. 
The meropenem degradation between the different brands of meropenem was 
comparable for the time period tested (related samples Friedman’s two way of analysis of 
variance by ranks, p=0.282).  
1.1.4. Discussion 
At 25°C, all commercially available vials of meropenem in a concentration of 10 and 20 
mg/L were stable for 12 hours in 0.9% sodium chloride, and stable for 8 hours in a 
concentration of 40 mg/L in 0.9% sodium chloride. These results are in line with previous 
findings from literature. There has been one other report which also investigated the 
stability of meropenem hospira® in a concentration of 5 mg/mL at different temperatures 
(25-35°C). These authors found the stability to be time- and temperature dependent, with 
stability > 8 h if the temperature is ≤ 30°C [307].  
 This paper is the first to show that the stability of three worldwide commercially 
available generic brands of meropenem is comparable to that of the original formulation.  
For clinical practice, we suggest to divide the daily dose of 3 g (6 g in case of central 
nervous infections) in 3 solutions of 1 g (or 2 g in the case of central nervous infections) in 50 
mL-100 mL isotonic saline. However, it must be noted that there is still much debate about 
which target is needed for treating serious infections in critically ill patients. In vitro studies 
and animal studies have show that for carbapenems, a 40 % fT>MIC is sufficient because of the 
significant post-antibiotic effect [308]. However, limited data from studies in critically ill 
patients seem to show that higher targets may be beneficial in these patients[42]. Currently, 
a multi centre study is ongoing comparing intermittent versus bolus infusion for 3 β-lactam 
antibiotics, including meropenem. The results of the feasibility study show higher plasma 
concentrations in the continuous infusion group and an improvement clinical cure[142].  
This study has a number of limitations. First, we have only tested one lot for each brand, 
but physicochemical properties are not expected to vary across different lots. Secondly, we 
did not test stability for longer than 12 hours for the 10 and 20 mg/mL solution. Stability in 







































































































































































































































































































Meropenem 10 and 20 mg/mL solutions were stable for 12 hours at 25°C when diluted at 
0.9% sodium chloride. The stability of the 40 mg/mL solution in 0.9% sodium chloride 
decreased to 8 hours at 25°C. The rate of meropenem degradation was similar between the 
tested brands. Clinicians can safely use these generic forms of meropenem as 8-hour 
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Abstract   
Purpose: Extended or continuous infusions of broad-spectrum β-lactam antibiotics are 
increasingly used to improve pharmacokinetic target attainment. Concerns over drug 
stability have limited use of infusions for some β-lactam antibiotics. The purpose of this 
study was to assess stability of amoxicillin as a 10 g/L solution and amoxicillin/clavulanic acid 
as a 10/2 g/L solution in 0.9% saline at room temperature (22°C). 
Methods:  Solutions were prepared in triplicate in physiologic saline in polypropylene 
infusion bags to a concentration of 10 g/L for amoxicillin and 2 g/L for clavulanic acid.  
Solutions were sampled immediately after preparation and following up to 12 hours storage 
at room temperature. The amoxicillin/clavulanic acid solution was sampled immediately 
after preparation and up to 6 h. Drug concentrations were determined using a stability 
indicating validated high performance liquid chromatography coupled to tandem mass 
spectrometry method. The solution was considered stable if less than a 10% reduction in 
drug concentration occurred during storage.  
Results: Amoxicillin was stable for at least 12 hours at room temperature. The combination 
of amoxicillin and clavulanic acid was less stable because of instability of clavulanic acid. The 
concentration of clavulanic acid fell below 90% after 3 hours of storage at room 
temperature.  
Conclusions: Amoxicillin/clavulanic acid as a 10 g/L solution in physiologic saline cannot be 
administered in extended or continuous infusion at room temperature due to limited 





An increasing proportion of intensive care units use extended or continuous infusion 
when administering broad-spectrum β-lactam antibiotics. Extended or continuous infusions 
increase pharmacokinetic/pharmacodynamic target attainment and are associated with 
improved outcomes for critically ill patients [142, 298]. After identification of a causative 
microorganism, antimicrobial  therapy may be adapted to the susceptibility profile of the 
microorganism. Use of focused, narrower-spectrum agents reduces selection pressure for 
resistant pathogens. This process, known as antibiotic de-escalation, is an important 
component of antibiotic stewardship programs[54, 284]. Among others antibiotics, 
amoxicillin/clavulanic acid is frequently used in de-escalation from broader spectrum β-
lactam antibiotics. Currently extended and continuous infusions of amoxicillin/clavulanic 
acid are not used. However a recent population pharmacokinetic study of 
amoxicillin/clavulanic acid in critically ill patients shows that higher dosages and alternate 
dosing strategies, such as prolonged infusion, may improve pharmacokinetic target 
attainment [155]. 
Little is known about the physicochemical stability of amoxicillin and the combination 
of amoxicillin and clavulanic acid in infusion solutions. Amoxicillin at a concentration  of 20 
g/L re-constituted in 0.9% saline stored at 20°C in an elastomeric infusion system (Baxter 
Healthcare Corporation, Deerfield, ILL, USA) remained stable for 48 hours[250]. Significant 
degradation of clavulanic acid at 4 g/L, in combination with amoxicillin 20 g/L re-constituted 
in 0.9% saline in polyolefin infusion bags (Macoflex N, MacoPharma, Mouvaux, France) was 
observed after 3 hours[250, 309]. The product insert for amoxicillin/clavulanic acid, when 
diluted into 100 mL of 0.9% saline, states the drug is stable for 2-3 hours. However, there is 
increasing evidence that packet inserts may not truly reflect β-lactam antibiotic stability. This 
was for example the case for meropenem where the producing companies mentioned 
stability for 2-3 h for reconstituted meropenem, although multiple investigators found 
stability for over 8 h when diluted in 0.9 % NaCl, when sufficiently diluted and kept at room 
temperature[301, 302, 310]. Additionally adsorption of drug onto the inner surface of the 
plastic container may occur leading to reduction in the delivered drug concentration 




The aim of this study was to assess the stability of amoxicillin (10 g/L) solution 
(Clamoxyl® 1000mg, GlaxoSmithKline Wavre, Belgium) and amoxicillin/clavulanic acid (10/2 
g/L) solution (Augmentin® 1000mg/200mg, GlaxoSmithKline Wavre, Belgium) re-constituted 
in 0.9% saline and stored in a polypropylene infusion bag at room temperature (22°C, RT). 
Each agent was dissolved in 20 mL of 0.9 % sodium chloride for injection taken from a 100 
mL polypropylene infusion bag (Braun, Diegem, Belgium) according to local practice. The 
reconstituted drug was then injected into the remaining 80 mL, from the 100 mL infusion 
bag, to reach the target concentration. We prepared each antibiotic solution in triplicate and 
all samples were analyzed five times. The mean concentrations of amoxicillin and clavulanic 
acid, measured from each sample, was used for analysis. 
The polypropylene infusion bags were stored at 22° (standard deviation 0.14°C). The 
amoxicillin solution was sampled immediately after preparation and after 6, 8 and 12 hours. 
The amoxicillin/clavulanic acid solution was sampled immediately after preparation and 
after 1, 2, 3, 4, 5 and 6 hours. At each sampling time point, the infusion bags were gently 
shaken before a 2 mL aliquot was aspirated with a syringe and immediately assayed. Color 
and clarity were assessed by visual inspection and pH was measured (HI 8520, Hanna 
Instruments, Temse, Belgium).  
Amoxicillin and clavulanic acid concentrations were determined using a stability 
indicating high-performance liquid chromatography method coupled to tandem mass 
spectrometry operating in the multiple reaction monitoring mode based on a previously 
published method.[181] Briefly, chromatographic separation was performed on a Waters 
Acquity UPLC system (Waters, Milford, Massachusetts) using a BEH C18 column (1.7 μm, 100 
x 2.1 mm) using an injection volume of 5 μL. Amoxicillin D4 (Toronto Research Chemicals, 
Toronto, ON, Canada) was used as an internal standard. The mobile phase consisted of a 
mixture of solution A (0.1 % formic acid and 2 mM ammonium acetate in water) and solution 
B (0.1 % formic acid and 2mM ammonium acetate in methanol). The total run time was 2.5 
minutes. Chromatographic analysis was carried out after diluting the samples 200 times (10 
μL in 1990 μL water containing 2.5 mg/L amoxicillin D4). Amoxicillin or clavulanic acid 
concentration, at each sampling time point, was  expressed as a percentage of the initial 
 
 
drug concentration. We used the, generally accepted, criterion of less than 10% 
decomposition to define drug stability.[312] 
When dissolved without clavulanic acid, amoxicillin was stable for at least 12 hours at 
RT (figure 1). The concentration of clavulanic acid fell below 90% after only 3 hours storage 
at RT.  Due to the instability of clavulanic acid at RT, the combination of 
amoxicillin/clavulanic acid should not be delivered by continuous infusion. 
 
Fig. 1 : Stability of amoxicillin and clavulanic acid over time : mean % intact drug in function 
of time and type of solution: amoxicillin (amoxicillin/clavulanic acid combination), clavulanic 
acid (amoxicillin/clavulanic acid combination) and amoxicillin. Error bars : ± 1 standard 
deviation. Black line : limit of stability (≥90% of the initial concentration). ○ amoxicillin 
(amoxicillin/clavulanic acid combination) , □ clavulanic acid (amoxicillin/clavulanic acid 
combination), × amoxicillin  
All amoxicillin solutions were clear and colorless. The solutions containing both 
amoxicillin and clavulanic acid changed from colorless at time 0 to very slightly yellow after 4 
hours. The pH for amoxicillin remained constant over the 12 h sampling period (mean 8.76; 
standard deviation (SD) 0.027). The pH for amoxicillin/clavulanic acid decreased slightly over 
time from 8.80 (SD 0.017) at time 0 to 8.66 (SD 0.006) after 6 hours (p=0.003). 
 
 
The results for amoxicillin dissolved alone are in line with previous studies and the 
packet insert. Amoxicillin, alone, could be administered as a continuous infusion. We found 
the combination of amoxicillin/clavulanic acid was stable for a maximum of 2 hours. This is 
similar to previous studies which reported only 4 hour stability of amoxicillin/clavulanic acid 
at between 20 and 25°C[309]. Amoxicillin/clavulanic acid stability is limited by degradation 
of clavulanic acid which when dissolved in aqueous solutions is catalyzed by both acids and 
bases. Clavulanic acid stability is reported to be maximal at a pH of 6.3[313]. The unbuffered 
amoxicillin/clavulanic acid solution has a pH of 8.80. The stability of clavulanic acid may be 
increased by acidification of the solution but this approach is not feasible in clinical practice. 
[314] 
This study has a number of limitations. First, we have only tested one lot. However, 
physicochemical properties are not expected to vary across different lots. Secondly, we did 
not test stability for longer than 12 h for amoxicillin. Infusion at lower temperatures (via a 
infusion pump stored in a cold pouch between freezer packs for example) might be a 
solution to improve stability but was not further evaluated in this method, because this 
seemed impractical. Finally, we did not test stability in other solvents such as 5% glucose. 
However, according to the package insert, amoxicillin/clavulanic acid should not be mixed 
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Background : Correct antibiotic dosing remains a challenge for the clinician. The aim of this 
study was to assess the influence of augmented renal clearance on 
pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving 
meropenem or piperacillin/tazobactam, administered as an extended infusion. 
Methods : This was a prospective, observational, pharmacokinetic study executed at the 
medical and surgical intensive care unit at a large academic medical center. Eligible patients 
were adult patients without renal dysfunction receiving meropenem or 
piperacillin/tazobactam as an extended infusion. Serial blood samples were collected to 
describe the antibiotic pharmacokinetics. Urine samples were taken from a 24-hour 
collection to measure creatinine clearance. Relevant data were drawn from the electronic 
patient file and the intensive care information system. 
Results: We obtained data from 61 patients and observed extensive pharmacokinetic 
variability. Forty-eight percent of the patients did not achieve the desired 
pharmacokinetic/pharmacodynamic target (100 % fT>MIC), of which almost 80 % had a 
measured creatinine clearance > 130 mL/min. Multivariate logistic regression demonstrated 
that high creatinine clearance was an independent predictor of not achieving the 
pharmacokinetic/pharmacodynamic target. Seven out of nineteen patients (37 %) displaying 
a creatinine clearance > 130 ml/min did not achieve the minimum 
pharmacokinetic/pharmacodynamic target of 50 % fT>MIC.  
Conclusions: In this large patient cohort, we observed significant variability in 
pharmacokinetic/pharmacodynamic target attainment in critically ill patients. A large 
 
 
proportion of the patients without renal dysfunction, most of whom displayed a creatinine 
clearance > 130 mL/min, did not achieve the desired pharmacokinetic/pharmacodynamic 
target, even with the use of alternative administration methods. Consequently, these 
patients may be at risk for treatment failure without dose up-titration. 
2.1. Introduction 
Infection is a well recognized but persisting problem in critical care medicine. Sepsis 
alone is the leading cause of mortality in non-cardiac intensive care units, with up to 30 % of 
patients dying within one month of diagnosis [1, 2]. Adequate antibiotic therapy is one of the 
mainstays in treatment, with the emphasis on timely administration and appropriateness of 
the spectrum [24]. Optimizing antibiotic exposure is highly important as well, however, this 
is proving to be a greater challenge with recent data showing that antibiotic concentrations 
in critically ill patients are highly variable, unpredictable and commonly sub-optimal [93, 109, 
236, 315].  
Antibiotic dosing regimens are usually determined in healthy adults with normal 
physiology or non-critically ill hospitalized patients. Both the volume of distribution and 
clearance are the key determinants of the pharmacokinetics of a drug. Unfortunately, 
pathophysiological changes in critically ill patients have profound effect on both [39].  
One of these pathophysiological changes is the development of augmented renal 
clearance (ARC). This is a phenomenon in which renal elimination of circulating molecules – 
including antibiotics - is enhanced. This, in turn, may lead to sub therapeutic concentrations 
of time-dependent antibiotics such as -lactam antibiotics, potentially causing therapeutic 
failure and selection of antibiotic-resistant pathogens. Critically ill patients are at risk for 
ARC, because of their pathophysiological disturbances, as well as the clinical interventions 
administered [110, 316]. The incidence of ARC in critically ill patients is high and varies 
between 30 and 85 % depending on the studied population and the definition of ARC [276, 
317, 318].  
One study has demonstrated the relationship between renal clearance and low antibiotic 
concentrations [120], but the relationship between renal clearance and -lactam 
pharmacokinetic/pharmacodynamic characteristics has not been evaluated in a large cohort 
 
 
of patients. However, various pharmacokinetic modeling and simulation studies have 
suggested that using extended infusions will prevent low antibiotic exposure. However, this 
has never been tested in a large cohort of relevant patients with ARC. Therefore, the aim of 
this study was to assess the influence of renal clearance on 
pharmacokinetic/pharmacodynamic (PK/PD) target attainment when the antibiotic was 
administered as an extended infusion. Both the minimum target (50 % fT>MIC), as well as the 
target of 100 % fT>MIC which is considered to have higher bactericidal activity [43] were 
calculated. Notably this study enrolled patients without renal dysfunction, defined as an 
estimated glomerular filtration rate (eGFR) assessed by the MDRD equation of <80mL/min.   
2.2 Materials and Methods 
Inclusion and exclusion criteria 
The data used for this analysis were collected in two separate studies performed in the 
medical and surgical ICU of Ghent University Hospital, a tertiary care hospital with a total of 
50 adult ICU beds. Both studies were approved by the Ethics Committee of the Ghent 
University Hospital (study 1: registration number 2009/543, study 2: 2010/814). Written 
informed consent was obtained from the patient or his/her legal representative. 
Adult patients receiving either meropenem (Meronem®, AstraZeneca) or 
piperacillin/tazobactam (Tazocin®, Pfizer) were included if they did not meet exclusion 
criteria which included renal dysfunction (defined as an estimated glomerular filtration rate 
(eGFR) assessed by the MDRD equation of <80mL/min/1.73 m²), absence of an arterial 
catheter or absence of informed consent. 
Antibiotic administration 
Patients received a loading dose (1g meropenem or 4.5 g piperacillin/tazobactam) 
administered over 30 minutes, followed immediately by the first extended infusion dose of 
either antibiotic (1g meropenem or 4.5 g piperacillin/tazobactam) every 6h for 
piperacillin/tazobactam and every 8 hours for meropenem. Extended infusion doses were 




Sampling and -lactam assay 
The sampling strategy and -lactam assay used was different in the studies that 
contributed patients for this analysis. Twenty patients were included in the first study, and 
forty-one in the second. 
Study 1 (20 patients) 
Eight serial plasma concentrations were obtained from each patient between 24-48 
hours after the initiation of therapy at baseline and after 1, 1.5, 3, 3.5, 4, 6 and 8 hours for 
meropenem; at baseline and after 1, 1.5, 3, 3.5, 4, 5 and 6 hours for piperacillin. For each 
sample, 5mL of blood was collected in heparin anticoagulant tubes without separator gel, via 
the arterial catheter. Specimens were centrifuged at 3000 rpm for 10 min within 30 minutes 
of sampling, and then frozen at minus 80°C. They were shipped to the Burns, Trauma & 
Critical Care Research Centre of the University of Queensland, Australia for analysis by a 
specialized carrier. 
The samples were analysed at the Burns Trauma and Critical Care Research Centre, 
University of Queensland. The plasma concentrations of meropenem and piperacillin were 
determined by validated high performance liquid chromatography (HPLC) methods based on 
a published procedure that has been optimized for each drug [168]. Sample preparation was 
by protein precipitation with acetonitrile and a wash step with dichloromethane. 
Separations were performed on a Waters X-bridge C18 column (2.1 x 30 mm, 2.5 μm) with 
an acetonitrile: phosphate buffer mobile phase (pH 2.5 for meropenem, pH 3 for 
piperacillin). Detection was by UV at 304 nm (meropenem) or 210 nm (piperacillin). The 
meropenem assay was linear from 0.2 to 100 mg/L with an imprecision and inaccuracy <7% 
at high, medium and low concentrations. The piperacillin assay was linear from 0.5 to 500 
mg/L with an imprecision and inaccuracy <10% at high, medium and low concentrations. 
Observed concentrations were corrected for protein binding (piperacillin 30%; meropenem 
2%). 
Study 2 (41 patients)  
Two plasma samples were obtained per patient (mid-dose and trough), after 
administration of at least 3 doses, to ensure steady-state. For each sample, 5 mL of blood 
was collected in heparin-anticoagulant tubes without separator gel, via the arterial catheter. 
 
 
The samples were then sent to the core laboratory of the Dept of Laboratory Medicine at the 
Ghent University Hospital, where they were centrifuged and frozen immediately upon arrival 
at minus 20°C and were analyzed on the same day. 
These samples were analysed at the toxicology laboratory of the Dept of Laboratory 
Medicine at the Ghent University hospital. The plasma concentrations of meropenem and 
piperacillin were determined by validated ultra high performance liquid chromatography 
coupled to tandem mass spectrometry (UPLC-MS/MS). Samples were deproteinized using 
acetonitrile. After centrifugation, a portion of the supernatant was diluted and injected on a 
Waters BEH C18 column (1.7 μm, 100 mm x 2.1 mm) kept at 50 °C and a gradient elution of 
water and acetonitrile, both containing 0.1 % formic acid. Compounds were detected with a 
Waters Acquity TQD mass spectrometer operating in positive electrospray ionization using a 
compound specific MRM method. The assay was linear from 2 to 80 mg/L for meropenem, 
and from 4 to 250 mg/L for piperacillin with an imprecision and inaccuracy < 15 % at high, 
medium and low concentrations. Observed concentrations were corrected for protein 
binding (piperacillin 30%; meropenem 2%).  
It should be highlighted that the samples in Study 1 and Study 2 were analysed using 
different assays in two different laboratories. Although a formal inter laboratory validation 
was not undertaken, both methods have been independently validated according to FDA 
guidelines. Furthermore, both laboratories monitor the quality of their analysis by using 
internal quality controls at 3 levels.  
Pharmacodynamic analysis 
Depending on the study and number of samples available, different methods were used 
to calculate the fT>MIC. When enough samples were available, the fT>MIC was calculated by 
observing the time during the dosing interval that the log-linear least squares regression 
analysis intersected the target MICs for Pseudomonas aeruginosa (16 mg/L for piperacillin 
and 2 mg/L for meropenem based on EUCAST breakpoints [235]. 
In the case when only two concentrations were available per patient, another approach 
was used. One concentration (C1) was taken halfway through the dosing interval, the second 
sample was a trough concentration (C2). Using these two concentrations, it is possible to 
calculate the elimination constant (equation 1).  
 
 
Equation 1 : C2 = C1 - ek . t 
Assuming one compartmental first order kinetics, this is sufficient to calculate the time 
within the dosing interval where the concentration reaches or drops beneath a certain 
threshold. In order to investigate if these two approaches are comparable, the fT>MIC for the 
samples from the first study was calculated using the pharmacodynamic analysis used for 
the second study. This was performed for validation purpose only and was not used for the 
analyses. 
Measurement of creatinine clearance and calculation of estimates 
To calculate a reliable creatinine clearance, urine samples were taken from a 24-hour 
collection. Creatinine was measured in both serum/plasma and urine using the rate blanked, 
compensated and uncompensated Jaffe technique, respectively (Modular P and Cobas 6000, 
Roche Diagnostics GmbH, Mannheim, Germany). The creatinine clearance was calculated as 
follows : 
24 hour creatinine clearance = Uv x Ucr/( 1440 x Scr ), where Uv is the urinary volume (mL), 
Ucr the urinary creatinine concentration (μmol/L) and Scr the serum creatinine concentration 
(μmol/L).For assessment of ARC a cut-off of creatinine clearance ≥ 130 mL/min was used 
[120]. 
Statistical analysis 
The statistical analysis was performed using the statistical software package IBM-SPSS 
statistics version 20.0 (IBM Corp, New York USA). Data are expressed as median values with 
interquartile ranges (IQR) for continuous variables, numbers and percentages for categorical 
variables. In order to identify important covariates, multivariate logistic regression analyses 
(single step, forced entry) were conducted with target attainment 100 % fT>MIC and target 
attainment 50 % fT>MIC as dependent variable using the variables which gave a p-value of 
<0.10 in the univariate analysis. In the case of covariates which were closely related (such as 
weight, height and BMI), the one with the most significant p-value was chosen. Goodness of 
fit was assessed by the Hosmer-Lemeshow statistic. A receiver operator characteristic (ROC) 
curve was constructed to examine the sensitivity and specificity.  






Sixty-one patients were included in the analysis. Patient characteristics on the day of 
study, and the comparison between the patients who did and did not reach the PK/PD target 
of both 100% fT>MIC and 50%fT>MIC are shown in table 1. The median (IQR) creatinine 
clearance from all patients included in the study was 125 (93-173) mL/min ranging from 55 
to 310 mL/min.  
Validation of the pharmacodynamic analyses 
It was found that the results for both methods used for determination of fT>MIC were 
comparable. 
Creatinine clearance and PK target attainment 
Sixty-one patients were included in the study. One patient was excluded from the 
analyses since no urine was collected, as a result of which the creatinine clearance could not 
be calculated. Six patients treated with meropenem had a trough concentration which was 
lower than the lower limit of quantification (2 mg/L), which is also the breakpoint MIC of 
Pseudomonas aeruginosa. This implies that these patients did not reach the desired target of 
100 % fT>MIC, but the exact % fT>MIC could not be calculated, as this is not possible using only 
one sample. Two patients treated with piperacillin/tazobactam could also not be used for 
this analysis, because only the trough concentration was available, which is not enough to 
calculate the exact % fT>MIC . These eight patients were included in the analysis using the 
PK/PD target of 100 % fT>MIC, but could not be entered in the analysis using the PK/PD target 































































































































   

































































































































































































































































































































































































































































































































































































































Target 100 % fT>MIC 
Only 33 out of 60 patients (55%), for whom both creatinine clearance and trough 
concentrations were available, reached the PK/PD target of 100% fT>MIC. Patients who did 
not attain the predefined PK target (100%fT>MIC) were younger, had a higher creatinine 
clearance and a higher weight (table 1). Twenty-nine patients (48 %) had ARC, of which 22 
(76 %) did not reach the PK target of 100%fT>MIC. 
Figure 1 illustrates the fT>MIC for the patients with and without ARC. The mean fT>MIC in 
patients with and without ARC is shown in figure 2 and was 61% vs. 94% in patients with and 
without ARC respectively (p<0.001). 
 
Fig. 1 Histogram %fT>MIC for patients with and without ARC 
 
Fig. 2 Mean % fT>MIC for patients with and without ARC. 
 
 
The results of the multivariate logistic regression are shown in table 2. As the antibiotic 
administered was not significantly different between the groups who did and did not achieve 
the PK/PD target, this was not included in the multivariate analysis (p=0.264). Contrary to 
creatinine clearance, age and weight were not significant in the multivariate analysis. The 
area under the ROC-curve was 0.86 (figure 3a), with a sensitivity of 81% and a specificity of 
81% for predicting target attainment at 50 % probability. 
Table 2 Multivariate regression model with attainment of 100 % fT>MIC as dependent variable 
 Attainment of 100 % fT>MIC as dependent variable 
B p-value Exp(B) 95% C.I.for Exp(B) 
 Lower Upper 
Creatinine 
clearance  
(ml/min) -0.028 0.002 0.972 0.955 0.990 
Weight (kg) -0.040 0.114 0.961 0.915 1.010 
Age (years) 0.020 0.331 1.020 0.980 1.063 
Constant 5.788 0.033 326.34   
      
As an illustration of the impact of an increase in creatinine clearance, the probability of 
achieving the PK/PD target of 100% fT>MIC was plotted according to the creatinine clearance 
using the logistic model for a patient aged 55 years, weighing 75 kg (figure 4).  
 
Fig. 4 Predicted probability of 100% fT>MIC target attainment. 
Target 50 % fT>MIC 
Using the data from these 52 patients for whom both creatinine clearance and fT>MIC 
were available, we found that out of 19 patients displaying ARC, 7 (37 %) did not achieve the 
lower PK/PD target of 50 % fT>MIC(p = 0.002) (table 1) 
 
 
The results of the multivariate logistic regression analysis are shown in table 3. As the 
antibiotic administered was not significantly different between the groups who did and did 
not achieve the PK/PD target, this was not included in the multivariate analysis (p=0.515). 
The area under the ROC- curve was 0.99, with a sensitivity of 95 % and a specificity of 100% 
for predicting target attainment at 50 % probability (figure 3b). Only creatinine clearance 
was found to be significant in the multivariate analysis. 
Table 3 Multivariate regression model with attainment of 50 % fT>MIC as dependent variable 
 Attainment of 50 % fT>MIC as dependent variable 
B p-value Exp(B) 95% C.I.for Exp(B) 
 Lower Upper 
Creatinine 
clearance  
(ml/min) -0.114 0.045 0.892 0.798 0.997 
Weight (kg) -0.035 0.616 0.965 0.841 1.108 
Age (years) 0.005 0.906 1.005 0.926 1.096 
Constant 24.07 0.07 2.8 x 1010   
  
Fig. 3 ROC curves of the binary logistic model. A : 50 fT>MIC target, b : 100 % fT>MIC target 
2.4. Discussion 
In this large observational PK study, using clinical data from 61 critically ill patients with 
normal to increased renal function treated with meropenem or piperacillin/tazobactam, we 
found that ARC was associated with a higher risk of not achieving different PK/PD-targets in 
critically ill patients, even when administering these drugs by extended infusion. This calls 
into question the present approach to antibiotic dosing in these patients and supports use of 
more aggressive dosing strategies to minimize the likelihood of clinical failure. 
 
 
In patients with apparent normal renal function, the relationship between creatinine 
clearance and low target attainment may not come as a surprise as previous studies have 
already demonstrated the correlation between creatinine clearance and clearance of -
lactam antibiotics [92, 158, 241, 319-324]. However, to the best of our knowledge, this study 
is the first to report the association between creatinine clearance and the lack of attainment 
of different PK/PD targets including the lower target of 50 % fT>MIC in patients with apparent 
normal renal function receiving antibiotic therapy administered as an extended infusion. 
Using trough antibiotic concentrations, Udy et al have demonstrated the association 
between subtherapeutic -lactam concentrations and creatinine clearance in select critically 
ill patients [120]. In the current study we could also investigate other targets as we were 
able to use data from the entire antibiotic infusion, including the lower PK-target of 50 % 
fT>MIC. We found that - even when the dose was administered as an extended infusion - up to 
37% of the patients with ARC did not achieve this minimum PK/PD target - and may thus be 
at risk for treatment failure.  
Controversy exists in contemporary literature which PK target should be aimed for in 
critically ill patients, as it is not clear which PK/PD target is associated with highest 
probability of reaching clinical cure. Studies have shown that - depending on the antibiotic - 
40 to 70% fT>MIC is necessary to treat infections [40]. However, recent research has shown 
that achieving higher targets may be associated with a higher probability of reaching clinical 
cure. In order to maximize the effect of -lactam antibiotics, it may therefore be necessary 
to increase the fT>MIC to 100 % or even maintaining the concentration four to five times the 
MIC for the entire dosage duration [42, 43, 325]. Nevertheless, irrespective of the PK/PD 
target considered relevant, increasing creatinine clearance is associated with lower target 
attainments.  
Although ARC is a relatively new concept in intensive care medicine, its relevance should 
not be underestimated. The incidence in critically ill patients is high [276, 317, 318]. 
Implications for therapy with renally excreted drugs are considerable. Case reports have 
shown that some patients require up to 6, 8 or even 12 g meropenem per day to reach 
adequate serum concentrations [275, 282]. The effects of renal clearance are important not 
only for -lactam antibiotics, but have also already been described for other antibiotics, such 
as vancomycin [120, 326].  
 
 
This study has a number of limitations. First of all, this study did not look at clinical 
outcomes as the data were drawn from PK studies. Logically, clinical cure and mortality 
should be investigated in future validation studies of altered antibiotic dosing, although 
these studies should be even larger than the present study. Secondly, we have described 
renal function at inclusion using the MDRD which has been shown to underpredict 
glomerular filtration rate in some critically ill patients [248, 249]. Moreover this study was 
only a snapshot, and might not be representative for the entire course of treatment as 
creatinine clearance varies in the course of the disease. Also, this study is a single-center 
study, which only included patients with apparent normal renal function, which limits 
extrapolation of these finding to all ICU patients. Finally, we have measured total drug 
concentrations with correction for protein binding based on literature. This is an 
oversimplification, but our data show that this approach is acceptable for these two 
antibiotics, although is not for more highly protein bound drugs.  
The findings from this study suggest that an even more sophisticated method of 
optimization may be necessary in selected patients - patient-tailored antibiotic therapy – 
which is the adaptation of antibiotic therapy to the need of the individual patient in order to 
maximize efficacy and minimize toxicity through therapeutic drug monitoring and dose 
adaptation. Unfortunately, TDM of -lactam antibiotics is currently challenging with long 
turn-around times, expensive equipment, logistical problems related to the instability of the 
antibiotics in the samples and the need for well-trained personnel. Efforts to overcome 
these limitations, and clinical studies to assess utility in the clinical setting are urgently 
needed [153].  
2.5. Conclusions 
In conclusion, this study has demonstrated that in critical care patients receiving 
meropenem or piperacillin/tazobactam as an extended infusion, creatinine clearance is a key 
factor in the probability of PK/PD target attainment – irrespective if this is 50 or 100% fT>MIC. 
This study, which excluded patients with renal dysfunction, demonstrated that a specific 
subset of patients is at risk for PK/PD target non-attainment, more specifically those patients 
with increased creatinine clearances, even if the dose is administered as an extended 
infusion, which improves the fT>MIC. By means of multivariate logistic regression, it was found 
that a high creatinine clearance was an independent predictor of not achieving the PK/PD 
 
 
target, implying that without dose up-titration, these patients are at risk of treatment 
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Abstract 
Purpose: There is variability in pharmacokinetics (PK) of antibiotics (AB) in critically ill 
patients. Therapeutic drug monitoring could overcome this variability and increase PK target 
attainment. The objective of this study is analyzing the effect of a dose adaption strategy 
using daily therapeutic drug monitoring on the target attainment.  
Methods: This was a prospective, partially blinded, and randomized controlled trial in 
patients with normal kidney function treated with meropenem (MEM) or 
piperacillin/tazobactam (PTZ). The intervention group underwent daily therapeutic drug 
monitoring, with dose adjustment when necessary. The predefined 
pharmacokinetic/pharmacodynamic (PK/PD) target was 100% fT>4MIC. The control group 
received conventional treatment Primary endpoint was the proportion of patients that 
reached 100% fT>4MIC and 100% fT>MIC at 72 h. 
Results: Forty-one patients (median age was 56) were included in the study. Pneumonia was 
the primary infectious diagnosis. At baseline 100% fT>4MIC was achieved in 21% of the PTZ 
patients and in none of the MEM patients; 100% fT>MIC was achieved in 71% of the PTZ 
patients and 46% of the MEM patients. Eighty-five percent of patients in the intervention 
group needed dose adaptation, 5 required an additional increase. At 72h, target attainment 
rates for 100% fT>4MIC and 100% fT>MIC were higher in the intervention group: 58% vs. 16% 
(p=0.007) and 95% vs. 68% (p= 0.045) respectively.  
Conclusions: A strategy of dose adaptation based on daily therapeutic drug monitoring lead 
to an increase in PK/PD target attainment compared to conventional dosing in critically ill 




Infections are an important problem in critically ill patients, and an important source of 
morbidity and mortality in intensive care units (ICUs)[1]. Antimicrobial therapy has emerged 
as one of the most crucial elements in the treatment of severe infections, and has been 
studied extensively in recent years[59, 327]. Timely initiation of the antimicrobial agent as 
well as the appropriate spectrum have shown to be important determinants of clinical 
success. Antimicrobial therapy in ICU patients most often is based on standard dosing 
protocols, with little or no attention to the baseline characteristics (e.g. weight) or the 
altered physiology of the patient that results in changes in pharmacokinetics [328].  
Numerous studies [93, 133, 140, 223, 329] have demonstrated that antibiotic plasma 
concentrations - especially of hydrophilic antibiotics, such as β-lactams - are variable and 
unpredictable in ICU patients. Increased volume of distribution, changes in protein binding 
as well as changes in elimination rate from the circulation through the kidney or the use of 
extracorporeal circuits contribute to this phenomenon, which has important implications 
[39, 97, 330]. A significant number of patients therefore do not reach 
pharmacokinetic/pharmacodynamic (PK/PD) targets required for the treatment of severe 
infections [331, 332]. 
Several strategies have been proposed to overcome this problem, such as continuous or 
extended infusion[140, 157]. Recent literature demonstrated higher PK/PD target 
attainment [156] as well as improved outcomes [298] when extended or continuous infusion 
strategies are used, and a randomized controlled trial comparing intermittent with 
continuous infusion resulted in better antibiotic exposure, as well as improved clinical cure 
in the continuous infusion group [142]. Although this may be an improvement over 
intermittent dosing, in some patients even higher doses may be required. 
There have been multiple reports of patients with augmented renal clearance (ARC) in 
whom standard dosing is not adequate [120, 282]. Some patients required up to 4 fold 
increases in dosing for the treatment of severe infections – and often, therapeutic drug 
monitoring (TDM) was used to guide treatment[120, 275, 281]. Pharmacokinetic studies also 
confirmed that some patients may require higher doses of β-lactam antibiotics or 
glycopeptides, especially when aiming for higher PK/PD targets [157, 256, 333, 334]. 
 
 
A more individualized approach using TDM guided antimicrobial therapy with dosing 
tailored to the altered PK of the patient may be a proper strategy to overcome this variability 
and the problem of underdosing[335]. Therefore we designed a randomized controlled trial 
using a TDM based dose-adaptation strategy in patients at risk of underdosing who required 
therapy with piperacillin/tazobactam (PTZ) and meropenem (MEM) in patients with normal 
kidney function. We hypothesize that a TDM based approach results in higher attainment of 
PK/PD targets.  
3.2. Methods 
Study design 
Between April 2011 and February 2012 we conducted a prospective, partially blinded, 
randomized controlled trial, at the medical and surgical ICU of the Ghent University Hospital. 
Criteria for inclusion were the need for antibiotic treatment with PTZ and/or MEM, age of 18 
years or older and the presence of an arterial catheter. Patients were excluded in case of 
pregnancy and/or lactation, allergy to the administered medication, impaired renal function 
(estimated glomerular filtration rate (eGFR) as assessed by the CKD-EPI equation <80 
mL/min [28], hemoglobin < 7g/dL, do-not–resuscitate orders or if the patient was expected 
not to survive the first 48h.  
Patients were randomly assigned to the control group, receiving conventional dosing, or 
the intervention group, subjected to TDM guided dosing which consisted of daily monitoring 
of the antibiotic plasma concentration, followed by dosing adjustment if the concentration 
did not meet the predefined target. In the control group antimicrobial concentration was 
also measured daily, but the treating physician was blinded for the results that were used for 
comparison only. Total duration of the study was 7 days. Patients were followed up until 
hospital discharge. 
All antibiotics were administered according to the extended infusion protocol used at 
Ghent University Hospital: patients received a loading dose (1g MEM or 4g PTZ) 
administered over 30 minutes, followed immediately by the first extended infusion dose of 
either antibiotic (1g MEM or 4g PTZ) every 6 hours for PTZ and every 8 hours for MEM. 
Extended infusion doses were administered over 3 hours using a syringe pump. All 
antibiotics were administered via a central venous catheter.  
 
 
Target concentrations in the intervention group were in line with previous studies using 
TDM in critically ill patients. It is traditionally accepted that maintaining concentrations 
above the minimal inhibitory concentration (MIC) of the causative organisms during 40-70% 
of the time is adequate. However, recent studies suggest that higher targets are needed in 
critically ill patients. Given the fact that concentrations 4-5 times greater than the MIC are 
associated with maximal bactericidal activity[42, 336, 337], the PK/PD target in this study 
was set at 100% fT>4MIC as in previous studies[120, 236].  
Based on actual antibiotic concentrations, dosing of intervention patients then followed 
a pre-established algorithm (figure 1). Until the MIC of the causative microorganism was 
known, the epidemiological cutoff (ECOFF) of wild type Pseudomonas spp. (16mg/L for PTZ 
and 2mg/L for MEM) was targeted, and this MIC was used for all calculations in the study as 
we only investigated the effect of dose adaptation in the first 72 hours – the time it would 
usually take to have an MIC of the actual infecting organism available. Target trough 
concentrations were therefore >64mg/L for PTZ and >8mg/L for MEM respectively (>4xMIC). 
In case of lower concentrations, dosing frequency was increased as a first step in the 
intervention (4g/0.5g every 4h for PTZ and 1g every 6h for MEM). If MEM concentrations 
remained below the target, the dose was increased by 50%. If these adjustments failed to 
reach the targets, no further actions were taken. In patients with trough concentrations > 
10xMIC, the antibiotic dose was decreased by 50%, or the dosing frequency reduced if this 
had been increased in an earlier step.  
 
Fig. 1 Therapeutic drug monitoring (TDM)-based dose adaptation strategy. MIC Minimal 
inhibitory concentration, MEM meropenem. Asterisk see text for details 
 




Target attainment defined as 100% fT>MIC and 100% fT>4MIC within the first 72 hours of 
treatment were the primary endpoints. The fT>MIC and fT>4MIC at 72h was compared between 
intervention and control groups, as well as between baseline and at 72h. Although 4 times 
the MIC was the target of the intervention we wanted also to study the effect of the 
intervention on a more conservative PK target hence 100% fT>MIC was used as an endpoint as 
well. 
Secondary endpoints were absolute values of fT>MIC and fT>4MIC,  
Clinical response at the end of the study (day 7) was evaluated by two of the 
investigators. Resolution was defined as disappearance of all signs and symptoms related to 
infection, improvement was defined as a marked or moderate reduction in the severity 
and/or number of signs and symptoms of infection and failure was defined as insufficient 
lessening of the signs and symptoms of infection to qualify as improvement, including death. 
Response to therapy was also evaluated by bacterial persistence at day 7. 
Patient data collection 
Relevant data were retrieved from the hospital’s Electronic Patient File and the unit’s 
Patient Data Management System and included demographic parameters (gender, age), 
weight, length, date of hospital/ICU admission and discharge, start and end date of the 
antibiotic treatment with PTZ/MEM, comorbidities, admission diagnosis, type of infection, 
Acute Physiology And Chronic Health Evaluation (APACHE)-II score, daily Sequential Organ 
Failure Assessment (SOFA) score, daily body temperature, urinary output and outcome 
(survival or death) including cause of death. The following lab results were recorded: white 
blood cell count, platelet count, fibrinogen, C-reactive protein (CRP), serum creatinine, 
urinary creatinine and microbiological data.  
Study samples 
Blood samples were collected daily; during the first 3 days mid-dose (i.e. halfway the 
dosing interval) and trough samples were obtained, during the last four days of the study 
only trough concentrations were determined. On the first study day, the first sample 
(baseline concentration) was drawn after at least 3 completed infusions of the antibiotic. 
 
 
Twenty-four hour urinary creatinine clearance was measured throughout the study period. 
The calculated creatinine clearance was corrected for the Body Surface Area (BSA).  
Sample analysis 
Analysis of the TDM samples was done at the Department of Laboratory Medicine at the 
Ghent University Hospital. PTZ and MEM concentrations were assayed by validated ultra 
high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-
MS/MS) using oxacillin as an internal standard [33]. 
Sample preparation consisted of protein precipitation using acetonitrile and subsequent 
dilution. Five μl was injected onto a BEH C18 column (1,7μm, 100mm x 2,1mm) (Waters®), 
kept at 50°C. The mobile phase consisted of 0.1% formic acid in water and 0.1% formic acid 
in acetonitrile at a flow rate of 0.350 mL/min. Separated compounds were detected with the 
Waters® TQD mass spectrometer, which operated in positive electrospray ionization, using a 
compound specific MRM method. Runtime was 5.5 minutes. The method was linear 
between 4 - 250 mg/L for PTZ and 2 - 80mg/L for MEM. Imprecision and inaccuracy were 
found to be < 15 % at high, medium and low concentrations. Concentrations below the 
linear range were reported as < 4 mg/L for PTZ and as < 2 mg/L for MEM. System 
performance was monitored by analyzing 3 internal quality control samples at low, medium 
and high concentrations in each run. 
Pharmacokinetic and pharmocodynamic calculations  
One concentration (C1) was taken halfway through the dosing interval; the second 
sample was a trough concentration (C2). Using these two concentrations, it is possible to 
calculate the elimination constant (equation 1). Equation 1 : C2 = C1 - ek . t 
Assuming one compartmental first order kinetics, this is sufficient to calculate the time 
within the dosing interval where the concentration drops beneath a certain threshold (1 or 4 
x MIC)  
Power analysis 
Power analysis computed a required sample size of 16 patients per study group, taking 
into account a one sided test with α = 0.05, β = 0.20 and an expected increase of target 
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attainment (with trough concentrations of at least 4xMIC as a target) from 50% to 90% of 
the patients. Considering a dropout rate of 20%, 20 patients per group were projected.  
Statistical analysis 
Statistical analysis was performed using IBM® SPSS® Statistics 19.0. Data are expressed as 
median values with interquartile ranges (IQR) for continuous variables, numbers and 
percentages for categorical variables. Mann-Whitney U test for comparison of median values 
and the Friedman test or the Wilcoxon matched-pairs Signed-ranks test were used where 
appropriate. Proportions were compared using 2x2 tables and the Chi² or Fisher’s Exact as 
appropriate. A p-value of ≤ 0.05 was considered statistically significant. 
Ethics 
The study was approved by the Ethics Committee of the Ghent University Hospital 
(registration number 2010/814), and approved by the Belgian regulatory agency 
(B67021020250). Written informed consent was obtained from the patient or his/her legal 
representative. 
3.3. Results 
Forty-one patients were included in the study, 21 in the intervention group and 20 in the 
control group. Twenty-eight patients received PTZ: 15 in the intervention group, and 13 in 
the control group; 13 patients received MEM: 6 in the intervention group and 7 controls. 
The majority of the patients were male (n=35, 85%). Characteristics of intervention and 
control patients were comparable and are summarized in table 1. Most patients were 
treated for pneumonia (78%), other diagnoses included tracheobronchitis, - peritonitis, and 








Table 1 Patient characteristics of the study population 
Characteristics All patients (n = 41) 
Intervention 
(n = 21) 
Control 
(n = 20) P value 
Age (years) 56 (46–69) 57 (42–76) 56 (48–64) 0.804 
Weight (kg) 76 (67–88) 77 (69–89) 75 (66–88) 0.657 
Body mass index 
(kg/m2) 25 (22–27) 25 (22–28) 24 (22–25) 0.705 
APACHE II score 18 (13–24) 19 (12–24) 17 (13–23) 0.557 
Day 1 SOFA score 5 (2–6) 5 (3–6) 5 (2–6) 0.711 
Day 1 CrCL (mL/min) 99 (80–135) 130 (92–177) 108 (88–145) 0.291 
Day 2 CrCL (mL/min) 115 (82–170) 129 (100–167) 106 (74–175) 0.461 
Day 3 CrCL (mL/min) 131 (90–172) 155 (83–182) 110 (90–165) 0.697 
Infection characteristics     
 Pneumonia 32 (78 %) 16 (80 %) 16 (76 %)   
 Tracheobronchitis 2 (%) 1 (5 %) 1 (5 %)   
 Peritonitis 5 (12 %) 3 (15 %) 2 (10 %)   
 Blood stream infection 1 (2 %) 0 (0 %) 1 (5 %)   
 Febrile neutropenia 1 (2 %) 0 (0 %) 1 (5 %)   
 Community-acquired 
infection 3 (7 %) 2 (10 %) 1 (5 %)   
 Hospital-acquired 
infection 38 (93 %) 18 (90 %) 20 (95 %)   
CrCl : creatinine clearance 
Forty-three causative microorganisms were cultured from 27 patients; isolates included 
E. Coli (n=7), Klebsiella pneumoniae (n=7), Pseudomonas aeruginosa (n=6), Enterobacter 
cloacae (n=4), Staphylococcus aureus (n=4), Klebsiella oxytoca (n=2), Acinetobacter baumanii 
(n=2), Enterococcus faecalis (n=2), Prevotella spp. (n=2), Citrobacter spp. (n=2), Morganella 
morganii (n=2), Serratia marcescens (n=2), Enterobacter aerogenes (n=1) and Streptococcus 
viridans (n=1). The median MIC was 2 mg/L (IQR 1.5-8) for PTZ and 0.125 (0.125-0.690) mg/L 
for MEM.  
Median antibiotic concentrations before randomization were 30 mg/L (IQR 18-56 mg/L) 
for PTZ and <2 mg/L (IQR <2-4 mg/L) for MEM.  
 
 
Baseline target attainment was as follows: 100% fT>4MIC was achieved in 21.4% of the PTZ 
patients and in none of the MEM patients; 100% fT>MIC was achieved in 71.4% of the PTZ 
patients and 46.2% of the MEM patients. The median fT>4MIC at baseline was comparable for 
both antibiotics with 46.5% for PTZ (IQR 18-86.25) and 56.5% for MEM (IQR 15-65). Median 
baseline fT>MIC was much higher at 100% for both PTZ and MEM.  
Patients in the intervention group had numerically lower baseline median concentrations 
(PTZ 26 mg/L vs. 40 mg/L and MEM <2 vs. 2 mg/L). As a consequence, at baseline fewer 
intervention patients achieved 100% fT>4MIC (9.5 vs. 20%) and their fT>4MIC is lower (44.5 vs. 
58%).  
In the intervention group, dose adaptation was necessary in 16 patients (76%); the initial 
step of increasing the frequency was enough to reach the target of 4xMIC in 69% (11/16) of 
these patients.  
Three patients did not complete the study protocol, and from them target attainment at 
day 3 could not be calculated. In the remaining 38 patients, the use of a TDM based dose 
adaptation protocol significantly increased the proportion of patients reaching the PK/PD 
target within the first 72 hours of treatment: 94.7% of the intervention patients reached 
100% fT>MIC in contrast to 68.4% of the control patients (P = 0.045). Also for the target of 
100% fT>4MIC, attainment rates were higher in the intervention group (57.9% vs. 15.8%, 
p=0.007). (Figure 2 and 3). No adverse events occurred. 
 
Fig. 2 Percentage of control and intervention patients reaching 100 % fT>MIC at baseline and 
on day 3. f T >MICCumulative percentage of a 24-h period that the free (f) drug 




Fig. 3 Percentage of control and intervention patients reaching 100 % fT>4MIC at baseline 
and on day 3. >4MICFourfold the MIC 
The intervention significantly increased the median fT>4MIC from 44.5% to 86% and 90% 
on day 2 and 3 respectively (p=0.012)(Fig. 4).  
 
Fig. 4 Boxplots of time above the 4× MIC (fT>4MIC) during the first 3 days of treatment in 
control and intervention patients. Top, bottom of box 25 and 75 % percentile, 
respectively, dark horizontal line in box median,whiskers minimum and maximum, 
respectively 
Clinical failure was present in 4 patients in the control group, and in 2 in the intervention 
group (p=0.41); bacterial persistence at day 7 was present in 5 patients in the control group, 
vs. 1 in the intervention group (p=0.09).  
 
 
The recovery of organ function during the study was evaluated using the SOFA score in 
patients who completed the 7-day study protocol (n=15). Median SOFA score changed from 
5.5 to 3 in intervention patients (P = 0.093), and from 5 to 4 in the control group (P = 0.575).  
Five patients died in the ICU, 4 control patients (20%) and 1 intervention patient (4.8%) 
(p= 0.18). Hospital and 28-day mortality were also not significantly different with 5 deaths in 
the control group and 3 in the intervention group (25% vs. 14.3%%, p= 0.45).  
3.4. Discussion 
In this study we found that daily TDM with dose adaptation resulted in higher median 
fT>4MIC, and a higher proportion of patients attaining both the 100% fT>MIC and 100% fT>4MIC 
target in patients with normal kidney function. This required doses of 33-100% higher 
compared to standard dosing regimens. 
We also demonstrated that standard dosing – even using extended infusion – does not 
reach target antibiotic concentrations in all patients, either the 100% fT>MIC or 100% fT>4MIC 
target. Extended and continuous infusion of β-lactam antibiotics have been found to 
increase exposure of the microorganism to the antibiotic, which in case of time-dependent 
antibiotics such as piperacillin and MEM, should theoretically lead to a more efficient 
antibiotic effect, faster control of the infection and improved outcomes. The literature is 
scattered with simulation data – most often coming from healthy or non-critically ill patients 
but all consistently demonstrating that extended or continuous infusion results in improved 
target attainment rates. Small-scale clinical studies did confirm this for both piperacillin and 
MEM [140, 157]. However, extended infusion may not be sufficient to overcome the 
changed physiology of the patient, notably when higher PK targets are used or (borderline) 
resistant microorganisms are involved, but also in more common settings such as 
augmented renal clearance (ARC). Taccone et al. recently reported a patient infected with a 
highly resistant microorganism who needed a daily dose of 12g meropenem to treat the 
infection [256].  
The question remains if our findings apply to all patients in the ICU. This study was 
performed in patients considered to be at the highest risk of underdosing, i.e. patients with 
apparent normal renal function. ARC is a frequent finding in this population[316], and for a 
lot of antibiotics, including piperacillin and MEM drug clearance is largely determined by 
 
 
renal clearance[39]. ARC has been linked to inadequate antibiotic concentrations [120], and 
will also have played a role in the current study. Possibly, ARC patients are the best 
candidates for a TDM based approach to optimize antibiotic exposure. But also other patient 
categories may be at risk of underdosing. Hites et al. recently reported that obese critically ill 
patients treated with carbapenems had lower concentrations compared to non-obese 
patients [280]. 
This study has a number of limitations. First of all, this study was performed in selected 
ICU patients and patients with impaired renal function or on renal replacement therapy 
(RRT) were excluded. Patients on RRT are at particular risk of underdosing when package 
insert dosing recommendations are followed, and they may indeed also benefit from a TDM 
based antibiotic dosing approach. Secondly, we only measured total antibiotic 
concentrations, and not free antibiotic concentrations. Protein binding is limited for 
piperacillin and almost nil for MEM [123], and therefore the potential effect of changes in 
protein binding is expected to be limited. Furthermore, the study was not designed or 
powered to detect any difference in clinical outcome parameters. Finally, we did not include 
a second step of dose increase in the patients who had inadequate piperacillin 
concentrations. This would have increased the daily dose to 36g piperacillin and 4.5g of 
tazobactam, a very high dose of which the PK has never been investigated. As the PK of both 
compounds are not completely alike, administration of a high dose of PTZ could potentially 
lead to accumulation of tazobactam and related toxicity.  
Potential benefits of a TDM based approach include better outcome because of more 
appropriate antibiotic concentrations, but also less resistance development and avoidance 
of toxicity. Although considered safe, β-lactam antibiotics have a number of adverse effects 
including neurotoxicity, liver damage and bone marrow suppression, and some of these are 
dose-dependent. TDM may thus not only be helpful to increase efficacy, but also to reduce 
toxicity. 
Although TDM was able to increase target attainment, it should be noted that 
underdosing remains frequent in the initial phase; TDM may be useful to correct initial 
underdosing but alternative strategies remain warranted to avoid underdosing in the first 24 




The literature on TDM based approach for β-lactam dosing is limited [224]and the use of 
TDM in clinical practice remains controversial [38]. Roberts et al. demonstrated that 74% out 
of 236 patients treated with β-lactam antibiotics did not reach adequate concentrations, and 
needed dose adjustment[236]. However, the effect of this was not systematically evaluated; 
only 21% of the patients were re-sampled, and only 43% of them reached adequate 
concentrations, confirming our findings. TDM has also proved beneficial in specific 
populations such as burn patients. Patel et al. found that TDM was able to detect 
underdosing in up to 60% of the patients[338]. Several case reports have shown that in 
difficult situations, either patients with a complex physiology or microorganisms with 
increased resistance to an antibiotic, TDM may indeed be useful to guide therapy[256, 275, 
281, 282] [19, 21-23]. This study is however the first to pharmacokinetically confirm that 
dose adaptation results in better target attainment. 
In conclusion, TDM based dose adaptation of β-lactam antibiotic therapy improves 
antibiotic exposure in critically ill patients with normal renal function. Whether this 




Chapter Seven: Discussion and Future Perspectives 
Early initiation of antibiotic therapy with an appropriate spectrum after source 
control is currently the most important clinical intervention to reduce mortality and 
morbidity in severely infected patients with sepsis and septic shock. To be effective, the 
antibiotic needs to reach the infected tissue in optimal concentrations. For -lactam 
antibiotics, the concentrations have to exceed the minimal inhibitory concentration (MIC) of 
the microorganism for at least 40-60% of the time, which is considered the minimum 
pharmacodynamic (PD) target. In recent studies it was suggested that for critically ill patients 
higher plasma concentrations (100%fT>MIC or even 4 times the MIC) are required for optimal 
efficacy. However, because of grossly altered pharmacokinetics of hydrophilic antibiotics, 
dosing remains a significant challenge for the treating physician. Recent research has shown 
that because of altered pharmacokinetics of hydrophilic antibiotics, current standard dosing 
– most often based on experiments in healthy volunteers – does not reach even the minimal 
targets in many critically ill patients, let alone the higher targets mentioned.  
Antibiotic dosing that is not optimized for critically ill patients may lead to clinical 
failure. In this respect, it is interesting to note that two non-inferiority studies of two new β-
lactam antibiotics, ceftobiprole and doripenem were stopped prematurely, because of 
greater mortality in the intervention group, where a greater proportion of patients 
happened to display augmented renal clearance [339]. In order to improve dosing in 
critically ill patients, it may be necessary to change current dosing practices from “one dose 
fits all” to a more individualized patient tailored antibiotic therapy.  
The overall objective of this research was to develop tools to individualize antibiotic 
therapy in critically ill patients. In this respect we have first developed an ultrafast 
quantification method that allows for fast determination of β-lactam antibiotic 
concentrations in plasma. We have minimized sample preparation and investigated the pre-
analytic phase. In this project we have also confirmed the high variability of antibiotic 
concentrations, as well as variability over time in within the same patient. We have 
developed population pharmacokinetic models for amoxicillin/clavulanic acid and 
 
 
cefuroxime in critically ill patients without acute kidney injury, and a population 
pharmacokinetic model for cefepime in septic shock patients during continuous renal 
replacement therapy. We have shown in a simulation study that standard dosing of broad 
spectrum β-lactam antibiotics leads to better target attainment than standard dosing of 
narrower spectrum β-lactam antibiotics for a number of organisms in which de-escalation 
can be performed. Some more practical studies were also performed, such as the stability 
studies for meropenem and amoxicillin/clavulanic acid. Furthermore, we found that 
increased creatinine clearance is a risk factor for subtherapeutic conentrations. Finally, we 
have shown that daily therapeutic drug monitoring leads to improved pharmacokinetic 
target attainment.  
 Studies like the ones performed for this thesis have improved our knowledge of the 
altered pharmacokinetics of many antibiotics. We now have better insights in the 
determinants of pharmacokinetics in the critically ill. However, there are still many questions 
that need to be answered before we can truly move from current dosing practice to a more 
patient tailored antibiotic therapy.  
1. Analytical considerations 
For this research we have developed an accurate and ultrafast chromatographic 
method coupled to tandem mass spectrometry. Although this was possible in this tertiary 
center university hospital, this may not be feasible in smaller centers. Therefore, more 
research is needed in the analytical field of biosensors and immunoassays, which does not 
require expensive equipment or highly trained staff. Moreover, if therapeutic drug 
monitoring would be performed on a routine basis, it should be available at least once a day 
and preferably 24/7. The best of all cases would be a bedside sample collection device that 
requires only a small volume of whole blood but immobilizes the proteinaceous and cellular 
component of the specimen to isolate the free fraction, thus yielding a sample requiring 
minimal preparation and providing maximal pharmacokinetic information. If such a device 
were not feasible, research should focus on easy transportation (using for example dried 
blood spots or other alternative sampling devices) of samples from the hospitals to the 
reference center. If analysis of -lactam concentrations were to be performed on a large 
scale in multiple centers, there will also be a need for certified reference material, 
 
 
commercial calibrators and controls and proficiency testing schemes in order to ensure 
quality control.  
2. Population pharmacokinetic studies 
As critically ill patients are a very heterogeneous group, population pharmacokinetic 
studies are needed in each subpopulation, such as morbidly obese patients, patients treated 
with extracorporeal techniques, such as extra corporeal membrane oxygenation (ECMO) and 
renal replacement therapy (note that a separate study is needed for each mode of 
clearance, such as sustained low efficiency dialysis (SLED), continuous venoveno 
hemofiltration (CVVH), continuous venoveno hemodialysis, (CVVHD), continuous venoveno 
hemodiafiltration (CVVHDF), intermittent hemodialysis, …), burn patients, patients with liver 
failure etc.  The developed population pharmacokinetic models can be used to develop 
dosing algorithms based on the covariates from the pharmacokinetic model. These 
algorithms should then be prospectively validated. Research should not only focus on broad 
spectrum but should also be focused on dosing of narrower spectrum and less frequently 
used drugs such as amoxicillin, cefuroxime, and even flucloxacillin and penicillin G.  
3. Tissue concentrations 
In our research we have only investigated total plasma concentrations. However, the 
bloodstream is not the site of infection is in most cases. It is unclear whether total (or even 
unbound for that matter) concentrations accurately reflect the concentrations at the site of 
infection. The required dose to result in optimal tissue concentrations remains unknown.  
 Studying tissue concentrations is a complex issue. Lung infections are a good 
example to illustrate the difficulties of studying tissue concentrations. First of all, the 
location of the proliferating bacteria within the different lung compartments is often 
uncertain [340]. The infection may affect different sites within the lung (alveoli, interstitium, 
bronchioles, etc.). Each site has its own diffusion constant, and therefore its own 
concentrations. Therefore, the specimen to determine the representative drug 
concentration must be wisely chosen  [340]. Possible specimens are : epithelial lining fluid, 
lung interstitial fluid, alveolar macrophages, blood, lung tissue, bronchial secretions and 
sputum. Epithelial lining fluid is often considered to be the most representative of the 
extracellular environment where the most common pulmonary pathogens are located. 
However, obtaining a representative specimen is invasive and technically challenging, as 
epithelial lining fluid is often contaminated with antibiotics released from alveolar 
macrophages, giving rise to falsely elevated concentrations.  Moreover, it is not feasible to 
sample multiple times within one dosing interval [340].  
An emerging technique used to determine the concentration in tissues is 
microdialysis. A microdialysis probe is inserted into the tissue, and is constantly perfused 
with physiological fluids (perfusate) with similar composition comparing to the interstitial 
fluid. The tip of the microdialysis catheter is semi-permeable, which allows the drug to 
diffuse from the interstitial fluid into the microdialysate. This recovered fluid can then be 
collected and analysed. This technique is graphically shown in figure 1.  
 
Fig. 1 : Principle of microdialysis (copied from [341]with permission) 
Roberts et al have already performed some exploratory studies in a limited number 
of sepsis patients [133, 140]. Tissue penetration may be more severely impaired in septic 
shock, which was explored by Joukhadar et al, again in only a limited (n= 6) number of 
patients, treated with piperacillin in an intermittent infusion [134]. Therefore, future 
research should more closely investigate concentrations at the site of infection, preferably 
over multiple days starting from the first day of treatment. These tissue concentrations 
should be linked to total and free plasma concentrations and other covariates such as renal 
function, body weight, vasopressor therapy and so on using pharmacokinetic population  




analysis, so dosing simulation studies can be performed to investigate which dose results in 
optimal concentrations. 
4. Continuous infusion 
It seems that continuous infusion of -lactam antibiotics is becoming the 
administration method of choice in critically ill patients. However, it is unclear how this 
mode of infusion influences tissue penetration. Does continuous infusion improve tissue 
penetration in septic shock? Does it result in more stable concentrations? This way of 
infusion may hypothetically lead to more stable tissue concentrations and may therefore 
prevent the overgrowth of less susceptible organisms and therefore minimize resistance, 
which should be investigated in prospective studies. Developing methods to improve 
stability of unstable antibiotics such as amoxicillin/clavulanic acid and imipenem may also be 
worthwhile, such as cooled infusion syringes.  
5. Pharmacokinetic/pharmacodynamic target 
Probably the biggest hurdle to overcome before one can truly investigate the impact 
of TDM on clinical outcome is the PK/PD target, used to decide if dosing adaptations are 
needed. From in vitro and animal models it has become clear that -lactam antibiotics exert 
time dependent killing. However, it is not clear whether the target value is 50% fT>MIC, or 
100% fT>MIC or even 100% fT>4XMIC. Moreover, when establishing the optimal PK/PD target, 
one should not only consider short term outcomes such as clinical cure of the patient, but 
also long term outcomes, such as the minimization of the emergence of antibiotic resistance, 
as emerging resistance is an important global issue.  
 From pre-clinical studies it is clear that the relationship between antibiotic exposure 
and resistance development is very different from the relationship between bactericidal 
effect [342]. The magnitude of the threshold for resistance suppression is markedly higher 
than the threshold needed for optimal clinical success. Therefore, dosing that only aims to 
optimize bactericidal effect may actually increase resistance formation by selecting less 
susceptible mutant strains, which is a hypothesis called the mutant selection window and 
mutant prevention concentration. However, the doses required for achieving concentrations 
above the mutant prevention concentration are often higher than the maximal 
 
 
recommended dose, and sometimes not achievable for some antibiotic-pathogen 
combinations [342].  
 In order to elucidate the optimal PK/PD target, large multicenter studies are needed 
in critically ill patients investigating the relationship between concentrations, susceptibility 
of the microorganism and outcome in patients. Large observational datasets are needed 
incorporating as much information as possible, such as details on the causative pathogen 
and its susceptibility, antibiotic concentrations, site of infection, severity of illness scores and 
other patient characteristics which may all influence outcome. Using this information, a 
multivariate analysis incorporating these potential confounders can then be performed, 
investigating whether failure of achieving the PK/PD target attainment is an independent 
predictor of outcome (clinical failure or the emergence of resistance).  
6. How to perform patient tailored antibiotic therapy ?  
Once the PK/PD target has been established, studies are needed that investigate how 
to perform patient tailored antibiotic therapy. Considering the importance of timely 
antibiotic therapy, the patient should be initiated on a dose based on population 
pharmacokinetic studies performed in this target population which gives the best prior 
Bayesian probability of reaching the PK/PD target. Although this dose gives the best 
probability of reaching the PK/PD target for this population, it does not guarantee that the 
PK/PD target will be reached in each individual, because of large between subject variability, 
and therefore, concentrations should subsequently be monitored.  
However, there are many questions to be resolved, such as the exact timing of the 
first sample. There are arguments to be made to wait a sufficient amount of time in order to 
reach pharmacokinetic steady state (a concept which can be questioned in critically ill 
patients, as steady state requires stable patients), while others would stress the importance 
of time, and would sample sooner. Another practical issue is the method of dose adjustment 
when deemed necessary. Should a generalized dose adjustment method be used (such as: 
increase the dose by 50% or reduce the frequency by 50%), or should the dose be adjusted 
using specific software which can estimate patient clearance from the measured 
concentration and so determine which dosing regimen would most likely result in optimal 
concentrations (Bayesian forecasting)?  
 
 
As already mentioned above, these studies should not only be focused on the broad 
spectrum antibiotics such as meropenem and piperacillin, but also on narrower spectrum 
drugs, as these are still an important part of our armamentarium against antimicrobial 
resistance. Focusing research on only the broad spectrum antibiotics may create an illusion 
of safety for these drugs, and may promote general use of these antibiotics and therefore 
further driving emergence of resistance.  
The ideal design for this study is a randomized controlled trial, where the control 
group receives the standard dose of antibiotic therapy. If by then, there is sufficient 
evidence that continuous infusion leads to better outcome, then both arms should receive 
the antibiotic as a continuous infusion. The intervention group  should be started on the 
dose which is most likely to result in optimal concentration using Bayesian Forecasting. The 
initial dose should therefore be based on patient characteristics such as weight and renal 
function. After a few hours a sample can already be taken and sent to the lab. The results 
should be made available as quickly as is feasible for the lab, and these results should be 
interpreted using specific dosing software, which predicts individual pharmacokinetic 
parameters and calculates which dose will most likely result in optimal PK/PD target 
attainment and takes into account that these are non-steady state conditions. The dose 
should then be promptly adapted if needed.  The probability to achieve a better outcome 
(clinical cure or prevention of the emergence of resistance) should be compared between 
both groups. If this study reveals that  TDM is a useful intervention, effort should be made to 
try to reduce the burden of this intervention. Future studies should then be focused on 
achieving the PK/PD target with less difficulties, such as performing TDM only in the initial 
phase and then monitoring covariates such as renal function.  
7. More and more accurate MIC values 
As already mentioned, the likelihood of therapeutic success is based on exposure and 
susceptibility of the pathogen. Since the MIC values are reported in factors of two, this 
means that for each level of decreased susceptibility, the PK component of the PK/PD index 
has to be doubled in order to maintain the pre-defined target PK/PD ratio. Therefore, the 
susceptibility of the microorganism is a very important parameter to take into account when 
moving towards more individualized antibiotic therapy. 
 
 
However, to date, the susceptibility of a microorganism is mostly reported as 
S(sensitive)/I(intermediary resistant) or R (resistant). These arbitrary values are in PK/PD 
terms less useful than an actual MIC value, as there is a whole range in MIC values that are 
considered to be sensitive to a certain antibiotic. The PK/PD target will always be achieved 
with standard dosing if the MIC value is very low. However, when the MIC value shifts to 
higher values (closer to the intermediary value, but still reported to be sensitive), it may 
become more difficult to achieve the PK/PD target using standard dosing. On the other 
hand, MIC values which are considered intermediary or even resistant, may still be 
attainable, if higher doses are given and/or using alternative administration techniques, and 
if the MIC value is only 1 or 2 dilutions higher than the breakpoint MIC. Therefore, MIC 
values should be preferred over the 3 categories S, I and R.  
All currently used methods rely on detecting phenotypic resistance by measuring 
bacterial growth in presence of the antibiotic being tested. These methods are generally 
slow, as these require isolation from the clinical sample before testing and require 
incubation time, and generally take between 24 and 72 h during which broad spectrum 
empirical is started based on local epidemiology. In the last few years, the knowledge on the 
molecular basis of antibiotic resistance has widely increased, and therefore novel 
approaches for rapid detection of bacterial resistance are to be expected, based on 
polymerase chain reaction (PCR) techniques, mass spectrometry, microarrays, microfluidics, 
cell lysis-based approaches and whole-genome sequencing, which may also improve 
outcome and decrease resistance development. However, it is yet to be investigated 
whether these methods achieve the same level of sensitivity and specificity compared to 
standard methods and can be available 24/7 with a short turn-around time. Moreover, these 
methods are currently associated with a significant cost [343]. 
8. Pharmacoeconomics 
Shifting from standard dosing to patient tailored antibiotic therapy will definitely be 
costly, because of the need for concentration determinations, determination of MIC values, 
the need for higher doses of antibiotics in some patients and the need for a multidisciplinary 
team consisting of intensive care physicians, microbiologists, pharmacists and clinical 
chemists. When a definitive study is undertaken evaluating the impact of patient tailored 
 
 
antibiotic therapy, one should also perform a cost benefit-analysis, to investigate whether 
the quantitative benefits of this intervention outweigh its costs. 
The costs can be estimated relatively easily. The lab analysis would cost around € 35 
per sample, and it is estimated that it takes maximum 0.5 h per TDM to draw the sample, 
send it to the lab, spin the blood down and to transport the sample to the analyzing 
laboratory. Assuming an hourly wage of € 40/h,  one analysis would cost around € 55 per 
sample. The cost of one MIC determination using an E-test can be estimated at € 5 
consumables and 0.5 h per sample, which would costs around € 25/MIC determination. The 
costs of this intervention should then be compared to the benefit which may be achieved. 
This can be evaluated on multiple levels. It can be evaluated on the hospital level, for 
example by comparing how much antibiotic has been given in the intervention group 
compared to the control group. There will probably not be a large difference between the 2 
groups with respect to antibiotic consumption, as some patients will require higher doses, 
while others will need less. Moreover, since the introduction of the generics, antibiotics have 
become a lot cheaper. The purpose of health-economics is to improve the life expectancy, 
which is expressed in years of life saved (YOLs). The costs of the intervention can then be 
expressed as the cost to gain 1 YOLs. The conventionally adopted threshold of one YOLs is 
between € 20 000 to € 40 000 [343]. An intervention with costs less than € 20 000 / YOLs are 
considered to be very cost-efficient. Ofcourse, this requires very large studies which may be 
very difficult to conduct. Length of hospital stay, length of ICU stay or number of days free of 
organ support may be good alternative if such large studies are deemed not feasible.  
The value of some other benefits may be more difficult to estimate, for example the 
potential prevention of the emergence of resistance. It is unclear which costs are associated 
with this global problem, and how much money can be saved if this process can be 
prevented. Without question, patients with a resistant infection are more likely to die, have 
longer ICU stays and need more costly procedures, such as isolation, however, the exact 
economic burden attributable to these infections is not well known [344]. 
It is clear that the pharmaco-economic analysis will be an interesting, yet difficult 
exercise which should look beyond the mere easy to calculate savings on the hospital level 




In this era of emerging resistance and high ICU-infection related mortality and morbidity 
rates, where very few antibiotics are in development, a rational use of antibiotics has been 
advocated. Optimized use of antibiotics to improve outcome and reduce antibiotic 
resistance is therefore the next challenge. 
In the heterogeneous population of an intensive care setting, correct antibiotic dosing is 
problematic because of grossly altered and variable pharmacokinetics, which leads to 
underdosing in some and overdosing in others. The decreased susceptibility is an additional 
factor that makes dosing even more problematic. Considering this wide variability of 
antibiotic concentrations in critically ill patients, individually tailored antibiotic therapy may 
be a useful strategy to improve outcome, both on short and long term end points. However, 
before we can truly change to this, more research is needed, both in the analytical field as 








1. APACHE II score sheet 
Physiologic variable +4 +3 +2 +1 0 +1 +2 +3 +4 Points 
























 70 to 
109 
 50 to 
69 
 ≤49  








 70 to 
109 






ventilated or ventilated) 












 ≤5  
Oxygenation : A-aD02 or 
PaO2 (mm Hg) 
a. Fi02 ≥ 0.5 record A-
aDO2 



































          




Serum HCO3 (venous mEq/L) 
(not preferred but may use 








































































 ≤2.5  
Serum Creatinine (mg/dL) 
Double point score for acute 
renal failure 





 0.6 to 
1.4 
 <0.6    








 20 to 
29.9 
 <20  
White Blood Count 
(total/mm³)  








 1 to 
2.9 
 <1  
Glasgow Coma Score 
Score = 15 – minus actual 
GCS 
          
 
A. Total Acute Physiology Score (sum of 12 above points) 
B. Age Points (years) : ≤ 44 = 0, 45 to 54 = 2, 55 to 64 = 3, 65 to 74 = 5, ≥ 75 = 6 
C. Chronic Health Points 
 1) Cirrhosis of the liver confirmed by biopsy  
2) New York Heart Association Class IV  
3) Severe COPD - Hypercapnia, home O2 use, or pulmonary hypertension  
4) On regular dialysis  
 5) Immunocompromised  = mmunosuppression from chemotherapy, radiation therapy, 
long-term or recent high-dose steroids, immunodeficiency  (eg, leukemia, lymphoma, AIDS) 
None : 0 points 
Non-Surgical : 5 points 
Emergent operation : 5 points 
Elective operation : 2 points 
Total APACHE II score = A+B+C  
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AKI : acute kidney injury 
APACHE II : Acute Physiology and Chronic Health Evaluation II 
ARC : augmented renal clearance 
AUC : area under the curve 
BMI : body mass index 
BSV : between subject variability 
CrCL : creatinine clearance  
CL : clearance 
Cmax : maximum concentration 
CPE : carbapenemase  producing Enterobacteriaceae 
CRRT : continuous renal replacement therapy 
CV : coefficient of variation 
ECMO : extracorporeal membrane oxygenation  
EMA : European medicine agency 
ESBL : extended spectrum beta lactamases 
EUCAST : European committee on antimicrobial susceptibility testing 
FDA : food and drug  administration 
fT>MIC : percentage of the dosing interval for which the free antibiotic concentration exceeds 
the MIC 
ICU: intensive care unit 
IQR : interquartile range 
LC : liquid chromatography 
LLOQ : lower limit of quantification  
MEM : meropenem  
MIC : minimal inhibitory concentration 
MRSA : methicillin resistant staphylococcus aureus 
MS/MS: tandem mass spectrometry 
MSSA : methicillin susceptile staphylococcus aureus 
NONMEM : non linear mixed effect modeling  
PCR : polymerase chain reaction 
PD : pharmacodynamic 
PK : pharmacokinetic 
PTZ : piperacillin/tazobactam 
Q : intercompartmental clearance 
QCL : low concentration quality control  
QCM : medium concentration quality control 
QCH : high concentration quality control 
RIFLE : Risk Injury Failure Loss End-Stage Kidney Disease 
RUV : residual unexplained variability 
SD : standard deviation 
SIRS : systemic inflammatory response system  
SLED : sustained low efficiency dialysis 
SOFA : sequential organ failure assessment 
TDM : therapeutic drug monitoring 
ULOQ : upper limit of quantification 
UV: ultraviolet 
VRE : vancomycin resistant enterococcus 
Vc : volume of the central compartment 
Vd : volume of distribution 
Vp  : volume of the peripheral compartment 
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